Antiviral application of nucleoside analog or combination formulation containing nucleoside analog

MX439108BActive Publication Date: 2026-10-05SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MX2022013270
Authority / Receiving Office
MX · MX
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-09-27
Filing Date
2022-10-20
Publication Date
2026-10-05
Estimated Expiration
2041-04-16

AI Technical Summary

Technical Problem

There is an urgent need for low-toxicity and high-efficiency antiviral drugs to combat viral infections, particularly those caused by coronaviruses such as SARS-CoV-2, influenza viruses, respiratory syncytial viruses, and porcine epidemic diarrhea virus, as current treatments are lacking.

Method used

Development of nucleoside analogues with specific chemical structures (formula I) that inhibit viral replication, including their pharmaceutically acceptable salts, solvates, and prodrugs, which can be combined with other antiviral agents to treat and prevent viral infections.

Benefits of technology

The nucleoside analogues effectively inhibit the replication of viruses like SARS-CoV-2, influenza, and PEDV, offering potential therapeutic benefits with low toxicity and broad-spectrum antiviral activity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to an antiviral application of a nucleoside analog. Specifically, the present invention relates to uses of the nucleoside analog and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and / or porcine epidemic diarrhea virus (PEDV); and / or (b) medicines for treating and / or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and / or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analog according to the present invention may treat and / or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by the 2019 novel coronavirus infection.
Need to check novelty before this filing date? Find Prior Art

Description

ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINED FORMULATION CONTAINING NUCLEOSIDE ANALOG Technical field The present invention relates to the field of medicine, and specifically, it relates to an antiviral application of a nucleoside analogue or a combination formulation containing a nucleoside analogue. Background The vast majority of acute infectious diseases are viral infectious diseases; Both the morbidity and mortality rate of viral infectious diseases are high. Viruses are a group of pathogenic microorganisms that are extremely small, lack independent metabolism, and exist parasitically. There are several types of viruses. Nowadays, many highly infectious and pathogenic viruses have been found. These viruses often cause local or even global outbreaks of infectious diseases and are extremely harmful to human society, such as influenza virus, respiratory syncytial virus (RSV), parainfluenza virus, atypical pneumonia virus ( SARS), Middle East respiratory syndrome virus (MEFiS), Ebola virus and the like. Some viruses can also infect animals, causing various mild to severe diseases, while animals also become the source of infection for these viruses, leaving humans defenseless against them. Coronaviruses belong to Nidovirale, Coronaviridae and Coronavirus, and are a large group of single-stranded positive-strand RNA viruses that are widespread in nature and can cause respiratory, digestive and neurological diseases in humans and animals. According to the phylogenetic tree, coronaviruses can be divided into four genera: α, β, and δ, in which coronaviruses of genus β can be divided into four independent subgroups A, B, C, and D. As of April 2020, the new coronavirus (SARS-CoV-2) has caused more than 100,000 deaths, marking another very serious global public health event since the Spanish pandemic of 1918. SARS-CoV-2, coronavirus atypical pneumonia (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) all belong to the β genus coronaviruses, and currently, these three viruses have become the most pathogenic coronaviruses for humans. Currently, there are no specific vaccines and antiviral medications against severe pneumonia caused by the SARS-CoV-2 coronavirus. These infectious diseases have seriously affected people's lives and health, so there is an urgent need to develop antiviral drugs with good effects. It is of great social importance to develop low-toxicity and high-efficiency antiviral drugs for SARS-CoV-2 coronavirus to meet the clinical needs of patients infected with SARS-CoV-2 coronavirus at home and abroad. The coronavirus can also infect many mammals, including bats, pigs, dogs, cats, mice, cattle, horses, camels, etc. Most of these viruses belong to the a and β genera. iv ze ίη / ζζηζ / Ε / γίΛΐ Porcine epidemic diarrhea virus (PEDV) is a type of coronavirus that can cause acute intestinal infectious diseases in pigs. Pigs of all ages can be infected, especially suckling piglets and newborn piglets are the most affected, and the aquaculture industry often suffers heavy losses due to the outbreak of PEDV. Respiratory virus infection is the most common and clinically influential viral infectious disease, causing a large number of deaths in the world each year. In addition to coronavirus, influenza virus, respiratory syncytial virus and parainfluenza virus and the like can also cause respiratory tract infection and lead to pneumonia, which are key killers that threaten human life and health. In summary, there is an urgent need in this field to develop inhibitors to inhibit viral replication that are used to treat related diseases caused by viral infections. Brief description of the invention The purpose of the present invention is to provide an active ingredient that can effectively inhibit viral replication and its novel use in diseases associated with viral infections. Specifically, the present invention provides a use of nucleoside analogs having formula (I) and their compositions to combat viruses (for example, coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and / or of porcine epidemic diarrhea), in particular, the new coronavirus (SARS-CoV-2). In the first aspect of the present invention, it provides a compound of formula (I), or its pharmaceutically acceptable salts or its crystalline hydrate or its solvate or its prodrug, η / ζΓίη / ζζηζ / Ε / γίΛΐ in which, Ri is selected from hydrogen, deuterium, halogen, cyano, azido, amino, amino substituted with C1-6 alkyl, Ci-e acyl, Ci-e alkyl, C1-6 alkoxy, amino substituted with C1-6 alkanoyl, C1-alkyl 6 halogenated, C2 e alkenyl, C2 6 alkenoxy, C2-6 alkynyloxy, C2 e alkynyl, C3 6 cycloalkyl, halogenated C3 6 cycloalkyl, carbamoyl, hydroxymethyl, cyanomethyl (-CH2CN), guanyl, guanidyl, carbamido, thiocyanate (-SCN) , cyanate (-OCN); R2 is selected from hydrogen, halogen, OR3, cyano, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl; R3 is selected from hydrogen, C1-20 alkanoyl, amino-C1-20 alkanoyl, amino Ci-6 alkyl-C1-6 alkanoyl, C1-6 alkoxy C1-6 alkyl, amino acid a, and the carboxyl of amino acid a is attached to hydroxyl on the furan ring through the ester bond; R4 is selected from hydrogen, deuterium, halogen, azido, cyano, C1-6 alkyl, halogenated C1-6 alkyl, azido C1-6 alkyl, cyano C1-6 alkyl, hydroxyl C1-6 alkyl, C2-6 alkenyl, C2-alkynyl 6, C3-6 cycloalkyl, C1-6 alkanoyl, C2-6 alkenoxy, C2-6 alkynyloxy, C1-6 alkoxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkylamino C1-6, guanyl, guanidyl, carbamido, thiocyanate, cyanate; iv ze Ln / zznz / E / YiAi R10 Rs is selected from R3, EITHER P-OM OM ; Re is selected from amino, hydroxy, halogen, cyano, cyanate, thiocyanate, C1-6 alkoxy, C1-6 alkylamino, NHOH, NHCOR12, NHOCOR12, NHCOOR12; R7 is selected from hydrogen, deuterium, halogen, amino, methyl, NHCOOR12, NHCOOR12; Re is selected from hydrogen, deuterium, halogen, cyano, carbamolo, C1-6 alkyl substituted carbamoyl, C1-6 alkoxyamido, C1-6 alkoxycarbonyl, hydroxy, C1-6 hydroxyalkyl, amino, C1 alkanoyl substituted amino e, substituted amino with C1 e alkyl, C1 e alkyl, C16 alkoxy, C2 6 alkenyl, C2 e alkynyl; X is selected from -CH2-, -CD2-, -CHD-; Rase selects from C1-6 alkyl, C3-6 cycloalkyl, C6-20 aryl, 5-15 membered heteroaryl; R10 is selected from C1-18 alkyl, C6-20 aryl methylene; R11 is selected from C1-6 alkyl, C3-6 cycloalkyl, Ce-20 aryl, 5-15 membered heteroaryl; R12 is selected from C1-20 alkyl; M is each independently selected from hydrogen, metal, -NHU, or protonated organic amines; In another preferred embodiment, each position indicated as deuterium (D) has a deuterium enrichment of at least 50%; preferably, each position indicated as deuterium (D) has a deuterium enrichment of at least 80%; more preferably, each position indicated as deuterium (D) has a deuterium enrichment of at least 90%; More preferably, each position indicated as deuterium (D) has a deuterium enrichment of at least 95%. In another preferred embodiment, the heteroaryl contains 5-15 1-, 2-, 3- or 4-membered heteroatoms selected from N, O and S. In another preferred embodiment, the metal is selected from the group consisting of alkali metal, alkaline earth metal, or the combination thereof. In another preferred embodiment, in the formula of the compound of formula (I), R1 is selected from hydrogen, deuterium, halogen, cyano, azido, methyl, chloromethyl, fluoromethyl, ethenyl, ethynyl, cyclopropyl, carbamoyl, hydroxymethyl, methoxyl, formyl, guanyl; I R2 is selected from halogen, cyano, amino, formyl, OR3; I R3 is selected from hydrogen, C1-20 alkanoyl, amino acid a, the carboxyl of amino acid a is attached to the hydroxyl on the furan ring through the ester bond; preferably, the amino acid a is selected from the group consisting of alanine, valine, isoleucine, tryptophan, phenylalanine; I R4 is selected from hydrogen, deuterium, halogen, azido, cyano, methyl, chloromethyl, fluoromethyl, difluoromethyl, ethenyl, ethynyl, cyclopropyl, hydroxymethyl, azidomethyl (-CH2N3), formyl, acetyl, formamido, acetamido; and / or η / ζΓίη / ζζηζ / Ε / γίΛΐ EITHER P-OM OM and / or Re is selected from amino, hydroxy, halogen, cyano, methylamino (-NH2CH3), NHOH, NHCOR12, NHOCOR12, NHCOOR12; I R7 is selected from hydrogen, deuterium, halogen, amino; I Re is selected from hydrogen, deuterium, halogen, cyano, carbamoyl, N-methylcarbamoyl (CH3NHCO-), methyl, ethyl, ethynyl, methoxycarbonyl, ethoxocarbonyl, hydroxy, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, formyl, acetyl, formamido, acetamido, methoxycarbonylamino (CH3OCONH2-), ethoxycarbonlamino (C2H5OCONH2-), methoxycarbonyloxy (CH3OCOO-), ethoxycarbonyloxy (C2H5OCOO-); I X is selected from -CH2-, -CD2-, -CHD-; I Rase selects from aryl Ce-20, 5-15 membered heteroaryl; I R10 is selected from Ci-is alkyl, Ce-20 aryl methylene; I R11 is selected from C1e alkyl, C36 cycloalkyl, Ce20 aryl, 5-15 membered heteroaryl; I R12 is selected from C120 alkyl; I M is each independently selected from hydrogen, zinc, magnesium, calcium, sodium, potassium, NHL, protonated trimethylamine, protonated triethylamine, protonated tri-n-butylamine. In another preferred embodiment, R1, R2, R3, R4, Rs, Re, Rz, Rs and In another preferred embodiment, the compound of formula (I) in any one of Compounds A1 to A221 having the following structure, or the combination thereof: HO OH HÓ OH HÓ 'OH A16 HO' 'OH A17 A18 η / ζΓίη / ζζηζ / Ε / γίΛΐ Α79 Α80 Α81 Α82 Α83 η / ζΓίη / ζζηζ / Ε / γίΛΐ Α111 Α112 η / ζΓίη / ζζηζ / Ε / γίΛΐ η / ζΓίη / ζζηζ / Ε / γίΛΐ ÍV ίη / ΖΖΩΖ / Ε / ΥΙΛΙ In another preferred embodiment, the compound of formula (I) is selected from the group consisting of: η / ζΓίη / ζζηζ / Ε / γίΛΐ Α108 Α109 Α110 Α111 η / ζΓίη / ζζηζ / Ε / γίΛΐ η / ζΓίη / ζζηζ / Ε / γίΛΐ ÍV ίη / ΖΖΩΖ / Ε / ΥΙΛΙ In another preferred embodiment, the compound of formula (I) is selected from the group consisting of: Compound A1, A9, A10, A11, A12, A49, A50, A51, A52, A53, A69, A70, A71, A72, A74 , A75, A76, A77, A84, A87, A102, A106, A107, A108, A109, A124, A131, A138, A140, A144, A146, A147, A151, A164, A171, A173, A174, A180, A181, A188 , A196, A198, A209, A212, A213, A214, A215, A216, A221, or a combination thereof. η / ζΓίη / ζζηζ / Ε / γίΛΐ In the second aspect of the present invention, it provides a use of an active ingredient or a formulation containing said active ingredient, the active ingredient being a compound of formula (I) or the pharmaceutically acceptable salts thereof or the crystalline hydrate of the themselves or their solvate or their prodrug: Ri is selected from hydrogen, deuterium, halogen, cyano, azido, amino, Ci e alkyl substituted amino, Ci e acyl, C1-6 alkyl, Ci e alkoxy, Ci e alkanoyl substituted amino, halogenated Ci 6 alkyl, C2 alkenyl -6, C2-6 alkenoxy, C2-6 alkynyloxy, C2-6 alkynyl, C3-6 cycloalkyl, halogenated C3-6 cycloalkyl, carbamoyl, hydroxymethyl, cyanomethyl (-CH2CN), guanyl, guanidyl, carbamido, thiocyanate (-SCN) , cyanate (-OCN); R2 is selected from hydrogen, halogen, OR3, cyano, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl; R3 is selected from hydrogen, C1-20 alkanoyl, C1-20 aminoalkanoyl, Ci-e-C1-6 alkylamino, C1 6 alkoxy C1 e alkyl, amino acid a, and the carboxyl of amino acid a is attached to the hydroxyl on the ring furan via ester bond; R4 is selected from hydrogen, deuterium, halogen, azido, cyano, C1-6 alkyl, halogenated C1-6 alkyl, azido C1-6 alkyl, cyano C1-6 alkyl, hydroxy Ci-s alkyl, C2-6 alkenyl, C2 6 alkynyl , C3-6 cycloalkyl, C1-6 alkanoyl, C2-6 alkenoxy, C2-6 alkynyloxy, C1-6 alkoxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkyl C1-6 alkylamino, guanyl, guanidyl, carbamido , thiocyanate, cyanate; Ίο 7° °, yes? °γ\ i-ρ-ο-ρ-ο-ρ-οινι -|p-om O OM OM OM OM Re is selected from amino, hydroxy, halogen, cyano, cyanate, thiocyanate, C1-6 alkoxy, C1-6 alkylamino, NHOH, NHCOR12, NHOCOR12, NHCOOR12; R7 is selected from hydrogen, deuterium, halogen, amino, methyl, NHCOOR12, NHCOOR12; Rs is selected from hydrogen, deuterium, halogen, cyano, carbamolo, carbamoyl substituted with C1 alkyl, C1 6 alkoxyamido, C1 6 alkoxycarbonyl, hydroxy, hydroxy C16 alkyl, amino, amino substituted with C1-6 alkanoyl, amino substituted with C1-alkyl 6, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl; X is selected from -CH2-, -CD2-, -CHD-; Rgse selected from C1 e alkyl, C3-6 cycloalkyl, Ce-20 ring, 5-15 membered heteroaryl; R10 is selected from C1-18 alkyl, Ce-2 aryl or methylene; R11 is selected from C1-6 alkyl, C3-6 cycloalkyl, C6-20 aryl, 5-15 membered heteroaryl; R12 is selected from C1-20 alkyl; M is each independently selected from hydrogen, metal, NHL, or protonated organic amines; and the active ingredient or the formulation containing said active ingredient is used to prepare (a) inhibitors for inhibiting viral replication; and / or (b) medications to treat and / or prevent, alleviate diseases associated with viral infections. In another preferred embodiment, each position indicated as deuterium (D) has a deuterium enrichment of at least 50%; preferably, each position indicated as deuterium (D) has a deuterium enrichment of at least 80%; more preferably, each position indicated as deuterium (D) has a deuterium enrichment of at least 90%; More preferably, each position indicated as deuterium (D) has a deuterium enrichment of at least 95%. In another preferred embodiment, the active ingredient or the formulation containing said active ingredient is used to prepare (a) inhibitors to inhibit coronavirus replication; and / or (b) medicines to treat and / or prevent, alleviate diseases associated with coronavirus infections. In another preferred embodiment, the active ingredient or the formulation containing said active ingredient is used to prepare (a) inhibitors to inhibit the replication of respiratory syncytial virus (RSV); and / or (b) medications to treat and / or prevent, alleviate diseases associated with respiratory syncytial virus (RSV) infections In another preferred embodiment, the active ingredient or the formulation containing said active ingredient is used to prepare (a) inhibitors to inhibit the replication of the influenza virus; and / or (b) medications to treat and / or prevent or alleviate illnesses associated with influenza virus infections. In another preferred embodiment, the active ingredient or the formulation containing said active ingredient is used to prepare (a) inhibitors to inhibit the replication of the flaviviridae virus; and / or (b) medications to treat and / or prevent, alleviate diseases associated with flaviviridae virus infections. η / ζΓίη / ζζηζ / Ε / γίΛΐ In another preferred embodiment, the active ingredient or the formulation containing said active ingredient is used to prepare (a) inhibitors to inhibit the replication of the filoviridae virus; and / or (b) medications to treat and / or prevent, alleviate diseases associated with filoviridae virus infections. In another preferred embodiment, the active ingredient or the formulation containing said active ingredient is used to prepare (a) inhibitors to inhibit the replication of porcine epidemic diarrhea virus (PEDV); and / or (b) medicines to treat and / or prevent, alleviate diseases associated with porcine epidemic diarrhea virus (PEDV) infections. In another preferred embodiment, the active ingredient or the formulation containing said active ingredient is used to prepare (a) inhibitors to inhibit the replication of the new coronavirus (SARS-CoV2); and / or (b) medicines to treat and / or prevent, alleviate diseases associated with novel coronavirus (SARS-CoV-2) infections. In another preferred embodiment, the virus is selected from; (1) coronaviruses that infect humans: severe acute respiratory syndrome coronavirus (SARSCoV), 2019 novel coronavirus (2019-nCoV or SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV); (2) Coronavirus causing the common cold: The coronavirus causing the common cold is preferably selected from the group consisting of Human Coronavirus OC43, Human Coronvirus 229E, Human Coronvirus NL63, Human Coronvirus HKUL; (3) human respiratory syncytial virus (RSV); (4) human influenza viruses: influenza A virus, influenza B virus, and influenza C virus; (5) flaviviridae viruses: hepatitis C virus (HCV), dengue virus (DENV), Zika virus (Zika); (6) filoviridae viruses: Marburg virus (MBV) and Ebola virus (EBV); (7) Coronavirus that infects other mammals: porcine epidemic diarrhea virus (PEDV). In another preferred embodiment, related diseases caused by viruses are selected from the group consisting of (D1) common cold, high-risk symptoms infection, respiratory tract infection, pneumonia and its complications caused by human coronavirus infection; (D2) common cold, high-risk symptoms infection, respiratory tract infection, pneumonia and its complications caused by human respiratory syncytial virus (RSV) infection; (D3) common cold, high-risk symptoms infection, respiratory tract infection, pneumonia and its complications caused by human influenza virus infection; (D4) chronic hepatitis C and its complications caused by hepatitis C virus (HCV); (D5) dengue fever and its complications caused by dengue virus (DENV); (D6) infection and complications thereof caused by the Zika virus (Zika); (D7) hemorrhagic fever and its complications caused by Marburg virus (MBV) and Ebola virus (EBV); (D8) new coronavirus pneumonia (corona virus disease 2019) caused by SARSCoV-2 (COVID-19); (D9) porcine epidemic diarrhea caused by porcine epidemic diarrhea virus (PEDV); η / ζΓίη / ζζηζ / Ε / γίΛΐ (D10) any combination of the above diseases. In another preferred embodiment, related diseases caused by the 2019 novel coronavirus infection are selected from the group consisting of respiratory tract infection, pneumonia and its complications, or the combination thereof. In another preferred embodiment, the compound of formula (I) in any one of Compounds A1 to A221, or the combination thereof. In another preferred embodiment, the active ingredient is a nucleoside analogue selected from the following group, or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof: Composite A1, A5, A6, A8, A9, A10, A11, A12, A13, A14, A28, A30, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A49 , A50, A51, A52, A53, A54, A55, A57, A58, A63, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A84, A86, A87 , A88, A89, A91, A95, A97, A99, A101, A102, A105, A106, A107, A108, A109, A110, A111, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135,A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151,A152, A153, A154, A155, A156, A157, A158, A159, A160, A161, A162, A163, A164, A165, A166, A167,A168, A169, A170, A171, A172, A173, A174, A175, A176, A177, A178, A179, A180, A181, A182, A183,A184, A185, A186, A187, A188, A189, A190, A191, A192, A193, A194, A195, A196, A197, A198, A199,A200, A201, A202, A203, A204, A205, A206, A207, A208, A209, A210, A211, A212, A213, A214, A215,A216, A217, A218, A219, A220, A221, or a combination thereof. In another preferred embodiment, the compound of formula (I) is selected from the group consisting of: Compound A1, A9, A10, A11, A12, A49, A50, A51, A52, A53, A69, A70, A71, A72, A74 , A75, A76, A77, A84, A87, A102, A106, A107, A108, A109, A124, A131, A138, A140, A144, A146, A147, A151, A164, A171, A173, A174, A180, A181, A188 , A196, A198, A209, A212, A213, A214, A215, A216, A221, or a combination thereof. In another preferred embodiment, the formulations (or pharmaceutical compositions containing the compounds) may further contain other antiviral agents. In another preferred embodiment, the other antiviral agents further comprise additional components selected from the group consisting of: Remdesivir (GS-5734), favipiravir, Galidesivir, GS-441524, NHC (EIDD-1931), EIDD-2801, GC376, Lopinavir, Ritonavir, Nelfinavir; Chloroquine, hydroxychloroquine, cyclosporine, carrimycin, baicalin, baicalein, forsythoside, chlorogenic acid, emodin, mycophenolic acid, mycophenolate mofetil, naphthoquine, ciclesonide, ribavirin, penciclovir, leflunomide, teriflunomide, nafamostat, nitazoxanide, darunavir, arbidol, camostat, niclosamide, bar icitinib , Ruxolitinib, Dasatinib, Saquinavir, Beclabuvir, Simeprevir, Palivizumab, Motavizumab, RSV-IGIV (RespiGam®), MEDI-557, A-60444 (RSV-604), MDT-637, BMS-433771, or their pharmaceutically acceptable salts, or the combination thereof. In another preferred embodiment, the pharmaceutical composition containing the compound further comprises administering a therapeutically effective amount of at least one other η / ζΓίη / ζζηζ / Ε / γίΛΐ therapeutic agent selected from the group consisting of corticosteroids, anti-inflammatory signal transduction modulators, β2 adrenergic receptor agonist bronchodilators, anticholinergic agents, mucolytic agents, hypertonic saline and other medications to treat viral infections; or the combination thereof. IV 7Γ ίη / ΖΖΩΖ / Ε / ΥΙΛΙ In another preferred embodiment, the formulation is a pharmaceutical composition. In another preferred embodiment, the formulation (or pharmaceutical composition) includes oral formulation and non-oral formulation. In another preferred embodiment, the formulation includes powder, granule, capsule, injection, inhalation, tincture, oral liquid, tablet, buccal tablet or dropper. In the third aspect of the invention, a pharmaceutical composition is provided comprising: (a1) first active ingredient, the first active ingredient is a compound of formula (I), and its pharmaceutically acceptable salts or the crystalline hydrate thereof or the solvate thereof or their prodrug: R8Re ΑΛν VN. Jk. R.N R7 °rX7'R’ R3O R2 in which, R1 is selected from hydrogen, deutenium, halogen, cyano, azido, amino, amino substituted with C1-6 alkyl, C1-6 acyl, C1-6 alkyl, C1-6 alkoxy, amino substituted with C1-6 alkanoyl, C1-alkyl 6 halogenated, C2-6 alkenyl, C2-6 alkenoxy, C2-6 alkynyloxy, C2-6 alkynyl, C3-6 cycloalkyl, halogenated C3-6 cycloalkyl, carbamoyl, hydroxymethyl, cyanomethyl (-CH2CN), guanyl, guanidyl, carbamido, thiocyanate (-SCN), cyanate (-OCN); R2 is selected from hydrogen, halogen, OR3, cyano, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl; R3 is selected from hydrogen, C1-20 alkanoyl, C1-20 aminoalkanoyl, amino Ci-6 alkyl-C1-6 alkanoyl, C1-6 alkoxy C1-6 alkyl, amino acid a, and the carboxyl of amino acid a is attached to the hydroxyl in the furan ring through the ester bond; R4 is selected from hydrogen, deuterium, halogen, azido, cyano, C1e alkyl, halogenated C1e alkyl, azido C16 alkyl, cyano C1-6 alkyl, hydroxyl C1s, C26 alkenyl, C26 alkynyl, C3-6 cycloalkyl, C1-6 alkanoyl, C2-6 alkenoxy, C2-6 alkynyloxy, C1-6 alkoxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkyl C1-6 alkylamino, guanyl, guanidyl, carbamido, thiocyanate, cyanate; > Sκ c N N fe 'j I ° O O O o cογΚ -j-P-O-P-O-P-OM -^-P-OM O ¿M om OM Óm Re is selected from amino, hydroxy, halogen, cyano, cyanate, thiocyanate, C1-6 alkoxy, Ci-e alkylamino, NHOH, NHCOR12, NHOCOR12, NHCOOR12; R? is selected from hydrogen, deuterium, halogen, amino, methyl, NHCOOR12, NHCOOR12; Re is selected from hydrogen, deuterium, halogen, cyano, carbamolo, C1-6 alkyl substituted carbamoyl, C1-6 alkoxyamido, C1-6 alkoxycarbonyl, hydroxy, C1-6 hydroxyalkyl, amino, C1 alkanoyl substituted amino e, substituted amino with C1 e alkyl, C1 e alkyl, C1 6 alkoxy, C2 e alkenyl, C2 e alkynyl; X is selected from CH2, CD2, -CHD-; Rgse selected from C1-6 alkyl, C3-6 cycloalkyl, Cs-20 aryl, 5-15 membered heteroaryl; R10 is selected from O 13 alkyl, Ce 20 aryl methylene; R11 is selected from Ci-e alkyl, C3-6 cycloalkyl, Ce-2o aryl, 5-15 membered heteroaryl; R12 is selected from C1-20 alkyl; M is each independently selected from hydrogen, metal, NFU, or protonated organic amines; and (b) pharmaceutically acceptable carriers. In another preferred embodiment, the composition further comprises (a2) a second active ingredient; wherein, the second active ingredient is an antiviral drug selected from the group consisting of interferon, RNA-dependent RNA polymerase inhibitors (e.g., Remdesivir (GS5734), favipiravir, Galidesivir, GS-441524, NHC (EIDD- 1931), EIDD-2801), 3CL protease inhibitor (e.g., GC-376), lopinavir, ritonavir, nelfinavir; Chloroquine, hydroxychloroquine, cyclosporin, carrimycin, baicalin, baicalein, forsitoside, chlorogenic acid, emodin, mycophenolic acid, mycophenolate mofetil, naphthoquine, ciclesonide, ribavirin, penciclovir, leflunomide, teriflunomide, nafamostat, nitazoxanide, darunavir, arbidol, camostat, niclosamide, barici tinib , Ruxolitinib, Dasatinib, Saquinavir, Beclabuvir, Simeprevir, Palivizumab, Motavizumab, RSV-IGIV(Resp¡Gam®), MEDI-557, A-60444(RSV604), MDT-637, BMS-433771, or their pharmaceutically acceptable salts, or the combination thereof; and / or the second active ingredient is selected from the group consisting of bronchodilators and corticosteroids for the treatment of respiratory tract infections, wherein the corticosteroid includes dexamethasone, dexamethasone sodium phosphate, fluorometholone, fluorometholone acetate, loteprednol, loteprednol etabonate , hydrocortisone, prednisolone, fludrocortisone, triamcinolone, triamcinolone acetonide, betamethasone, beclomethasone dipropionate, methylprednisolone, fluocinolone, fluocinolone acetonide, flunisolide, fluoctin-21-butylate, flumetasone, flumetasone pivalate, budesonide, halobetasol propionate, mometasone oate , fluticasone propionate and ciclesonide; or the pharmaceutically acceptable salt thereof. and / or the second active ingredient is selected from the group consisting of Zinc, Fingolimod, Vitamm C, Olmesartan Medoxomil, valsaría, Losartan, Thalidomide, Glycyrrhizic acid, Artemisinin, dihydroartemisinin, Artesunate, Artemisone, Azithromycin, Escin, Naproxen, or the combination thereof. In another preferred embodiment, in the compound of formula (I), Ri is selected from hydrogen, deuterium, halogen, cyano, azido, methyl, chloromethyl, fluoromethyl, ethenyl, ethynyl, cyclopropyl, carbamoyl, hydroxymethyl, methoxyl, formyl, guanyl; Ra is selected from halogen, cyano, amino, formyl, ORs; Ra is selected from hydrogen, C1-20 alkanoyl, amino acid a, and the carboxyl of amino acid a is attached to the hydroxyl on the furan ring through the ester bond; preferably, the amino acid a is selected from alanine, valine, isoleucine, tryptophan, phenylalanine; R4 is selected from hydrogen, deuterium, halogen, azido, cyano, methyl, chloromethyl, fluoromethyl, difluoromethyl, ethenyl, ethynyl, cyclopropyl, hydroxymethyl, azidomethyl (-CH2N3), formyl, acetyl, formamido, acetamido; η / ζΓίη / ζζηζ / Ε / γίΛΐ Re is selected from amino, hydroxy, halogen, cyano, methylamino (-NH2CH3), NHOH, NHCOR12, NHOCOR12, NHCOOR12; R7 is selected from hydrogen, deuterium, halogen, amino; Rs is selected from hydrogen, deuterium, halogen, cyano, carbamoyl, N-methylcarbamoyl (CH3NHCO-), methyl, ethyl, ethynyl, methoxycarbonyl, ethoxocarbonyl, hydroxy, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, formyl, acetyl, formamido, acetamido, methoxycarbonylamino (CH3OCONH2-), ethoxycarbonlamino (C2H5OCONH2-), methoxycarbonyloxy (CH3OCOO-), ethoxycarbonyloxy (C2H5OCOO-); X is selected from CH2, CDa, -CHD-; Rose selects from aryl Ce20, 5-15 membered heteroaryl; Rw is selected from C1-18 alkyl, C6-20 aryl methylene; R11 is selected from C1-6 alkyl, C3-6 cycloalkyl, Cs-20 aryl, 5-15 membered heteroaryl; R12 is selected from C1-20 alkyl; I M is each independently selected from hydrogen, zinc, magnesium, calcium, sodium, potassium, NH4, protonated trimethylamine, protonated triethylamine, protonated tri-n-butylamine. In another preferred embodiment, the compound of formula (I) in any one of Compounds A1 to A221, or the combination thereof. In another preferred embodiment, the compound of formula (I) is selected from the group consisting of Compound Α1, Α5, Α6, Α8, Α9, Α10, Α11, Α12, Α13, Α14, Α28, Α30, Α35, Α36, Α37, Α38, Α39, Α40, Α41, Α42, Α44, Α45, Α46, Α49 , Α50, Α51, Α52, Α53, Α54, Α55, Α57, Α58, Α63, Α69, Α70, Α71, Α72, Α73, Α74, Α75, Α76, Α77, Α78, Α79, Α80, Α81, Α84, Α86, Α87 , Α88, Α89, Α91, Α95, Α97, Α99, Α101, Α102, Α105, Α106, Α107, Α108, Α109, Α110, Α111, Α113, Α114, Α115, Α116, Α117, Α118, Α119, Α120, Α121, Α122, Α123, Α124, Α125, Α126, Α127, Α128, Α129, Α130, Α131, Α132, Α133, Α134, Α135, Α136,Α137, Α138, Α139, Α140, Α141, Α142, Α143, Α144, Α145, Α146, Α147, Α148, Α149, Α150, Α151, Α152,Α153, Α154, Α155, Α156, Α157, Α158, Α159, Α160, Α161, Α162, Α163, Α164, Α165, Α166, Α167, Α168,Α169, Α170, Α171, Α172, Α173, Α174, Α175, Α176, Α177, Α178, Α179, Α180, Α181, Α182, Α183, Α184,Α185, Α186, Α187, Α188, Α189, Α190, Α191, Α192, Α193, Α194, Α195, Α196, Α197, Α198, Α199, Α200,Α201, Α202, Α203, Α204, Α205, Α206, Α207, Α208, Α209, Α210, Α211, Α212, Α213, Α214, Α215, Α216, Α217, Α218, Α219, Α220, Α221, or the combination thereof. In another preferred embodiment, the compound of formula (I) is selected from the group consisting of Compound A1, A9, A10, A11, A12, A49, A50, A51, A52, A53, A69, A70, A71, A72, A74, A75, A76, A77, A84, A87, A102, A106, A107, A108, A109, A124, A131, A138, A140, A144, A146, A147, A151, A164, A171, A173, A174, A180, A181, A188, A196, A198, A209, A212, A213, A214, A215, A216, A221, or a combination thereof. In another preferred embodiment, the second active ingredient is selected from the group consisting of (Y1) RNA replicase inhibitors (e.g., Remdesivir (GS-5734), favipiravir, Galidesivir, GS441524, NHC, EIDD-2801); (Y2) lopinavir; (Y3) ritonavir; (Y4) favipiravir; (Y5) chloroquine, hydroxychloroquine or their pharmaceutically acceptable salts (for example, chloroquine phosphate), (Y6) nelfinavir; (Y7) any combination of the above Y1 to Y6. In another preferred embodiment, the pharmaceutical composition is used to inhibit the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and / or porcine epidemic diarrhea virus (PEDV). In another preferred embodiment, the drug is used to inhibit the replication of the 2019 novel coronavirus (SARS-CoV-2). In the fourth aspect of the present invention, a use of the pharmaceutical composition according to the third aspect of the present invention is provided in the preparation of (a) inhibitors that inhibit the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae, filoviridae virus and / or porcine epidemic diarrhea virus (PEDV); and / or (b) medicines to treat and / or prevent, alleviate related diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and / or porcine epidemic diarrhea virus (PEDV) infection . In another preferred embodiment, to prepare (a) inhibitors to inhibit the replication of the 2019 novel coronavirus (SARS-CoV-2); and / or (b) medications to treat and / or prevent, alleviate diseases associated with 2019 novel coronavirus (SARS-CoV-2) infections. In the fifth aspect of the present invention, a method is provided for inhibiting viral replication comprising the steps of: IV 7Γ ίη / ΖΖΩΖ / Ε / ΥΙΛΙ bringing a first active ingredient or a formulation containing the first active ingredient into contact with a virus, thereby inhibiting the replication of the virus; wherein the first active ingredient is a compound of formula (I), or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof: η / ζΓίη / ζζηζ / Ε / γίΛΐ Ri is selected from hydrogen, deuterium, halogen, cyano, azido, amino, amino substituted with Ci-e alkyl, Ci-e acyl, Ci-e alkyl, C1-6 alkoxy, amino substituted with C1-6 alkanoyl, C1-alkyl 6 halogenated, C2-6 alkenyl, C2-6 alkenoxy, C2-6 alkynyloxy, C2-6 alkynyl, C3-6 cycloalkyl, halogenated C3-6 cycloalkyl, carbamoyl, hydroxymethyl, cyanomethyl (-CH2CN), guanyl, guanidyl, carbamido, thiocyanate (-SCN), cyanate (-OCN); R2 is selected from hydrogen, halogen, OR3, cyano, C16 alkyl, C1 e alkoxy, C26 alkenyl, Ca e alkynyl; Rs is selected from hydrogen, C1-20 alkanoyl, C1-20 aminoalkanoyl, Ci-e-C1-6 alkylamino, C1-6 alkoxy C1-6 alkyl, amino acid a, and the carboxyl of amino acid a is attached to the hydroxyl in the furan ring via ester bond; preferably, the amino acid a is selected from alanine, valine, isoleucine, tryptophan, phenylalanine; R4 is selected from hydrogen, deuterium, halogen, azido, cyano, C1-6 alkyl, halogenated C1-6 alkyl, azido C16 alkyl, cyano C16 alkyl, hydroxyl C1 e, C2 6 alkenyl, C2 6 alkynyl, C3-6 cycloalkyl, C1-6 alkanoyl, C2-6 alkenoxy, C2-6 alkynyloxy, C1-6 alkoxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkyl C1-6 alkylamino, guanyl, guanidyl, carbamido, thiocyanate, cyanate; Re is selected from amino, hydroxy, halogen, cyano, cyanate, thiocyanate, C1-6 alkoxy, C1-6 alkylamino, NHOH, NHCOR12, NHOCOR12, NHCOOR12; R7 is selected from hydrogen, deuterium, halogen, amino, methyl, NHCOOR12, NHCOOR12; Rs is selected from hydrogen, deuterium, halogen, cyano, carbamolo, Ci-e alkyl substituted carbamoyl, C1-6 alkoxyamido, C1-6 alkoxycarbonyl, hydroxy, C1-6 hydroxyalkyl, amino, C1-6 alkanoyl substituted amino, amino substituted with C1-6 alkyl, C1-6 alkyl, C1-6 C2-6 alkoxy, alkenyl, C2-6 alkynyl; X is selected from CH2, CD2, -CHD-; Rgse selected from C1 e alkyl, C36 cycloalkyl, Ce-20 aryl, 5-15 membered heteroaryl; R10 is selected from C1-18 alkyl, Ce-20 aryl, methylene; R11 is selected from C1-6 alkyl, C3-6 cycloalkyl, Ce-20 aryl, 5-15 membered heteroaryl; R12 is selected from C1-20 alkyl; M is each independently selected from hydrogen, metal, NH4, or protonated organic amines; In another preferred embodiment, the virus is selected from the group consisting of coronaviruses, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus, porcine epidemic diarrhea virus, and the combination thereof. In another preferred embodiment, the virus is the 2019 novel coronavirus (SARS-CoV-2). In another preferred embodiment, the compound of formula (I) in any one of Compounds A1 to A221, or the combination thereof. In another preferred embodiment, the compound of formula (I) is selected from the group consisting of Compound A1, A5, A6, A8, A9, A10, A11, A12, A13, A14, A28, A30, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A49, A50, A51, A52, A53, A54, A55, A57, A58, A63, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A84, A86, A87, A88, A89, A91, A95, A97, A99, A101, A102, A105, A106, A107, A108, A109, A110, A111, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136,A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152,A153, A154, A155, A156, A157, A158, A159, A160, A161, A162, A163, A164, A165, A166, A167, A168,A169, A170, A171, A172, A173, A174, A175, A176, A177, A178, A179, A180, A181, A182, A183, A184,A185, A186, A187, A188, A189, A190, A191, A192, A193, A194, A195, A196, A197, A198, A199, A200,A201, A202, A203, A204, A205, A206, A207, A208, A209, A210, A211, A212, A213, A214, A215, A216,A217, A218, A219, A220, A221, or a combination thereof. In another preferred embodiment, the compound of formula (I) is selected from the group consisting of Compound A1, A9, A10, A11, A12, A49, A50, A51, A52, A53, A69, A70, A71, A72, A74, A75, A76, A77, A84, A87, A102, A106, A107, A108, A109, A124, A131, A138, A140, A144, A146, A147, A151, A164, A171, A173, A174, A180, A181, A188, A196, A198, A209, A212, A213, A214, A215, A216, A221, or a combination thereof. In another preferred embodiment, the method is an in vitro method. In another preferred embodiment, the method is neither therapeutic nor diagnostic. In the sixth aspect of the present invention, it provides a method for (a) inhibiting viral replication and / or (b) treating and / or preventing, alleviating related diseases caused by viral infection, comprising the steps of administering a safe amount and effective of a compound of formula (I), or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate of the η / ζΓίη / ζζηζ / Ε / γίΛΐ thereof or the prodrug thereof to the subject in need thereof : η / ζΓίη / ζζηζ / Ε / γίΛΐ in which Ri, R2, R3, R4, Rs, Re, R7, King X are defined as in the first aspect of the invention. In another preferred embodiment, the subject is a mammal (such as a human). It should be understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (e.g., examples) may be combined with each other, thus forming a new or preferred technical solution. Due to space limitations, it will not be repeated here. Brief description of the drawings Fig. 1 shows the replication status of viral RNA after administration for 2 days in the examples of the present invention, in which the virus control group, 50 mg / kg oral S group, A151 group -S oral 100 mg / kg, Remdesivir oral group 50 mg / kg and Remdesivir group 50 mg / kg by intraperitoneal injection. Fig. 2 shows the status of viral RNA replication after administration for 5 days in the examples of the present invention, in which the virus control group, 50 mg / kg oral A151-S group, group 100 mg / kg oral A151-S, 50 mg / kg oral Remdesivir group, and 50 mg / kg intraperitoneal injection Remdesivir group. Figure 3 shows the status of viral RNA replication after administration for 5 days in the examples of the present invention, in which a virus control group and a 100 mg intraperitoneal injection A151-S group are established. / kg. Detailed description of the invention After extensive and in-depth research, and through a large number of evaluations, the inventors unexpectedly developed a class of active ingredients that can effectively inhibit virus replication for the first time. The experimental result demonstrates that the active ingredient of the present invention can efficiently inhibit the replication and viability of the 2019 novel coronavirus (SARS-CoV-2) and other viruses, so it can be used to inhibit the replication of the coronavirus, the influenza virus and respiratory syncytial virus, flaviviridae virus, filoviridae virus and / or porcine epidemic diarrhea virus. The present invention is completed on this basis. Specifically, the present invention described a use of the nucleoside analogues of formula (I) and their compositions to combat viruses, for example, coronaviruses, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and / or swine epidemic diarrhea. Nucleoside analogues of formula (I) have an excellent inhibitory effect on the replication of SARSCoV-2 and other viruses, and have a good clinical application prospect. Terms As used herein, “active compound of the present invention”, “active ingredient of the present invention”, “nucleoside analog of the present invention” and “coronavirus replication-inhibiting active compound of the present invention” are used interchangeably and refer to nucleoside analogues having excellent inhibitory activity on coronavirus replication, including the compound of formula (I), or its pharmaceutically acceptable salts, or its solvates, or its prodrugs, or combinations thereof. As used herein, “formulation of the present invention” refers to a formulation containing the active compound of the invention. As used herein, the term “comprises” or variations thereof such as “comprises” or “comprising,” etc. It is understood that it includes said elements or components without excluding other elements or other components. As used herein, the term “novel coronavirus,” “2019-nCoV,” or “SARS-CoV-2” may be used interchangeably. 2019-nCoV is the seventh coronavirus known to infect people and cause novel coronavirus pneumonia (COVID-19), which is one of the serious infectious diseases threatening human health worldwide. As used herein, “halogen” generally refers to fluorine, chlorine, bromine and iodine; preferably fluorine, chlorine or bromine; more preferably fluorine or chlorine. As used herein, the terms “Cn-Cm” and “Cn-m” can be used interchangeably and mean having n to m carbon atoms. As used herein, the term "C1-C6 alkyl" refers to the straight or branched saturated hydrocarbon group containing 1-6 carbon atoms, for example, methyl, ethyl, N-propyl, / sopropyl, N-butyl, / sobutyl, tert-butyl, sec-butyl, N-pentyl, 1-ethylpropyl, isopentyl, neopentyl, isohexyl, 3-methylpentyl or N-hexyl, preferably, methyl, ethyl, N-propyl, / 'sopropyl, butyl, / sobutyl or tert-butyl. Halogenated C1-C6 alkyl refers to the straight or branched saturated hydrocarbon group containing 1-6 carbon atoms substituted with one or more equal or different halogen atoms; for example, trifluoromethyl, fluoromethyl, difluoromethyl, chloromethyl, bromomethyl, dichlorofluoromethyl, chloroethyl, bromopropyl, 2-chlorobutyl or pentafluoroethyl, and the like. C1-C6 alkoxy refers to straight or branched alkoxy containing 1-6 carbon atoms; for example, methoxy, ethoxy, N-propoxy, isopropoxy, N-butoxy, / sobutoxy, tert-butoxy, sec-butoxy, N-pentyloxy, / 'sopentyloxy, neopentyloxy, / sohexyloxy, 3-methylpentyloxy or N-hexyloxy and the like; preferably methoxy, ethoxy, N-propoxy, / sopropoxy, N-butoxy, / sobutoxy or tert-butoxy; Ci-Ce alkanoyl refers to straight or branched alkanoyl containing 1-6 carbon atoms, for example, formyl, acetyl, propionyl, butyryl, / sobutyryl, valeroyl, tert-butyryl or hexanoyl and the like. Amino substituted with C1-6 alkyl means that the hydrogen atoms in the amino are substituted with one or more C1-C6 alkyl, for example, -NHCH3, -NfCHsja and the like. Amino substituted with C1-6 alkanoyl means that the hydrogen atoms on the amino are substituted with one or more C1-C6 alkyl, such as -NHCOCH3, -NHCOCH2CH3 and the like. C2-C6 alkenyl refers to a straight or branched saturated hydrocarbon group containing 1 -3 η / ζΓίη / ζζηζ / Ε / γίΛΐ double bonds and 2-6 carbon atoms, including both cis and trans configurations; for example, vinyl, 1-propenyl, 2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl , 2-pentenyl, 3-pentenyl, 4-pentenyl, 1,3-butadienyl, 1,3-pentadienyl, 1hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 3,3-dimethyl-1 -propenyl or 2-ethyl-1-propende, and the like. Cz-Ce alkynyl refers to a straight or branched alkynyl containing carbon atoms 2-6, for example, ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 2-pentynyl or 2-hexynyl and the like. C2-C6 alkenoxy refers to a straight or branched alkenoxy containing 1 -3 double bonds and 2-6 carbon atoms, for example, vinyloxy, 1-propenyloxy, 1-methyl-1-propenyloxy, 2-methyl-1- propenyloxy, 1pentenyloxy, 1,3-pentadienyloxy or 2-pentenyloxy, and the like. C2-C6 alkynyloxy refers to a straight or branched alkynyloxy containing carbon atoms 2-6, for example, ethinyloxy, 2-propynyloxy, 2-butynyloxy, 3-butynyloxy, 1-methyl-2-propynyloxy, 2-pentynyloxy, 2-pentynyloxy or 2-hexynyloxy, and the like. C1-20 alkanoyl amino means that one carbon atom of a linear or branched alkanoyl containing 1 to 20 carbon atoms is bonded to an amino; for example, -COCH2NH2, -COCH2CH2NH2 and the like. C1-6 alkylamino - C1-6 alkanoyl means that the nitrogen atom of amino substituted with C1-6 alkyl is bonded to a non-carbonyl carbon atom of a linear or branched alkanoyl containing 1 -6 carbon atoms, e.g. -COCH2NHCH3, -COCH2CH2NHCH2CH3 and the like. C1-6 alkoxy C1-6 alkyl means that the oxygen atom of a straight or branched alkoxy containing 1-6 carbon atoms is attached to a carbon atom of C1-6 alkyl, for example, -CH2OCH3, CH2CH2OCH2CH3 and the like . Amino C16 alkyl means that one carbon atom of a straight or branched alkyl containing 1-6 carbon atoms is attached to an amino; for example, -CH2NH2, -CH2CH2NH2, -CH(NH2)CHs, CH2CH2CH2NH2, or -CH2CH2CH2CH2NH2, and the like. Carbamoyl substituted with C1-6 alkyl means that the hydrogen atom in carbamoyl is substituted with one or two identical or different C1-C6 alkyl; for example -CONHMe, -CONHEt, CON(Me)Et, -C0NEt2, or -CONMe2, and the like. Hydroxy C16 alkyl means that one carbon atom of a straight or branched alkyl containing 1-6 carbon atoms is attached to a hydroxy; for example, -CH2OH, -CH2CH2OH, -CH(OH)CH3, CH2CH2CH2OH, -CH2CH2CH2CH2OH, or -CH2CH(CH3)CH2OH, and the like. C1-6 alkoxyamido means that the oxygen atom of a straight or branched alkoxy containing 1 -6 carbon atoms is attached to the carbonyl of an amido, for example, -NHCOOCH3, -NHCOOCH2CH3, and the like. C1-6 alkoxycarbonyl means that the oxygen atom of a straight or branched alkoxy containing 1-6 carbon atoms is attached to a carbonyl, such as -COOCH3, -COOCH2CH3, and the like. Coronavirus η / ζΓίη / ζζηζ / Ε / γίΛΐ Coronavirus (CoV) belongs to Coronaviridae of Nidovirales, which is an enveloped positive-strand RNA virus, and its subfamily includes four genera a, β, δ, and γ. Among the currently known infecting coronaviruses, HCoV-229E and HCoV-NL63 belong to the alpha genus coronavirus, and HCoV-OC43, SARS-CoV, HCoV-HKU1, MERS-CoV and SARS-CoV2 are beta genus coronaviruses. SARS-CoV-2 is also known as 2019-nCoV. The highly pathogenic coronavirus “severe acute respiratory syndrome” (SARS-CoV) and “Middle East respiratory syndrome” (MERS-CoV), which emerged in 2003 and 2012 respectively, belong to the beta coronavirus genus. The novel coronavirus (SARS-CoV-2) that emerged in late 2019 has approximately 80% similarity to SARS-CoV and 40% similarity to MERS-CoV, and also belongs to the beta coronavirus genus. The genome of this type of virus is a single-stranded positive-sense RNA, one of the RNA viruses that has the largest genome; encoding replicase, spike protein, envelope protein, envelope protein and nucleocapsid protein and the like. In the initial stage of virus replication, the genome is translated into two peptide chains with thousands of amino acids, namely the precursor polyprotein, and then the protease cuts the precursor protein to produce non-structural proteins (such as RNA polymerase and helicase) and structural proteins (such as spike protein) and accessory protein. influenza virus The influenza virus is known as influenza virus for short. Common influenza viruses are divided into types A, B, C and D. Influenza virus can cause infection and morbidity in many types of animals, such as humans, birds, pigs, horses, bats and the like, and is the pathogen of human and animal diseases, such as human influenza, avian influenza, swine influenza and equine influenza. Clinical symptoms caused by the influenza virus include acute high fever, general pain, significant fatigue, and respiratory symptoms. Human influenza is mainly caused by influenza A virus and influenza B virus. Influenza A virus often undergoes antigenic variation, which can be divided into Η1Ν1, H3N2, H5N1, H7N9 and other subtypes. Respiratory syncytial virus Respiratory syncytial virus (RSV, syncytial virus for short, also belongs to Paramyxoviridae) is the most common pathogen causing viral pneumonia in children and can cause interstitial pneumonia. RSV is similar to parainfluenza virus and its viral particle size is about 150 nm slightly smaller than parainfluenza virus and it is an RNA virus. Flaviviridae Virus Flaviviridae viruses are a kind of RNA viruses that mainly infect mammals, including three genera of viruses, namely flavivirus, pestivirus and hepatitis C. Dengue fever virus (DENV) and Zika virus (Zika) belong to flaviviruses and are transmitted by mosquitoes. Dengue virus infection can cause obvious symptoms of fever and pain, and serious symptoms of dengue fever are headache, nausea, vomiting, loss of consciousness, and even collapse. The symptoms of Zika virus (Zika) infection are similar to those of dengue fever and are usually mild. Hepatitis C virus (HCV) belongs to Hepacivirus, which is the pathogen of chronic hepatitis C and can cause liver cirrhosis and liver cancer. Filoviridae Virus Filoviridae currently includes three genera, namely Ebola virus, Marburg virus, and Quiva virus. Both Marburg virus and Ebola virus can cause severe hemorrhagic fever. After infection, people will show high fever and bleeding symptoms, leading to a state of collapse, organ failure, and even death. Porcine epidemic diarrhea virus (PEDV) Porcine epidemic diarrhea virus (PEDV) belongs to the Coronaviridae coronaviruses. Porcine epidemic diarrhea is an acute intestinal infectious disease in piglets and fattening pigs caused by the PEDV virus. The PEDV virus directly enters the small intestine after oral and nasal infection. PEDV virus replication can take place in the cytoplasm of the villous epithelium of the small intestine and colon. PEDV can cause diarrhea belonging to osmotic diarrhea. Dehydration caused by severe diarrhea is the main cause of death of sick pigs. Active compounds and active ingredients of the present invention In the present invention, it provides active ingredients capable of effectively inhibiting the replication of coronavirus, influenza virus, respiratory syncytial virus and / or porcine epidemic diarrhea virus (PEDV), especially the 2019 novel coronavirus (SARS-CoV- 2). In the present invention, the active ingredients are selected from nucleoside analogues of formula (I) according to the first aspect of the present invention, or the pharmaceutically acceptable salts thereof or the prodrug thereof, or the combination thereof. , or the crystal thereof or the solvate thereof. Preferred nucleoside analogs have the structure of the compounds prepared in the examples, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or combinations thereof, or crystals thereof, or solvates thereof, in particular any of compounds A1 to A221, or the combination thereof. In another preferred embodiment, the compound of formula (I) is selected from the group consisting of Compound A1, A5, A6, A8, A9, A10, A11, A12, A13, A14, A28, A30, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A49, A50, A51, A52, A53, A54, A55, A57, A58, A63, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A84, A86, A87, A88, A89, A91, A95, A97, A99, A101, A102, A105, A106, A107, A108, A109, A110, A111, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136,A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152,A153, A154, A155, A156, A157, A158, A159, A160, A161, A162, A163, A164, A165, A166, A167, A168, A1 69, A170, A171, A172, A173, A174, A175, A176, A177, A178, A179, A180, A181, A182, A183, A184,A185, A186, A187, A188, A189, A190, A191, A192, A193, A194, A195, A196, A197, A198, A199, A200,A201, η / ζΓίη / ζζηζ / Ε / γίΛΐ Α202, Α203, Α204, Α205, Α206, Α207, Α208, Α209, Α210, Α211, Α212, Α213, Α214, Α215, Α216, Α217, Α218, 19, Α220, Α221, or the combination thereof. Experiments show that the active ingredients of the present invention can effectively inhibit the replication of the 2019 novel coronavirus (SARS-CoV-2), thereby preventing, treating and / or alleviating SARS-CoV-2-related diseases. As used herein, “active compounds of the present invention” and “virus replication-inhibiting active compounds of the present invention” are used interchangeably and refer to compounds that have excellent virus replication-inhibiting activity. , including nucleoside analogues of formula (I), or their pharmaceutically acceptable salts, or their crystals, or their solvates. It should be understood that the active ingredients of the present invention include compounds of formula (I), or pharmaceutically acceptable salts, enantiomers, diastereomers or clusters thereof, or prodrugs thereof. It should be understood that the active ingredients of the present invention also include crystalline forms, amorphous compounds, deuterated compounds and the like of the active compounds of the present invention. The "pharmaceutically acceptable salt" is a conventional non-toxic salt formed by the reaction of the active compound of the present invention with an inorganic acid or an organic acid. For example, conventional non-toxic salts can be prepared by reacting the active compound of the present invention with inorganic acids or organic acids. Inorganic acid includes hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, aminosulfonic acid and phosphoric acid and the like, and organic acid includes citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, benzenesulfonic acid, p acid -toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthaleneddisulfonic acid, maleic acid, malic acid, malonic acid, fumaric acid, succinic acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid, pamoic acid, hydroxymaleic acid, phenylacetic acid , benzoic acid, salicylic acid, glutamic acid, ascorbic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid and isethionic acid, and the like; or the esters formed by the active compound of the present invention with propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, aspartic acid or glutamic acid, and Asters also form sodium salt, zinc salt, potassium salt, calcium salt, aluminum salt or ammonium salt with inorganic base; or the esters formed by the active compound of the present invention with lysine, arginine, ornithine, and the esters further form the corresponding inorganic acid salt with hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid or phosphoric acid or form also the corresponding salts of organic acids with formic acid, acetic acid, picric acid, methanesulfonic acid or ethanesulfonic acid; or 1-4 phosphate groups in the molecule of the active compound of the present invention form salts with 1-4 molecules of organic amines, including, but not limited to, trimethylamine monophosphate salt, triethylamine monophosphate salt, tri-n salt -butylamine monophosphate, triphosphate salt trimethylamine salt, triethylamine triphosphate salt, tri-n-butylamine triphosphate salt. η / ζΓίη / ζζηζ / Ε / γίΛΐ Furthermore, the active ingredient of the present invention is particularly suitable for use with other antiviral drugs or anti-coronavirus drugs. Other representative antiviral drugs or anti-coronavirus drugs include (but are not limited to): interferon, RNA-dependent RNA polymerase inhibitor (e.g., Remdesivir (GS-5734), favipiravir, Galidesivir, GS-441524, NHC, EIDD2801), 3CL protease inhibitor (e.g., GC-376), lopinavir, ritonavir, nelfinavir; Chloroquine (Sigma-06628), hydroxychloroquine, cyclosporine, carrimycin, baicalin, baicalein, forsythoside, chlorogenic acid, emodin, mycophenolic acid, mycophenolate mofetil, naphthoquine, ciclesonide, ribavirin, penciclovir, leflunomide, teriflunomide, nafamostat, nitazoxanide, darunavir, arbidol , Camostat, niclosamide, baricitinib, ruxolitinib, dasatinib, saquinavir, beclabuvir, simeprevir, palivizumab, motavizumab, RSV-IGIV(RespiGam®), MEDI-557, A-60444 (RSV-604), MDT-637, BMS-433771, or pharmaceutically acceptable salts thereof, or the combination thereof. Interferon comprises one or more of the following: interferon a-2a, interferon a-2b, interferon a-n1, interferon a-n3, interferon β1a and interferon β-1 b. Additional active therapeutic agents may also be used to treat respiratory symptoms and sequelae of infection in combination with compounds of formula (I). Other agents are preferably administered orally or by direct inhalation. For example, other preferred additional therapeutic agents used in combination with compounds of formula (I) for the treatment of respiratory tract infections include, but are not limited to, bronchodilators and corticosteroids. Glucocorticoids, first introduced as therapies for asthma in 1950 (Carryer, Journal of Allergy, 21, 282-287, 1950), remain the most effective and consistently effective therapies for the disease, but their mechanisms of action are not clear. know completely (Morris, J Allergy Clin. Immunol., 75(1 Pt)1-13, 1985). Unfortunately, oral glucocorticoid therapy is associated with long-range undesirable side effects, such as concentric obesity, hypertension, glaucoma, glucose intolerance, accelerated cataract formation, bone mineral loss, and psychological effects, all of which limit their use as agents. long-term therapeutics. (Goodman and Gilman, 10th edition, 2001). The solution against systemic side effects is to administer steroids directly to the inflammatory sites. Inhaled corticosteroids (ICS) have been developed to relieve the serious side effects of oral steroids. Non-limiting examples of corticosteroids that can be used in combination with compounds of formula (I) are dexamethasone, dexamethasone sodium phosphate, fluorometholone, fluorometholone acetate, loteprednol, loteprednol etabonate, hydrocortisone, prednisolone, fludrocortisone, triamcinolone, triamcinolone acetonide, betamethasone , beclomethasone dipropionate, methylprednisolone, fluocinolone, fluocinolone acetonide, flunisolide, fluoctin-21-butylate, flumetasone, flumetasone pivalate, budesonide, halobetasol propionate, mometasone furoate, fluticasone propionate and ciclesonide; or the pharmaceutically acceptable salt thereof. η / ζΓίη / ζζηζ / Ε / γίΛΐ Other anti-inflammatory agents that act through an anti-inflammatory cascade mechanism may also be used as additional therapeutic agents in combination with compounds of formula (I) for the treatment of viral respiratory infections. The use of “anti-inflammatory signal transduction modulators” (referred to as AISTM in this document), phosphodiesterase inhibitors such as (for example, specific for PDE-4, PDE-5 or PDE-7), transcription factor inhibitors ( for example, blocking NF kB through inhibition of IKK) or kinase inhibitors (for example, blocking P38MAP, JNK, PI3K, EGFR or Syk), is a logical way to cut off inflammation, because the targets of these small molecules are the limited number of common intracellular pathways, those signal transduction pathways that are key points of anti-inflammatory therapeutic interventions (see, review by P.J. Barnes, 2006). These additional non-limiting therapeutic agents include 5-(2,4difluorophenoxy)-1-isobutyl-1 H-indazole-6-carboxylic acid (2-dimethylamino-ethyl)-amide (Map kinase inhibitor P38 ARRY-797); 3-cyclopropylmethoxy-N-(3,5-dichloro-pyridin-4-yl)-4-difluoromethoxy-benzamide (PDE-4 inhibitor, Roflumilast) ; 4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenyl-ethyl]-pyridino (PDE-4 inhibitor, CDP-840); N-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)-8-[(methylsulfonyl)amino]-1-dibenzofuranamide (PDE-4 inhibitor, Omester); N-(3,5-dichloro-pyridin-4-yl)-2-[1 -(4-fluorobenzyl)-5-hydroxyl-1 H-indol-3-yl]-2-oxo-acetamide ( PDE-4 inhibitor, AWD12-281); 8-methoxy-2-trifluoromethyl-quinoline-5-carboxylic acid (3,5-dichloro-1-oxypyridin-4-yl)-amide (PDE-4 inhibitor, Sch351591); 4-[5-(4-fluorophenyl)-2-(4-methylsulfinyl-phenyl)-1 H-imidazol-4yl]-pyridino (P38 inhibitor, SB-203850); 4-[4-(4-fluorophenyl)-1 -(3-phenyl-propyl)-5-pyridin-4-yl-1 H-imidazol-2-yl]butan-3-yn-1-ol (P38 inhibitor , RWJ-67657); 2-diethylamino-ethyl 4-cyano-4-(3-cyclopentyloxy-4-methoxy-phenyl)cyclohexanecarboxylate (a 2-diethyl-ethyl carboxylate prodrug of Cilomilast, PDE-4 inhibitor); (3chloro-4-fluorophenyl)-[7-methoxy¡-6-(3-morpholin-4-yl-propoxy¡)-quinazolin-4-yl]-amine (Gefitinib, EGFR inhibitor); and 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (Imatinib, inhibitor EGFR). Bronchodilator combinations that include inhaled p2-adrenergic agonists, such as formoterol, salbutamol or salmeterol, and compounds of formula (I) are also suitable, but not limiting, combinations for use in the treatment of respiratory viral infections. Combinations of inhaled β 2-adrenergic agonist bronchodilators, such as formoterol or salmeterol, and ICS are also used to treat both bronchial stenosis and inflammation. Combinations of these ICS and 32-adrenergic agonists together with compounds of formula (I) are suitable, but not additional limiting combinations for use in the treatment of respiratory viral infections. Anticholinergic agents have potential use in treating or preventing pulmonary bronchial stenosis, so they can be used as additional therapeutic agents in combination with compounds of formula (I) for the treatment of viral respiratory infections. These anticholinergic agents include, but are not limited to, muscarinic receptor antagonists (particularly of the M3 subtype) that have shown therapeutic efficacy in humans for the control of cholinergic properties in COPD (Witek, 1999); 1-{4-hydroxy-1-[3,3,3-tris-(4-fluorophenyl)-propioniI]pyrrolidino-2-carbonyl}-pyrrolidino-2-carboxylic acid (1-methyl-piperidin-4-ylmethyl) -amída; 3-[3-(2-diethylaminoacetoxy¡)-2-phenyl-prop¡onyloxy¡]-8-¡sopropyl-8-methyl-8-azonia-bicyclo[3.2.1]octane (N, N ester -diethylglycine or ipratropium salt); 1-aza-bicyclo[2.2.2]oct-3-ylde 1-cyclohexyl-3,4-dihydro-1 H-isoquinoline-2carboxylic acid ester (Solifenacin); 2-hydroxymethyl-4-methylsulfinyl-2-phenylbutyric acid ester 1-aza-bicyclo[2.2.2]octiv ze Ln / zznz / E / YiAi 3-yl (Revatropate); 2-{1-[2-(2,3-dihydro-benzofuran-5-yl)-ethyl]-pyrrolidin-3-yl}-2,2-diphenyl-acetamide (Darifenacin); 4-azacycloheptane-1-yl-2,2-diphenyl-butyramide (Buzepida); 7-[3-(2-diethylamine-acetoxy)-2-phenylpropion¡lox¡]-9-ethyl-9-methyl-3-oxa-9-azcat¡on-tric¡clo [3.3.1.02,4]nonane (Ν,Ν-diethylglycine ester or Oxitropium salt); 7-[2-(2-diethylamino-acetoxy)-2,2-dithiophen-2-l-acetoxy]-9,9-dimethyl-3-oxa-9- azcatontricyclo[3.3.1.02,4]nonane (Ν,Ν-diethylglycine ester or Tiotropium Bromide salt); 2-(3-diisopropylamine1-phenyl-propyl)-4-methyl-phenyl dimethylaminoacetate (N, N-dimethylglycine ester or tolterodine salt); 3-[4,4-bis-(4fluorophenyl)-2-oxo-imidazolin-1 -yl]-1 -methyl-1 -(2-oxo-2-pyridin-2-yl-ethyl)-pyrrolidinium; 1 -[1 -(3-fl uoro-benzyl)p¡perid¡n-4-¡l]-4,4-b¡s-(4-fluoro-phen¡l)-¡m¡dazol¡d¡ n-2-one; 1-cyclooctyl-3-(3-methoxy¡-1-aza-bicyclo[2.2.2]oct-3yl)-1-phenyl-propan-2-yn-1 -ol; 3-[2-(2-diethylamino-acetoxy)-2,2-dithiophen-2-l-acetoxy]-1 -(3-phenoxy-propy I) -1 azcation- bicyclo[2.2.2]octane (N, N-dietiIgIicin ester or aclidinium bromide salt); or (2-diethylamino-acetoxy)-di-thiophen-2-yl-acetic acid 1-methyl-1-(2-phenoxy-ethyl)-piperidin-4-yl ester. In addition, due to SARS-CoV-2 infection, it can cause acute lung injury, and the active ingredient of the present invention is particularly suitable for use in combination with drugs that have the effect of improving acute lung injury. Representative drugs include, but are not limited to, zinc, fingolimod, vitamin C, olmesartan medoxomil, valsartan, losartan, thalidomide, glycyrrhizic acid, artemisinin, dihydroartemisinin, artesunate, artemisone, azithromycin, escin, naproxen or the combination thereof. Zinc includes, but is not limited to, zinc sulfate, zinc glycyrrhate, and zinc gluconate. The active ingredient of the present invention can inhibit the infection activity of novel coronaviruses such as SARS-CoV-2. Therefore, when the active ingredient of the present invention is administered or dosed, the infection of the 2019 novel coronavirus (SARS-CoV-2) can be inhibited and then achieve an antiviral effect. The compounds of formula (I) can also be combined with mucolytic agents to treat both infection and symptoms of respiratory tract infection. A non-limiting example of a mucolytic drug is ambroxol. Similarly, the compounds of formula (I) can also be combined with expectorants to treat both infection and symptoms of respiratory tract infection. A non-limiting example of an expectorant is guaifenesin. Atomized hypertonic saline is used to improve immediate and long-term clearance of small airways in patients with lung disease (Kuzik, J. Pediatrics 2007, 266). The compounds of formula (I) can also be combined with atomized hypertonic saline, especially when paramyxoviridae virus infection is complicated by bronchiolitis. The combination of compounds of formula (I) and hypertonic saline may also include any of the additional agents discussed above. In a preferred aspect, 3% atomized hypertonic saline is used. It is also possible to combine any of the compounds of the present invention with one or more additional active therapeutic agents in a unit dosage form for simultaneous or sequential administration to a patient. Combination therapy can be administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations. Coadministration of a compound of the present invention with one or more additional active therapeutic agents generally means simultaneous or sequential administration of the compound of the present invention with one or more additional active therapeutic agents, therefore, therapeutically effective amounts of the compound of the present invention. the present invention, and one or more additional active therapeutic agents are present in the patient. Coadministration includes administering a unit dose of a compound of the present invention before or after administering a unit dose of one or more additional active therapeutic agents, for example, administering the compound of the present invention within several seconds, minutes or hours of the administration of one or more additional active therapeutic agents. For example, a unit dose of the compounds of the present invention may be administered first, followed by a unit dose of one or more additional active therapeutic agents within seconds or minutes. Alternatively, a unit dose of one or more other therapeutic agents may be administered first, followed by a unit dose of the compound of the present invention within seconds or minutes. In some cases, it may be necessary to first administer a unit dose of the compound of the present invention, followed by a unit dose of one or more additional active therapeutic agents after a period of several hours (e.g., 1-12 hours). In other cases, it may be necessary for a unit dose of one or more additional active therapeutic agents to be administered first, followed by a unit dose of the compound of the present invention after a period of several hours (e.g., 1-12 hours). . Combination therapy can provide “synergism” and “synergistic effect”, that is, the effect when the active ingredients are used together is greater than the sum of the effects when the compounds are used separately. The synergistic effect can be achieved when the active ingredients: (1) are formulated together and administered or delivered simultaneously in the form of combination formulations; (2) administered alternatively or delivered in parallel as separate formulations; or (3) delivered through other administration regimes. Synergistic effects can be achieved when administered in alternative therapy, when the compounds are administered or administered in turn, such as in separate tablets, pills or capsules, or by different injections using separate syringes. Typically, during alternative therapy, the effective amount of each active ingredient is administered sequentially, that is, continuously, while in combination treatments, two or more active ingredients of an effective dose are administered together. Synergistic antiviral effect means an antiviral effect greater than the intended pure cumulative effect of the individual compounds in the combination. In yet another embodiment, a method of inhibiting viral RNA polymerase in a cell is provided, comprising exposing a virus-infected cell to an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate and / or prodrug ( for example, ester) thereof, thus inhibiting the viral RNA polymerase. In yet another embodiment, a method for inhibiting viral RNA polymerase in a cell is provided, η / ζΓίη / ζζηζ / Ε / γίΛΐ comprising exposing a virus-infected cell to an effective amount of a compound of formula (I) or a salt. , solvate and / or pharmaceutically acceptable prodrug (e.g., ester) thereof, and at least one additional active therapeutic agent, thereby inhibiting viral RNA polymerase. In yet another embodiment, a method of inhibiting viral RNA polymerase in a cell is provided, comprising exposing a virus-infected cell to an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate and / or prodrug ( for example, ester) thereof, and at least one additional selected active therapeutic agent. In yet another embodiment, it provides a method of treating respiratory viral infections in humans or other mammals, comprising administering an effective amount of the compound of formula (I) or one of its pharmaceutically acceptable salts, solvates and / or prodrugs (e.g., esters ) for humans or other mammals. In yet another embodiment, it provides a method of treating respiratory viral infections in humans or other mammals, comprising administering an effective amount of the compound of formula (I) or one of its salts, solvates and / or prodrugs (e.g., esters) pharmaceutically. acceptable, and at least one additional active therapeutic agent, thus inhibiting the viral RNA polymerase. In yet another embodiment, it provides a method of treating respiratory viral infections in humans or other mammals, comprising administering an effective amount of the compound of formula (I) or one of its salts, solvates and / or prodrugs (e.g., esters) pharmaceutically. acceptable, and at least one additional active therapeutic agent. Pharmaceutical Compositions and Applications The present invention also provides the use of a mixture of one or more active compounds of the present invention for inhibiting virus replication, or a pharmaceutically acceptable salt thereof, or prodrugs thereof, as an active ingredient for preparing, treating and / or prevent, alleviate respiratory diseases, infections, pneumonia and other related diseases caused by infection with viruses such as coronavirus, influenza virus, respiratory syncytial virus and / or porcine epidemic diarrhea virus (PEDV) (especially 2019-nCoV ). The pharmaceutical compositions provided by the invention preferably contain the active ingredient in a weight ratio of 0.001-99% by weight. Their preferred ratio was that the active compounds of the present invention as active ingredient accounted for 0.1% by weight to 90% by weight or 1% by weight to 50% by weight of the total weight, and the rest are vehicles, diluents or pharmaceutically acceptable solutions or solutions or saline solution. When necessary, one or more pharmaceutically acceptable carriers may be added to the medicament of the invention. The carriers comprise diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorption carriers, lubricants and the like conventional in the pharmaceutical field. The pharmaceutical compounds and compositions provided by the invention may be in various forms, such as tablets, capsules, powders, syrups, solutions, suspensions and aerosols, etc., and may be stored in a suitable solid or liquid vehicle or dilute and in a storage device. η / ζΓίη / ζζηζ / Ε / γίΛΐ disinfection for injection or drip infusion. Various dosage forms of the pharmaceutical compositions of the invention can be prepared according to conventional preparation methods in the pharmaceutical field. The unit dose of the formulation generally contains 0.05 to 1000 mg of the active compounds of the present invention. Preferably, the unit dose of the formulation contains 1-500 mg of the active compounds of the present invention. The compounds and pharmaceutical compositions of the invention can be used clinically in mammals, including humans and animals, and can be administered through the mouth, nose, skin, lungs or gastrointestinal tract. The most preferred is through the mouth. The most preferred daily dose is 0.01 to 400 mg / kg body weight, single administration, or 0.01 to 200 mg / kg body weight in divided doses. Regardless of any method of administration, the optimal dosage for an individual must be determined based on the specific treatment. Typically, start with a small dose and gradually increase the dose until you find the most suitable dose. The drugs or inhibitors of the present invention can be administered in several different ways, such as introduced into the body such as muscular, intradermal, subcutaneous, venous or mucosal tissues by injection, spray, nasal, eye drops, osmosis, absorption , physically or chemically mediated methods; or be mixed or enveloped by other substances and introduced into the body. Typically, the active ingredient of the present invention or pharmaceutical compositions containing it can be administered in unit dosage form. The administration routes may be intestinal or parenteral administration, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eye, lung and respiratory tract, skin, vagina, rectum and the like. The administration dosage form may be a liquid dosage form, a solid dosage form, or a semi-solid dosage form. The liquid dosage form may be solutions (including true solutions and colloidal solutions), emulsions (including O / W type, W / O type and multiple emulsion), suspensions, injections (including water injection, powder injection and infusions), eye drops, nasal drops, lotions and liniments, and the like; The solid dosage form may be tablets (including ordinary tablets, enteric-coated tablets, buccal tablets, dispersible tablets, chewable tablets, effervescent tablets and orally disintegrating tablets), capsules (including hard capsules, soft capsules and enteric-coated capsules). , granules, powders, dolites, tablets, suppositories, films, patches, aerosols (powders for inhalation), sprays, and the like; Semisolid dosage forms may be ointments, gels, poultices, and the like. The active ingredient of the invention can be converted into a common preparation, it can also be converted into a sustained release preparation, a controlled release preparation, a targeted preparation and various microparticulate drug delivery systems. To convert the active ingredient of the invention into tablets, generally various excipients known in the art can be used, including diluents, binders, wetting agents, disintegrants, lubricants and glidants. The diluents may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, and the like; wetting agents may be water, ethanol, isopropanol, and the like; The binders may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, Arabica mucilage slurry, gelatin slurry, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, ethylcellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, and the like. ; disintegrants may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfonate and the like; Lubricants and glidants may be talcum powder, silica, stearate, tartaric acid, liquid paraffin, polyethylene glycol, and the like. The tablets can also be made into coating tablets, sugar-coated tablets such as, film-coated tablets, enteric-coated tablets or double-layered tablets and multi-layered tablets. To convert the administration unit into a capsule, the active ingredient of the present invention can be mixed with diluents, glidants; and the mixture is placed directly into a hard capsule or soft capsule. The active ingredients can also be prepared into pellets or granules with diluents, binders and disintegrants first, and then put into hard capsules or soft capsules. The type of each of the diluents, binders, wetting agents, disintegrants and glidants used to prepare the tablets of the invention can also be used to prepare the capsules of the invention. To prepare the active ingredient of the invention in an injection, water, ethanol, isopropanol, propylene glycol or their mixture can be used as a solvent, and an appropriate amount of solubilizer, cosolvent, pH modulator and osmotic pressure modulator can be added, which is common in the technique. Solubilizers or cosolvents can be poloxamer, lecithin, hydroxypropyl-p-cyclodextrin; pH modulator can be phosphate, acetate, hydrochloric acid, sodium hydroxide, and the like; Osmotic pressure modulator may be sodium chloride, mannitol, glucose, phosphate, acetate, and the like. For example, mannitol and glucose and the like can be further added as supporting agents to prepare the injection of lyophilized powder. Additionally, if necessary, colorants, preservatives, spices, flavorings or other additives can be added to pharmaceutical formulations. The active ingredient or composition of the present invention can be taken alone or in combination with other therapeutic or symptomatic drugs. When the active ingredient of the present invention has a synergistic effect with other therapeutic drugs, the dosage should be adjusted according to the actual situation. The main advantages of the present invention include: (a) The active compounds of the present invention can effectively inhibit the replication of SARS-CoV-2, human respiratory syncytial virus (RSV), human coronavirus OC43 (HCoV OC43), IV 7Γ ίη / ΖΖΩΖ / Ε / ΥΙΛΙ porcine epidemic diarrhea virus (PEDV), Zika virus (Zika), dengue fever virus (DENV) and other viruses with a low ECso value and broad antiviral characteristics spectrum. (b) The active compounds of the present invention have low toxic side effects (cytotoxicity CC50 > 10 μΜ), and have good medicinal properties which suggest that the nucleoside analogues of the present invention have good medicinal prospects in the field of treatment of viral disease, infectious diseases, especially the fight against new coronavirus pneumonia. The present invention is further described below in combination with specific embodiments. It should be understood that these examples are used solely to illustrate and not to limit the scope of the invention. The experimental methods without specific conditions in the following examples generally follow the conventional conditions or the conditions suggested by the manufacturer. Unless otherwise noted, percentages and parts are by weight. Preparation Example 1: Synthesis of Compound A1 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 1 -1 was synthesized by the method described in the literature (Nature. 2016, 531,381 385). Compound 1-1 (1.5 g, 2.67 mmol) was added to acetonitrile (30 ml), followed by the addition of 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate ) (Selectfluor, 1.13 g, 3.2 mmol, 1.2 eq) and sodium bicarbonate (0.67 g, 8.0 mmol, 3 eq). Once the addition was complete, the reaction was brought to room temperature for 3-4 hours. TLC showed that the reaction was complete. The reaction solution was added to water (120 ml) and extracted with ethyl acetate. The organic layer was separated, dried, concentrated and separated by silica gel column chromatography to give Compound 1-2 as an off-white solid (0.43 g, 28% yield). 1H NMR (500 MHz , DMSO-cfe) δ 8.12 (brs, 1H), 7.87 (s, 1H), 7.50 - 7.20 (m, 16H), 6.59 (s, 1H), 4.92 (d, J = 11.7 Hz, 1H), 4.85 - 4.78 (m, 2H), 4.57 4.46 (m, 4H), 4.42 - 4.35 (m, 1H) , 4.12 (t, J = 5.7 Hz, 1H), 3.73 (dd, J = 11.2, 3.2 Hz, 1H), 3.60 (dd, J = 11.2, 4 ,3Hz, 1H). Compound 1-2 (0.25 g, 0.43 mmol) was added to dichloromethane (10 ml), cooled to -60 °C and 1 M boron tribromide in dichloromethane (1.72 ml) was added dropwise. , 1.72 mmol, 4.0 eq). After addition, the mixture was naturally heated to −40 °C and stirred for 2 h at the same temperature. The reaction was monitored by TLC until completion. After cooling to -60 °C, methanol (0.2 ml) and triethylamine (0.52 g, 5.16 mmol, 12 eq) were successively added dropwise. After addition, the solvent was removed by evaporation to obtain a yellow solid. The solid was added to methanol (2 ml) and ethyl acetate (10 ml), stirred and then filtered to remove white insoluble substances. The filtrate was concentrated and separated on preparative TLC plates to give Compound A1 as an off-white solid (49 mg, 37% yield).1H NMR (500 MHz, DMSO-ok) δ 8.11 (brs, 1H) , 7.88 (s, 1H), 7.41 (brs, 1H), 6.80 (s, 1H), 6.23 (d, J= 6.1 Hz, 1H), 5.20 (d, J= 5.7 Hz, 1H ), 4.93 (t, J= 5.7 Hz, 1H), 4.54 (t, J = 5.5 Hz, 1H), 4.08 - 4.01 (m, 1H), 3.96 - 3.90 (m, 1H), 3.71 - 3.64 (m, 1H), 3.55 - 3.48 (m, 1H). MS m / z = 310.1 [M + 1]+. Preparation Example 2: Synthesis of Compound A2 η / ζΓίη / ζζηζ / Ε / γίΛΐ 2-1 Α2 Compound 2-1 was synthesized according to the method described in the literature (Nature. 2016, 531, 381385). Compound 2-1 (291 mg, 1.0 mmol) was added to N,N-dimethylformamide (5 ml), then to N-chlorosuccinimide (245 mg, 1.1 mmol, 1.1 eq) and trifluoroacetic acid ( 24 mg, 0.2 mmol, 0.2 eq.) were added and reacted at 50 °C for 1 hour. TLC showed that the reaction was complete. The reaction solution was added to the mixed solution of sodium sulfite and sodium carbonate and filtered to obtain Compound A2 as a white solid (185 mg, 57% yield).1H NMR (500 MHz, DMSO-cfe) δ 8.26 (brs, 1H), 7.95 (s, 1H), 7.09 (brs, 1H), 6.98 (s, 1H), 6.23 (d, J= 5.7 Hz, 1H), 5.18 (d, J = 5.6 Hz, 1H), 4.92 (t, J = 5.6 Hz, 1H), 4.52 (t, J = 5.0 Hz, 1H ), 4.06 - 4.00 (m, 1H), 3.96 - 3.88 (m, 1H), 3.69 - 3.61 (m, 1H), 3.54 - 3.45 ( m, 1H). MS m / z = 326.0 [M + 1 ]+. Α3 2-1 Compound 2-1 (291 mg, 1.0 mmol) was added to N,N-dimethylformamide (5 ml), then N-iodosuccinimide (245 mg, 1.1 mmol, 1.1 eq) and trifluoroacetic acid were added. (24 mg, 0.2 mmol) and reacted at 50 °C for 1 hour. TLC showed that the reaction was complete. The reaction solution was added to the mixed solution of sodium sulfite and sodium carbonate and filtered to obtain Compound A3 as a white solid (200 mg, 48% yield).1H NMR (500 MHz, DMSO-cfc) δ 7.98 (s, 1H), 7.12 (s, 1H), 6.21 (brs, 1H), 5.20 (brs, 1H), 4.91 (s, 1H), 4.52 ( d, J= 4.6 Hz, 1H), 4.11 -3.99 (m, 1H), 3.97 - 3.85 (m, 1H), 3.64 (d, J = 11.3 Hz , 1H), 3.49 (d, J= 10.9 Hz, 1H). MS m / z = 418.0 [M + 1]+. Preparation Example 4: Synthesis of Compound A4 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 1-1 (350 mg, 0.62 mmol) was added to an 80% aqueous acetic acid solution (10 ml) and cooled to 0 °C. Sodium nitrite (856 mg, 12.4 mmol, 20 eq) was added in portions. After addition, the temperature was maintained for 5 minutes. The mixture was stirred at room temperature for 30 min, then gradually heated to 90 °C and stirred for 4 h at the same temperature. The TLC showed that the conversion of raw materials had been completed. Water (5 ml) and toluene (15 ml) were added and the organic phase was separated. The aqueous layer was extracted again with toluene. The organic phases were combined. The organic phase was washed with water, aqueous sodium bicarbonate solution and saline successively, then dried, concentrated and separated by silica gel column chromatography to give Compound 4-1 as a yellow solid foam. clear (345 mg). Under nitrogen protection, the product 4-1 obtained from the previous step was dissolved in dichloromethane (3 ml), cooled to -35 °C and 1 M boron trichloride in dichloromethane (2.1 ml, 2.1 mmol). The addition was completed in approximately 10 minutes. The mixture was stirred at the same temperature for 15 minutes and methanol (0.3 ml) was slowly added. After addition, the temperature was maintained for 20 minutes, then the reaction solution was concentrated, followed by the addition of N-heptane (5 ml) and stirred at room temperature for 1 hour. The mixture was filtered and the filter cake was washed with a small amount of N-heptane to give a yellow solid (255 mg). The solid was refluxed in methanol (0.75 ml) and water (0.1 ml) for 30 minutes. Activated carbon (12 mg) was added, the mixture was filtered and the filter residue was washed with a small amount of methanol. The filtrate was evaporated until dry. A small amount of ethyl acetate was added, the resulting solid was suspended and filtered to obtain Compound A4 as a light yellow solid (85 mg, 44% yield).1H NMR (500 MHz, DMSO-ob) δ 11, 91 (d, J=4.1 Hz, 1H), 7.98 (d, J= 4.1 Hz,1H),6.91 (d, J= 4.4 Hz, 1 H), 6.81 (d, J= 4.4 Hz, 1H), 6.14 (brs, 1H), 5.22 (brs, 1H), 4.55 (d, J= 5.1 Hz, 1H), 4.06 -4.03 (m, 1H), 3.95 (t, J= 5.4 Hz, 1 H), 3.62 (dd, J = 12.2, 3.4 Hz, 1 H), 3, 49 (dd, J = 12.2, 4.6 Hz, 1 H). MS m / z = 293.0 [M + 1]+, m / z = 291.0 [M - 1] , Preparation Example 5: Synthesis of Compound A9 Compound 1-1 (561 mg, 1.0 mmol) was dissolved in N,N-dimethylformamide (5 ml), iodine (508 mg, 2 mmol, 2 eq) was added portionwise and reacted at temperature atmosphere during the night. The TLC showed that the starting material remained. The reaction solution was added to the mixed solution of sodium sulfite and sodium carbonate and extracted with ethyl acetate. The organic phase was separated and washed with water and saturated saline successively, dried over anhydrous sodium sulfate and separated by silica gel column chromatography to give Compound 9-1 as a white solid (400 mg, 58 % efficiency).1H NMR (500 MHz, DMSO-cfe) δ 7.98 (s, 1H), 7.40 - 7.22 (m, 15H), 6.86 (s, 1H), 4.91 (d, J= 11.7 Hz, 1H), 4.84-4.78 (m, 2H), 4.50 (q, J= 12.0 Hz, 4H), 4.41 -4.35 ( m, 1H), 4.12 - 4.08 (m, 1H), 3.72 (dd, J = 11.2, 2.8 Hz, 1H), 3.59 (dd, J = 11.2, 4.1Hz, 1H). Compound 9-1 (69 mg, 0.1 mmol) was dissolved in anhydrous tetrahydrofuran (5 mL), followed by the addition of trimethylchlorosilane (24 mg, 0.22 mmol, 2.2 eq) in an ice bath. The mixture was stirred for 10 minutes, then cooled to -10 °C and 3.0 M methylmagnesium bromide in 2-methyltetrahydrofuran (74 μΙ, 0.22 mmol, 2.2 eq) was added. After addition, the mixture was stirred for 30 minutes. The mixture was cooled to -20 °C, 1.3 M isopropylmagnesium chloride lithium chloride in tetrahydrofuran (0.1 ml, 0.13 mmol, 1.3 eq) was added and further stirred for 1 hour. Deuteroxide (0.2 ml) was added to the reaction solution. After stirring for 15 minutes, the reaction solution was added to a saturated ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, washed with water and saturated saline successively, dried over anhydrous sodium sulfate, and separated by silica gel column chromatography to obtain Compound 9-2 as a white solid (28 mg, 50 % yield).1H NMR (500 MHz, Methanol-cfo) δ 7.65 (s, 1H), 7.34 - 7.16 (m, 15H), 6.84 (s, 1H), 4.95 (d, J = 5.1 Hz, 1H), 4.74 (q, J = 11.9 Hz, 2H), 4.57 (d, J = 11.9 Hz, 1H), 4.53-4 .43 (m, 4H), 4.11 (t, J = 5.2 Hz, 1H), 3.73 (dd, J= 10.9, 4.1 Hz, 1H), 3.62 (dd, J= 10.9, 4.5 Hz, 1H). Compound 9-2 (90 mg, 0.16 mmol) was dissolved in dichloromethane (10 mL) and 1.0 M boron trichloride in dichloromethane (0.56 mL, 0.56 mmol) was added dropwise to - 60°C. After addition, the mixture was stirred at −40 °C for 1 hour. TLC showed that the reaction was complete. Methanol (0.1 ml) was added to the reaction solution, followed by the addition of triethylamine to adjust the pH to 7-8. The reaction solution was concentrated and separated by silica gel column chromatography to give Compound A9 as an off-white solid (15 mg, 50% yield). 1H NMR (500 MHz, DMSO-de) δ 8.03 - 7.78 (m, 3H), 6.87 (s, 1H), 6.09 (d, J= 6.3 Hz, 1H), 5.19 (d, J= 5.2 Hz, 1H) , 4.91 (t, J= 5.7 Hz, 1H), 4.64 (t, J= 5.7 Hz, 1H), 4.09-4.02 (m, 1H), 3.99- 3.92 (m, 1H), 3.68-3.59 (m, 1H), 3.55-3.47 (m, 1H). MS m / z = 293.0 [M + 1 ]+, Preparation Example 6: Synthesis of Compound A9 η / ζΓίη / ζζηζ / Ε / γίΛΐ 9-1 9-2 A9 Compound 9-1 (69 mg, 0.1 mmol) was added to a mixed solution of dry tetrahydrofuran (5 mL) and deuteroxide (1 mL). After concentrating the solution to dryness, dry tetrahydrofuran (5 mL) and deuteroxide (1 mL) were added again, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride complex. ) (8 mg, 0.01 mmol) and tetramethylethylenediamine (3 mg, 0.02 mmol). After addition, the mixture was stirred for 10 minutes and sodium borodeuteride (21 mg, 0.5 mmol) was added portionwise. 2 hours later, the TLC showed that the raw materials had fully reacted. The reaction solution was added to water and extracted with ethyl acetate. The organic phase was separated. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, and separated by silica gel column chromatography to give Compound 9-2 as a white solid (30 mg, 53% yield) with a deuteration rate of not less than 97%. According to the synthesis method of Example 5, Compound 9-2 (90 mg, 0.16 mmol) was deprotected to give Compound A9 as an off-white solid (15 mg, 50% yield).1H NMR (500 MHz, DMSO-cfc) δ 8.01 - 7.79 (m, 3H), 6.88 (s, 1H), 6.09 (d, J = 6.4 Hz, 1H), 5.19 ( d, J = 5.3 Hz, 1H), 4.91 (t, J = 5.8 Hz, 1H), 4.65 (t, J = 5.7 Hz, 1H), 4.08 - 4, 04 (m, 1H), 3.98 - 3.93 (m, 1H), 3.67 - 3.61 (m, 1H), 3.54-3.48 (m, 1H),13C NMR (126 MHz, DMSO-ofe) δ 156.08, 148.32, 124.35, 117.82, 116.94, 111.16, 85.92, 79.04, 74.72, 70.56, 61.43 . The deuteration rate was not less than 97%, MS m / z = 293.0 [M + 1 ]+. Preparation Example 7: Synthesis of Compound A10 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 2-1 (0.5 g, 1.72 mmol) was added to acetone (10 ml), followed by the successive addition of 2,2-dimethoxypropane (0.89 g, 8.6 mmol, 5 eq). and p-toluenesulfonic acid monohydrate (0.59 g, 3.1 mmol, 1.8 equiv.). After addition, the reaction was stirred at 45 °C for 2 hours and TLC showed that the reaction was complete. The reaction solution was added to saturated aqueous sodium bicarbonate (20 mL) and extracted with ethyl acetate. The organic layer was separated, dried and evaporated to give Compound 10-1 as a white solid (0.33 g, 58% yield). Compound 10-1 (0.25 g, 0.75 mmol) was added to acetonitrile / water (V / V=1 / 1, 15 ml), followed by the successive addition of TEMPO (0.047 g, 0.3 mmol , 0.4 eq), iodobenzene diacetate (1.06 g, 3.3 mmol, 4.4 eq) and sodium bicarbonate (0.25 g, 3 mmol, 4.0 eq). After addition, the mixture was stirred at room temperature for approximately 5 hours. TLC showed that the reaction was complete. The reaction solution was added to a 0.5 M sodium hydroxide solution (20 ml) and extracted twice with ethyl acetate (20 ml x 2). The organic phase was discarded and the pH of the aqueous layer was adjusted to 4-5 with dilute hydrochloric acid (2 M). The solution was extracted with ethyl acetate (50 ml x 2). The organic layers were combined, dried and concentrated to give Compound 10-2 as a white solid (0.23 g, 89% yield). The product 10-2 (0.18 g, 0.52 mmol) obtained from the previous step was added to tetrahydrofuran and methanol (8 ml, 1:1), and 2 M trimethylsilyldiazomethane in N-hexane (1.2 ml, 2.4 mmol, 4.5 eq) Added dropwise at room temperature. After addition, the reaction was carried out at room temperature and 1 hour later, the reaction was complete. Acetic acid was added to the reaction solution dropwise until no bubbles were generated. The solvent was removed by evaporation and the residue was separated on preparative TLC plates to obtain Compound 10-3 as a white solid (0.11 g, 59% yield). 1H NMR (500 MHz, DMSO-cfe) δ 8.06 - 7.88 (m, 3H), 6.92 (d, J= 4.6 Hz, 1H), 6.89 (d, J= 4.6 Hz, 1H), 5.52 (d , J = 6.1 Hz, 1H), 5.37 (dd, J= 6.1,2.2 Hz, 1H), 4.92 (d, J= 2.2 Hz, 1H), 3.40 (s, 3H), 1.62 (s, 3H), 1.42 (s, 3H). Compound 10-3 (0.10 g, 0.28 mmol) was added to anhydrous tetrahydrofuran (4 mL) and deuterated methanol (1 mL). Then, sodium borodeuteride (0.047 g, 1.12 mmol, 4 eq) was added in an ice bath. After addition, the reaction was carried out at room temperature and 1 hour later, TLC showed that the reaction was complete. Dilute hydrochloric acid was added dropwise to the reaction solution until no bubbles were generated. The reaction solution was concentrated and separated on preparative TLC plates to obtain Compound 10-4 as a white solid (0.06 g, 64% yield). The product 10-4 obtained from the previous step (60 mg, 0.18 mmol) was added to tetrahydrofuran (2 ml), followed by dropwise addition of concentrated hydrochloric acid (0.4 ml), and the reaction was brought to 40 °C until the reaction was complete. Sodium bicarbonate solution was added to the reaction solution until the pH was neutral. The mixture was extracted with tetrahydrofuran. The organic phase was separated, dried and evaporated to dryness to obtain an off-white solid. The resulting solid was added to ethyl acetate, stirred for 0.5 hours, filtered and dried to give Compound A10 as a white solid (34 mg, 64% yield). 1H NMR (500 MHz, DMSO- cfe) δ 8.03 - 7.82 (m, 3H), 6.92 (d, J= 4.5 Hz, 1H), 6.89 (d, J = 4.6 Hz, 1H), 6, 10 (d, J = 6.3 Hz, 1H), 5.20 (d, J = 5.2 Hz, 1H), 4.89 (s, 1H), 4.66 (t, J = 5.7 Hz, 1H), 4.06 (d, J=5.4Hz, 1H), 4.00 - 3.93 (m, 1H),13C NMR (126 MHz, DMSO-cfe) δ 156.10, 148 .35, 124.35, 117.81, 117.01,111.26, 101.27, 85.80, 79.04, 74.70, 70.54. The deuteration rate was 99%, MS m / z = 294.0 [M + 1]+. Preparation Example 8: Synthesis of Compound A11 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound A9 (1.17 g, 4.0 mmol, with a deuteration rate of not less than 97%) was added to acetone (20 ml), followed by the successive addition of 2,2-dimethoxypropane (2.08 g , 20.0 mmol, 5 eq) and p-toluenesulfonic acid monohydrate (1.37 g, 7.2 mmol, 1.8 eq). After addition, the reaction mixture was stirred at 45 °C for 2 hours. Many precipitates appeared and TLC showed that the reaction was complete. The reaction solution was added to saturated aqueous sodium bicarbonate and extracted with ethyl acetate. The organic layer was separated, dried and the solvent removed by evaporation to give Compound 11-1 as a white solid (0.86 g, 65% yield). Compound 11-1 (0.225 g, 0.68 mmol) was added to acetonitrile / water (V / V=1 / 1, 10 ml), followed by the successive addition of TEMPO (0.02 g, 0.14 mmol , 0.2 eq), iodobenzene diacetate (0.66 g, 2.04 mmol, 3.0 eq) and sodium bicarbonate (0.17 g, 2.04 mmol, 3.0 eq). After addition, the mixture was stirred at room temperature for 4-5 hours. TLC showed that the reaction was complete. The reaction solution was added to an aqueous KOH solution (0.5 M, 20 ml) and extracted with ethyl acetate (20 ml x 3). The aqueous layer was separated, then adjusted to pH 4-5 with dilute hydrochloric acid (2 M) and extracted with ethyl acetate (20 ml x 3). The organic layers were combined, dried and concentrated to obtain crude Compound 11-2, which was used directly in the next step. Crude compound 11-2 (0.68 mmol, based on 100% yield) was added to tetrahydrofuran / methanol (V / V = 1 / 1.8 ml) and trimethylsilyldiazomethane in N-hexane (2 M, 1. 36 ml, 4.0 eq.) Added dropwise at room temperature. After addition, the reaction was carried out at room temperature and 30 minutes later, the reaction was complete. Acetic acid was added dropwise to the reaction solution until no bubbles were generated. The reaction solution was evaporated to dryness and ethyl acetate (20 ml) was added. After washing with saturated sodium bicarbonate (10 ml x 2), the organic layer was separated, dried, concentrated and purified by silica gel column chromatography to give Compound 11-3 as a white solid (0.06 g , 24% performance in two stages). Compound 11-3 (0.06 g, 0.17 mmol) was added to methanol / deuterated tetrahydrofuran (V / V = 1 / 5, 6 ml) and NaBD4 (0.028 g, 0.68 mmol, 4 eq.) was added. ) in an ice bath. After addition, the mixture was reacted at room temperature and 1-2 hours later, the reaction was complete. The reaction solution was added to a liquid ethyl acetate / water mixture (20 ml / 20 ml). The organic layer was separated and the aqueous layer was extracted once with ethyl acetate (20 ml) again. The ethyl acetate layers were combined and evaporated to dryness. The obtained product was added to methanol (10 ml) and dilute hydrochloric acid (1 M) was added dropwise to adjust the pH of the solution to 2-3. The mixture was stirred at room temperature for 1-2 hours and the pH was adjusted to neutral using a saturated aqueous sodium bicarbonate solution. A mixed solution of ethyl acetate / water (20 ml / 20 ml) was added. The organic phase was separated. The aqueous layer was extracted once with ethyl acetate (20 ml) again. The organic layers were combined, dried, concentrated, and separated on silica gel preparative TLC plates to obtain Compound 11-4 as a white solid (0.05 g, 89% yield). 11-4 (0.05 g, 0.15 mmol) was added to tetrahydrofuran (1.5 ml) and then concentrated hydrochloric acid (0.3 ml) was added dropwise in an ice bath. After addition, the reaction mixture was stirred at room temperature for 2-3 hours. TLC showed that the reaction was complete. The pH of η / ζΓίη / ζζηζ / Ε / γίΛΐ reaction solution was adjusted to neutral with 1 M NaOH aqueous solution in an ice bath. The tetrahydrofuran was removed by evaporation and the mixture was filtered. The filter cake was slurried with distilled water (10 mL) and ethyl acetate (10 mL) successively, then filtered and dried to obtain Compound A11 as a white solid (0.03 g, 68% yield). 1H NMR (500 MHz, DMSO-cfc) δ 8.04-7.76 (m, 3H), 6.89 (s, 1H), 6.07 (d, J= 6.3 Hz, 1H), 5 .18 (d, J = 5.2 Hz, 1H), 4.87 (s, 1H), 4.67 (t, J = 5.8 Hz, 1H), 4.07 (d, J= 5, 3 Hz, 1H), 4.01 -3.93 (m, 1H), m / z = 295.0 [M + 1]+. The deuteration rates for the two positions were not less than 97%, respectively. Preparation Example 9: Synthesis of Compound A12 IV 7Γ ίη / ΖΖΩΖ / Ε / ΥΙΛΙ Compound 10-1 (662 mg, 2.0 mmol) was added to acetonitrile (15 ml), followed by the addition of sodium bicarbonate (336 mg, 4 mmol, 2 eq) and 1-chloromethyl-4-fluoro- Diazoniabicyclo[2.2.2]octane 1,4-bis(tetrafluoroborate) (850 mg, 2.4 mmol, 1.2 eq). The mixture was stirred at room temperature for 24 hours and TLC showed that some starting material remained. Ethyl acetate (50 ml) and water (20 ml) were added to the reaction solution. The organic layer was separated, dried, concentrated and purified by silica gel column chromatography to give Compound 12-1 as an off-white solid (140 mg, 20% yield). Compound 12-1 (140 mg, 0.4 mmol) was added to a mixed solution of acetonitrile and water (6 ml, 1:1), followed by the successive addition of iodobenzene diacetate (515 mg, 1.6 mmol , 4 eq), sodium bicarbonate (135 mg, 1.6 mmol, 4 eq) and TEMPO (25 mg, 0.16 mmol, 0.4 eq) at room temperature. The reaction was complete in approximately 3 hours. Aqueous sodium hydroxide solution (10 ml, 224 mg, 10 eq) was added to the reaction solution. The mixture was extracted twice with ethyl acetate and the organic phase was discarded. Dilute 2 M hydrochloric acid was added to the aqueous phase, adjusting the pH to 4-5, and extracted three times with ethyl acetate. The organic phases were combined, dried and evaporated to obtain Compound 12-2 as an off-white solid (116 mg, 80% yield). Compound 12-2 (116 mg, 0.32 mmol) was added to the mixed solution of tetrahydrofuran and methanol (4 ml, 1:1), followed by the addition of 2 M trimethylsilyldiazomethane in N-hexane (0.48 ml , 0.96 mmol, 3 eq.) slowly. The reaction was monitored by TLC, and if raw materials remained, an appropriate amount of trimethylsilyldiazomethane could be added until the reaction was complete. Acetic acid was added to the reaction solution dropwise until no bubbles were generated. The solvent was removed by evaporation and the residue was purified by silica gel column chromatography to obtain Compound 12-3 as a white solid (105 mg, 87% yield). The product 12-3 (105 mg, 0.28 mmol) obtained in the previous step was added to anhydrous tetrahydrofuran (2 ml), followed by the addition of deuterated methanol (0.5 ml) and sodium borodeuteinde (35 mg, 0.84 mmol, 3 eq) was added portionwise over 1 hour at room temperature. The mixture continued to stir for 5 hours and TLC showed that the reaction was complete. Ethyl acetate (0.5 ml) was added to the reaction solution. The reaction solution was concentrated and the residue was purified by preparative TLC to give Compound 12-4 as a white solid foam (80 mg, 82% yield). The product 12-4 obtained from the previous step (80 mg, 0.23 mmol) was added to tetrahydrofuran (3 ml), followed by the dropwise addition of concentrated hydrochloric acid (0.5 ml). The reaction was carried out at 40 °C until the reaction was complete. Insoluble substances were precipitated from the reaction solution and filtered to give 55 mg of a white solid. The solid was added to water (1.5 ml), followed by the addition of sodium carbonate (16 mg). The mixture was stirred for 0.5 h, filtered and dried to give Compound A12 as a white solid (44 mg, 62% yield). 1H NMR (500 MHz, DMSO-ofe) δ 8.10 (brs , 1 H), 7.88 (s, 1H), 7.41 (brs, 1H), 6.80 (s, 1H), 6.23 (brs, 1H), 5.20 (brs, 1H), 4.89 (s, 1H), 4.54 (d, J = 4.9 Hz, 1H), 4.04 (d, J = 6.3 Hz, 1H), 3.94 (t, J = 5.5Hz, 1H). The deuteration rate was 98%, MS m / z = 312.0 [M + 1]+. Preparation Example 10: Synthesis of Compound A35 η / ζΓίη / ζζηζ / Ε / γίΛΐ 35-1 A35 Compound 35-1 was synthesized according to the method reported in the literature (WO2015069939). Hydroxylamine hydrochloride (547 mg, 7.87 mmol, 30 eq) was added to water (3.2 ml), followed by slow addition of a 10% sodium hydroxide solution to adjust the pH of the solution to 6 .0, then compound 35-1 (69 mg, 0.26 mmol, 1 eq) and stirred overnight at 40 °C under nitrogen protection. TLC showed that the reaction was complete. The reaction solution was separated by reverse phase column chromatography to give A35 as an off-white solid (52 mg, 71% yield).1H NMR (500 MHz, DMSO-cfe) δ 10.61 (d, J= 4 .0 Hz, 1H), 10.06 (s, 1H), 7.39 (d, J = 4.0 Hz, 1H), 6.38 - 6.33 (m, 2H), 4.96 (d , J = 6.6 Hz, 1H), 4.93 (d, J = 6.3 Hz, 1H), 4.86 (d, J = 5.1 Hz, 1H), 4.74-4.68 (m, 1H), 4.15 (q, J= 6.1 Hz, 1H), 3.91 (q, J= 4.9 Hz, 1 H), 3.74 (q, J = 4.5 Hz, 1H), 3.55 3.49 (m, 1H), 3.47 - 3.43 (m, 1H). MS m / z = 283.0 [M + 1 ]+. Preparation Example 11: Synthesis of Compounds A49 and A124 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 2-1 (2.2 g, 7.6 mmol) was added to N, N-dimethylformamide (20 ml), followed by the addition of imidazole (3.1 g, 45.6 mmol, 6 eq) and 1,3-Dichloro-1, 1,3,3 Tetraisopropyldisiloxane (2.9 g, 9.5 mmol, 1.2 eq) was added dropwise in an ice bath. After addition, the reaction was carried out at room temperature and 4 hours later, the reaction was complete. The reaction solution was added to water (120 ml) and extracted with ethyl acetate. The organic layer was separated, dried, concentrated and separated by silica gel column chromatography to give Compound 49-1 as a white solid (3.2 g, 80% yield). 1H NMR (500 MHz, DMSO- ds) δ 7.99 - 7.82 (m, 3H), 6.88 (d, J = 4.5 Hz, 1H), 6.79 (d, J = 4.4 Hz, 1 H), 6.45 (d, J = 5.7 Hz, 1H), 4.56 (t, J = 5.0 Hz, 1H), 4.22 - 4.09 (m, 3H), 3.95 - 3.86 ( m, 1H), 1.09 - 0.76 (m, 28H). Compound 49-1 (1.2 g, 2.2 mmol) was added to toluene (20 ml), followed by the addition of N,Ndimethylformamide dimethyl acetal (0.52 g, 4.4 mmol, 2 eq), and the reaction was brought to 50 °C. The reaction was complete in approximately 3 hours. The solvent was evaporated under reduced pressure and ethyl acetate (60 ml) and water (20 ml) were added. The organic phase was separated, washed with saturated brine, dried and evaporated to give Compound 49-2 as a white solid (1.2 g, 92% yield). 1H NMR (500 MHz, DMSO-cfe ) δ 8.96 (s, 1H), 8.16 (s, 1H), 6.91 (d, J=4.5 Hz, 1H), 6.81 (d, J=4.4 Hz, 1H ), 6.49 (d, J= 5.8 Hz, 1H), 4.59 (t, J= 5.1 Hz, 1H), 4.26-4.11 (m, 3H), 3.93 (dd, J= 13.3 , 2.4 Hz, 1H), 3.26 (s, 3H), A124 Compound 49-2 (294 mg, 0.5 mmol) was added to dichloromethane (6 ml), followed by the successive addition of triethylamine (101 mg, 1 mmol, 2 eq), DMAP (12 mg, 0.1 mmol , 0.2 eq) and isobutyl chloride (85 mg, 0.8 mmol, 1.6 eq) at room temperature. The reaction was carried out overnight and TLC showed that the reaction was complete. Saturated aqueous sodium bicarbonate and dichloromethane were added to the reaction solution. The organic layer was separated, then dried, concentrated and purified by silica gel column chromatography to give Compound 49-3 as a white solid foam (240 mg, 72% yield). The product 49-3 (240 mg, 0.36 mmol) obtained in the previous step was added to tetrahydrofuran (5 ml), followed by the addition of 1 M tetrabutylammonium fluoride in tetrahydrofuran (0.72 ml, 0.72 mmol ). After 1 hour, the reaction was complete. Water (10 ml) was added to the reaction solution and extracted with ethyl acetate. The organic layer separated. The organic phase was dried and evaporated to dryness to give an oil. The oil was added to tetrahydrofuran (6 mL), followed by the addition of water (0.5 mL) and trifluoroacetic acid (205 mg, 1.8 mmol) and the mixture was stirred overnight at room temperature. An aqueous solution of sodium bicarbonate was added to the reaction solution and extracted with ethyl acetate. The organic layer was separated, dried, concentrated and separated using silica gel column chromatography to obtain Compounds A49 and A124. The proportion of A124 was more than 95% and recrystallization from isopropyl acetate gave A124 as a white solid (80 mg, 61% yield in two steps). For Compound A124 obtained:1H NMR (500 MHz, DMSO-cfe) δ 8.09 - 7.84 (m, 3H), 6.94 (d, J=4.6 Hz, 1H), 6.90 ( d, J= 4.6 Hz, 1H), 6.43 (d, J= 6.5 Hz, 1H), 5.22 (dd, J= 5.7, 3.3 Hz, 1H), 5, 07 (t, J = 5.8 Hz, 1H), 5.01 (t, J= 6.1 Hz, 1H), 4.31 -4.25 (m, 1H), 3.66-3.52 (m, 2H), 2.68-2.58 (m, 1 H), 1.19 (d, J= 7.0 Hz, 3H), 1.17 (d, J= 7.0 Hz, 3H ). MS m / z = 362.0 [M + 1]+. Preparation Example 12: Synthesis of Compound A50 10-1 50-1 50-2A50η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 10-1 (0.664 g, 2.0 mmol) was added to toluene (10 ml), followed by the addition of N,Ndimethylformamide dimethyl acetal (0.47 g, 4.0 mmol, 2.0 eq). After addition, the reaction was carried out at 60 °C for 2-3 hours. TLC showed that the reaction was complete. The solvent was removed by evaporation to give Compound 50-1 as a yellow solid (0.65 g, 84% yield). The product 50-1 (0.2 g, 0.52 mmol) obtained from the previous step was added to dichloromethane (10 ml), followed by the successive addition of triethylamine (0.1 g, 1.0 mmol, 2 eq. ), DMAP (0.012 g, 0.10 mmol, 0.2 eq) and isobutyryl chloride (0.083 g, 0.78 mmol, 1.5 eq). After addition, the mixture was stirred at room temperature for 1-2 hours. TLC showed that the reaction was complete. The reaction solution was added to 1 M dilute hydrochloric acid (10 ml). The mixture was extracted with dichloromethane and the organic phase was separated. The organic phase was washed with saturated sodium bicarbonate (20 ml), dried and concentrated to give Compound 50-2 as an off-white solid (0.2 g, 84% yield). Compound 50-2 (0.1 g, 0.22 mmol) was added to tetrahydrofuran (3 mL), followed by dropwise addition of concentrated hydrochloric acid (0.6 mL) in an ice bath. After addition, the mixture was stirred at room temperature for 3 hours. The TLC showed that a small amount of raw material remained. The reaction solution was added to a saturated aqueous sodium bicarbonate solution (20 ml) and extracted with ethyl acetate. The organic phase was separated. The organic phase was dried, concentrated and separated on preparative TLC plates to give Compound A50 as a white solid (13 mg, 16% yield). 1H NMR (500 MHz, DMSO-cfe) δ 8.00 - 7, 80 (m, 3H), 6.92 (d, J = 4.6 Hz, 1H), 6.82 (d, J = 4.5 Hz, 1H), 6.33 (d, J= 6.0 Hz, 1H), 5.39 (d, J = 5.8 Hz, 1H), 4.70 (t, J= 5.5 Hz, 1H), 4.32 (dd, J= 12.0, 2 .9 Hz, 1H), 4.27-4.21 (m, 1H), 4.18 (dd, J= 12.0, 5.3 Hz, 1H), 3.99-3.94 (m, 1H), 2.57-2.52 (m, 1H), 1.07 (d, J = 2.4 Hz, 3H), 1.06 (d, J = 2.4 Hz, 3H). MS m / z = 362.0 [M + 1 ]+. Preparation Example 13: Synthesis of Compound A51 and A212 IV 7Γ ίη / ΖΖΩΖ / Ε / ΥΙΛΙ Compound 49-2 (260 mg, 0.44 mmol) and Boc-L-valine (115 mg, 0.53 mmol, 1.2 eq) were added to dichloromethane (10 ml), followed by successive addition of HOBT (89 mg, 0.66 mmol, 1.5 eq), EDCI (169 mg, 0.88 mmol, 2 eq) and DMAP (214 mg, 1.76 mmol, 4 eq), and the mixture was stirred for overnight at room temperature. Dichloromethane (20 ml) and water (20 ml) were added to the reaction solution. After stirring for 5 min, the organic phase was separated, washed with saturated sodium chloride, dried, concentrated and separated by silica gel column chromatography to give Compound 51-1 as a white solid (260 mg, 75% yield).1H NMR (500 MHz, DMSO-cfe) δ 8.98 (s, 1H), 8.15 (s, 1H), 7.23 (d, J= 9.0 Hz, 1H), 6.96 (d, J=4.5 Hz, 1H), 6.85 (d, J=4.6 Hz, 1H), 5.90 (d, J= 5.0 Hz, 1H) , 4.57 (dd, J = 9.2, 4.9 Hz, 1H), 4.27-4.17 (m, 3H), 3.95 (dd, J= 13.8, 2.8 Hz , 1H), 3.27 (s, 3H), 3.21 (s, 3H), 2.30-2.19 (m, 1H), 1.45-1.34 (m, 9H), 1, 10-0.86 (m, 34H). Compound 51-1 (180 mg, 0.23 mmol) was added to tetrahydrofuran (4 mL), followed by the addition of 1 M tetrabutylammonium fluoride in tetrahydrofuran (0.46 mL, 0.46 mmol) at room temperature. After 1 hour, the reaction was complete. Water (10 ml) was added to the reaction solution and extracted with ethyl acetate. The organic phase was separated, dried and evaporated to dryness to give an oil. The oil was dissolved in tetrahydrofuran (6 ml), followed by the addition of water (0.5 ml) and trifluoroacetic acid (131 mg, 1.15 mmol, 5 eq) and stirred overnight at room temperature. An aqueous sodium bicarbonate solution was added to the reaction solution and extracted with ethyl acetate. The organic layer was separated, dried, concentrated and separated by silica gel column chromatography to obtain Compounds 51-2a and 51-2b. The proportion of 51-2b was greater than 90% and further recrystallization gave pure 51-2b as a white solid (70 mg, 62% yield in two steps). For Compound 51-2b obtained:1H NMR (500 MHz, DMSO-d6) δ 8.08 - 7.87 (m, 3H), 7.06 (d, J=8.6 Hz, 1H), 6, 94 (d, J=4.5 Hz, 1H), 6.91 (d, J=4.6 Hz, 1H),6.50 (d, J=6.7 Hz, 1H), 5.19- 5.14 (m, 1H), 5.10 - 5.05 (m, 1H), 5.03 - 4.98 (m, 1H), 4.26 - 4.20 (m, 1H), 4.10 (dd, J = 8.7, 5.5 Hz, 1H), 3.66 - 3.53 (m, 2H), 2.31 - 2.22 (m, 1H), 1.45 - 1.35 (m, 9H), 0.93 (d, J= 6.8 Hz, 3H), 0.90 (d, J= 6.8 Hz, 3H). Compound 51-2b (42 mg, 0.086 mmol) was added to a saturated solution of hydrogen chloride and methanol (4 ml). After stirring at 35 °C for 2 hours, TLC showed that the reaction was complete. The reaction solution was concentrated and methyl tert-butyl ether was added. The mixture was stirred and filtered to give Compound A212 as the dihydrochloride salt, white solid (45 mg, 81% yield). 1H NMR (500 MHz, Methanol-cfa) δ 8.17 (s, 1H), 7 .50 (d, J= 4.8 Hz, 1H), 7.21 (d, J= 4.8 Hz, 1H), 5.52 (dd, J= 5.8, 3.2 Hz, 1H) , 5.19 (d, J= 5.8 Hz, 1H), 4.54-4.48 (m, 1H), 4.16-4.10 (m, 1H), 3.83 (d, J = 3.7 Hz, 2H), 2.58-2.48 (m, 1H), 1.18 (d, J= 4.2 Hz, 3H), 1.17 (d, J= 4.2 Hz , 3H). MS m / z = 391.1 [M + 1]+. If the mixture of 51-2a and 51-2b (the proportion of 51-2a was 5-10%) obtained from the previous step was directly deprotected, the mixture of A51 and A212 could be obtained, and the content of A51 was approximately 10%. Preparation Example 14: Synthesis of Compound A52 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 2-1 (291 mg, 1.0 mmol) was added to pyridino (8 ml) and the pyridino was removed by evaporation under reduced pressure. The process was repeated once. Then, pyridino (8 ml) and N,N-dimethylformamide dimethylacetal (477 mg, 4.0 mmol) were added again at room temperature. The reaction was carried out under nitrogen protection at room temperature overnight. The reaction solution was concentrated to give Compound 52-1 as an oil, which was used directly in the next step without purification. Boc-L-valine (304 mg, 1.4 mmol), 1-hydroxybenzotriazole (203 mg, 1.5 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbomide hydrochloride were added. (422 mg, 2.2 mmol) to dichloromethane (10 ml). After stirring at room temperature for 15 minutes, 52-1 in dichloromethane (1 ml) obtained from the previous step and 4-dimethylaminopyridino (684 mg, 5.4 mmol) were added, and the mixture was stirred overnight at room temperature. atmosphere. The reaction solution was concentrated; Methanol was added and concentrated again to obtain an oil. Water was added and the mixture was extracted with ethyl acetate. The organic phase was separated, washed with water and saturated saline successively, dried over anhydrous sodium sulfate, and concentrated to obtain crude Compound 52-2 as an oil, which can be used directly in the next step. Compound 52-2 was dissolved in acetonitrile (10 ml) and 85% hydrazine hydrate (236 mg, 4.0 mmol) was added. After stirring at room temperature for 3 hours, the reaction solution was added to water and extracted with ethyl acetate. The organic phase was separated, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and separated by silica gel column chromatography to give Compound 52-3 as a white solid (104 mg, 21 % performance in three stages). Ή NMR (500 MHz, DMSO-ofe) δ 7.98 - 7.83 (m, 3H), 7.13 (d, J= 8.1 Hz, 1H), 6.91 (d, J= 4, 5 Hz, 1H), 6.82 (d, J= 4.5 Hz, 1 H), 6.33 (d, J=6.0 Hz, 1 H), 5.38 (d, J= 5, 9 Hz, 1H), 4.69 (t, J=5.4 Hz, 1H),4.33 - 4.28 (m, 1H), 4.27 - 4.20 (m, 2H), 3, 94 - 3.90 (m, 1H), 3.89 - 3.85 (m, 1H), 1.98 - 1.91 (m, 1H), 1.37 (s, 9H), 0.82 (t, J= 6.5 Hz, 6H). Compound 52-3 (104 mg, 0.21 mmol) was added to a saturated solution of hydrogen chloride and methanol (5 ml). The mixture was stirred at 36 °C. The reaction was complete after 1 hour. The reaction solution was concentrated and then isopropyl ether was added. The solid was precipitated and filtered to give Compound A52 as the dihydrochloride salt, white solid (80 mg, 82% yield). 1H NMR (500 MHz, Methanol-di) δ 8.15 (s, 1H), 7.49 (d, J = 4.8 Hz, 1H), 7.12 (d, J = 4.8 Hz, 1H), 4.74 (d, J = 5.2 Hz, 1H), 4, 62 (dd, J= 12.1, 7.4 Hz, 1H), 4.54 (dd, J= 12.1,2.8 Hz, 1H), 4.45 (td, J = 7.5, 2.7 Hz, 1H), 4.05 4.00 (m, 2H), 2.35 - 2.27 (m, 1H), 1.08 (d, J = 1.9 Hz, 3H), 1 .07 (d, J = 1.8 Hz, 3H). MS m / z = 391.1 [M + IbPreparation Example 15: Synthesis of Compound A53 iv ze Ln / zznz / E / YiAi Compound 49-1 (150 mg, 0.28 mmol) was dissolved in dichloromethane (2 mL), followed by the addition of pyridino (265 mg, 3.35 mmol, 12 eq), and then trimethylchlorosilane (93 mg , 0.86 mmol) in an ice bath. The mixture was stirred for 30 minutes and TLC showed that the raw material had been completely consumed. N-pentyl chloroformate (120 mg, 0.8 mmol) was added to the reaction solution and the mixture was stirred for an additional 2 hours in the ice bath. TLC showed that the reaction was complete. Dichloromethane and water were added to the reaction solution. The organic layer was separated, washed with dilute hydrochloric acid and saline successively, dried and concentrated to obtain 200 mg of crude 53-1 as a colorless oil. The oil was added to tetrahydrofuran (2 mL), followed by dropwise addition of 1 M tetrabutylammonium fluoride in tetrahydrofuran (0.2 mL, 0.2 mmol) at room temperature. After addition, the mixture was stirred at room temperature for 50 minutes and TLC showed that the reaction was complete. The reaction solution was concentrated and purified by silica gel column chromatography to obtain Compound A53 as a white solid (55 mg, 48% yield in two steps).1H NMR (600 MHz, DMSO-ofe) δ 10 .88 (s, 1H), 8.37 (s, 1H), 7.30 (d, J = 4.8 Hz, 1H), 7.11 (d, J= 4.8 Hz, 1H), 6 .21 (d, J= 6.2 Hz, 1H), 5.23 (d, J= 5.5 Hz, 1H), 4.90 (t, J= 5.6 Hz, 1H), 4.61 (t, J= 5.7 Hz, 1H), 4.18 (t, J= 6.7 Hz, 2H), 4.10-4.04 (m, 1H), 3.95 (q, J= 5.5 Hz, 1H), 3.68-3.61 (m, 1H), 3.54 - 3.47 (m, 1H), 1.71-1.61 (p, J = 6.8 Hz, 2H), 1.39 - 1.29 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H). MS m / z = 406.0 [M + 1]+. Preparation of Example 16: Synthesis of Compound A69 and A144 iv ze Ln / zznz / E / YiAi Compound A9 (879 mg, 3.01 mmol, with a deuteration rate of not less than 97%) was added to Ν,Ν-dimethylformamide (15 ml), followed by the addition of imidazole (819 mg, 12.03 mmol , 4 eq), and then 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (1.32 g, 4.21 mmol, 1.4 eq) was added dropwise in an ice bath. After addition, the mixture was stirred at room temperature and 1 hour later, the reaction was complete. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was separated, dried, concentrated and suspended in petroleum ether to give Compound 69-1 as a white solid (1.29 g, 80% yield). 1H NMR (600 MHz, DMSO-cfe ) δ 8.04 - 7.78 (m, 3H), 6.79 (s, 1H), 6.46 (d, J= 5.7 Hz, 1H), 4.56 (t, J= 5, 1 Hz, 1H), 4.24-4.08 (m, 3H), 3.91 (d, J= 12.0 Hz, 1H), 1,080.86 (m, 28H). Compound 69-1 (1.10 g, 2.07 mmol) was added to toluene (20 ml), followed by the addition of Ν,Νdimethylformamide dimethyl acetal (370 mg, 3.11 mmol, 1.5 eq) and It was reacted at 45 °C. The reaction was complete in approximately 30 minutes. The solvent was removed by evaporation under reduced pressure and ethyl acetate (60 ml) and water (20 ml) were added. The organic phase was separated, washed with saturated sodium chloride, dried and evaporated to give Compound 69-2 as a white solid (1.12 g, 92% yield). Compound 69-2 (614 mg, 1.04 mmol) was added to dichloromethane (10 ml), followed by the successive addition of triethylamine (210 mg, 2.08 mmol, 2 eq), isobutyryl chloride (166 mg, 1.56 mmol, 1.5 eq) and DMAP (127 mg, 1.04 mmol, 1 eq), and stirred at room temperature. The reaction was complete in approximately 1 hour. Saturated aqueous sodium bicarbonate and dichloromethane were added to the reaction solution. The organic layer was separated, dried, concentrated and purified by silica gel column chromatography to give Compound 69-3 as a white foam solid (494 mg, 72% yield). Compound 69-3 (350 mg, 0.53 mmol) was added to acetonitrile (8 mL), followed by the addition of 85% hydrazine hydrate (125 mg, 2.12 mmol, 4 eq) and then stirred. at room temperature. The reaction was complete in approximately 30 minutes. The reaction solution was added to water and extracted with ethyl acetate. The organic layer was separated, washed with dilute hydrochloric acid, saturated sodium bicarbonate and saturated sodium chloride, respectively, dried and evaporated to give Compound 69-4 as a white solid (289 mg, 90% yield). . Compound 69-4 (289 mg, 0.48 mmol) was added to tetrahydrofuran (10 ml), followed by the addition of 1 M tetrabutylammonium fluoride in tetrahydrofuran (0.48 ml, 0.48 mmol, 1 eq) and was stirred at room temperature. The reaction was complete in approximately 30 minutes. The reaction solution was added to water and extracted with isopropyl acetate. The organic layer was separated, washed with saturated sodium bicarbonate and saturated sodium chloride respectively, dried and evaporated to obtain Compounds A69 and A144. The proportion of A144 in the product was more than 95%. The product was suspended in the N-heptane / isopropanol mixture (1:1), then filtered and dried to give pure Compound A144 as a white solid (121 mg, 70% yield). For Compound A144 obtained:1H NMR (600 MHz, DMSO-de) δ 8.06 - 7.85 (m, 3H), 6.88 (s, 1H), 6.41 (d, J = 6.5 Hz, 1H), 5.21 (dd, J = 5.7, 3.3 Hz, 1H), 5.08 - 5.04 (m, 1H), 4.99 (t, J = 6.0 Hz , 1H), 4.26 (q, J = 3.7 Hz, 1H), 3.64 - 3.52 (m, 2H), 2.67 - 2.58 (m, 1H), 1.17 ( d, J= 7.0 Hz, 3H), 1.15 (d, J= 7.0 Hz, 3H),13C NMR (126 MHz, DMSO-cfc) δ 175.92, 156.13, 148.45 , 123.24, 117.50, 117.27, 111.60, 84.59, 78.30, 73.14, 72.69, 61.25, 33.81, 19.18, 19.08. MS m / z = 363.0 [M + IbPreparation Example 17: Synthesis of Compound A70 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound A9 (145 mg, 0.5 mmol, with a deuteration rate of not less than 97%) was added to pyridino (5 ml), and the pyridino was removed by evaporation under reduced pressure. The process was repeated once. Then, pyridine (5 ml) and Ν,Ν-dimethylformamide dimethyl acetal (240 mg, 2.0 mmol) were added again at room temperature. The reaction was carried out under nitrogen protection at room temperature overnight. The reaction solution was concentrated to obtain intermediate 70-1 as an oil, which was used directly in the next step without purification. The intermediate 70-1 obtained from the previous step was dissolved in pyridino (5 ml), followed by the successive addition of 4-dimethylaminopyridino (6 mg, 0.05 mmol) and isobutyryl chloride (80 mg, 0.75 mmol) . After 3 hours, methanol was added. The solvent was removed by evaporation to obtain intermediate 70-2 as an oil, which was used directly in the next step without purification. The intermediate 70-2 obtained from the previous step was added to acetonitrile (5 ml), followed by the addition of hydrazine hydrate (176 mg, 3.0 mmol) and stirred overnight at room temperature. Water was added to the reaction solution and the mixture was extracted with ethyl acetate. The organic phase was separated, washed with water and saturated saline successively, dried over anhydrous sodium sulfate, concentrated and separated by silica gel column chromatography to give Compound A70 as a white solid (80 mg, 44% efficiency).1H NMR (600 MHz, DMSO-cfe) δ 8.01 -7.79 (m, 3H), 6.80 (s, 1H), 6.32 (d, J= 6.0 Hz, 1H), 5.38 (d, J= 5.8 Hz, 1H), 4.69 (t, J= 5.4 Hz, 1H), 4.30 (dd, J= 12.1, 2 .9 Hz, 1 H), 4.25 - 4.21 (m, 1H), 4.17 (dd, J = 12.1, 5.3 Hz, 1H), 3.95 (q, J = 5 .9 Hz, 1H), 2.54 - 2.51 (m, 1H), 1.06 (d, J= 2.9 Hz, 3H), 1.05 (d, J = 2.9 Hz, 3H ),13C NMR (126 MHz, DMSO-cfc) δ 176.36, 156.06, 148.40, 123.99, 117.40, 117.00, 110.61, 81.78, 79.50, 74.49, 70.65, 63.40, 33.63, 19.19, 19, eleven. MS m / z = 363.0 [M + 1]+. Preparation Example 18: Synthesis of Compound A71 and A213 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 69-2 (160 mg, 0.27 mmol) was dissolved in dichloromethane (10 ml) followed by the successive addition of Boc-L-Val (82 mg, 0.38 mmol), 1-hydroxybenzotriazole (55 mg, 0.41 mmol), 1 -(3dimethylaminopropyl)-3-ethylcarbomide hydrochloride (113 mg, 0.59 mmol) and 4-dimethylaminopyridino (132 mg, 1.08 mmol) in an ice bath. After addition, the reaction was carried out at room temperature overnight. The reaction solution was concentrated; Water was added and extracted with ethyl acetate. The organic phase was washed successively with dilute hydrochloric acid, saturated sodium bicarbonate solution and saturated saline, dried over anhydrous sodium sulfate, concentrated and separated by silica gel column chromatography to give Compound 71-1. as a white solid (158 mg, 74% yield). Compound 71-1 (158 mg, 0.20 mmol) was dissolved in acetonitrile (10 mL), followed by the addition of 85% hydrazine hydrate (71 mg, 1.20 mmol) at room temperature. After stirring for 1 hour, water was added to the reaction solution and the mixture was extracted with ethyl acetate. The organic phase was separated, washed with dilute hydrochloric acid, saturated aqueous sodium bicarbonate solution and saturated saline successively, dried over anhydrous sodium sulfate and concentrated to obtain a white solid. The resulting white solid was added to tetrahydrofuran (8 ml), followed by the addition of acetic acid (14 mg, 0.24 mmol) and 1 M tetrabutylammonium fluoride in tetrahydrofuran (0.24 ml, 0.24 mmol) in a ice bath After addition, the mixture was stirred at room temperature. 2 hours later, TLC showed that the reaction was complete. The reaction solution was concentrated, water was added and extracted with isopropyl acetate. The organic phase was separated, washed with saturated brine, dried over anhydrous sodium sulfate and concentrated. The resulting product was suspended in petroleum ether, filtered and dried to obtain Compounds 71-2a and 71-2b. The proportion of 71-2b was greater than 90% and further recrystallization provided pure 71-2b as a white solid (60 mg, 61% yield in two steps). For Compound 71-2b obtained:1H NMR (500 MHz, DMSO-cfe) δ 8.07 - 7.86 (m, 3H), 7.06 (d, J = 8.6 Hz, 1H), 6, 91 (s, 1H), 6.50 (d, J = 6.7 Hz, 1H), 5.17 (dd, J = 5.8, 3.6 Hz, 1H), 5.07 (t, J = 5.8 Hz, 1H), 5.01 (t, J = 6.2 Hz, 1H), 4.27 - 4.21 (m, 1 H), 4.10 (dd, J = 8.6 , 5.4Hz, 1H), 3.66-3.53 (m, 2H), 2.31 -2.23 (m, 1H), 1.45-1.36 (m, 9H), 0.93 (d, J= 6.9 Hz, 3H), 0.90 (d, J= 6.9 Hz, 3H). Compound 71-2b (60 mg, 0.12 mmol) was added to a saturated solution of hydrogen chloride and methanol (5 ml). The mixture was stirred at 35 °C for 2 hours and TLC showed that the reaction was complete. The reaction solution was concentrated and the residue was suspended in methyl tert-butyl ether to give Compound A213 as the dihydrochloride, white solid (45 mg, 81% yield).1H NMR (500 MHz, Methanol-ck) δ 8 .17 (s, 1H), 7.21 (s, 1H), 5.55 - 5.50 (m, 1H), 5.19 (d, J = 5.8 Hz, 1 H), 4.53 4.48 (m, 1H), 4.12 (d, J= 4.4 Hz, 1H), 3.83 (d, J = 3.7 Hz, 2H), 2.58 - 2.49 (m , 1H), 1.18 (d, J= 4.3 Hz, 3H), 1.17 (d, 4.3 Hz, 3H),13C NMR (126 MHz, Methanol-^) δ 167.48, 148 .78, 135.20, 128.58, 115.31, 113.58, 113.19, 84.12, 77.64, 74.29, 73.56, 60.15, 57.64, 28.91,16.63, 16.32. MS m / z = 392.1 [M + 1]+. If the mixture of 71 -2a and 71 -2b obtained from the previous step was directly deprotected, the mixture of A71 and A213 could be obtained, and the content of A71 was about 10%. Preparation Example 19: Synthesis of Compound A72 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound A9 (350 mg, 1.2 mmol) was added to pyridino (10 ml) and the pyridino was removed by evaporation under reduced pressure. The process was repeated once. Pyridine (10 ml) and Ν,Ν-dimethylformamide dimethyl acetal (596 mg, 5.0 mmol) were then added again at room temperature. The reaction was carried out under nitrogen protection at room temperature overnight. The reaction solution was concentrated to give intermediate 70-1 as an oil, which was used directly in the next step without purification. Boc-L-valine (369 mg, 1.7 mmol), 1-hydroxybenzotriazole (243 mg, 1.8 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (498 mg, 2.6 mmol) were added. mmol) to dichloromethane (15 ml). After stirring at room temperature for 15 minutes, intermediate 70-1 in dichloromethane (2 mL) obtained from the previous step and 4-dimethylaminopyridino (733 mg, 6.0 mmol) was added, and the mixture was stirred overnight. at room temperature. The reaction solution was concentrated; Methanol was added and concentrated again to obtain an oil. Water was added and the mixture was extracted with ethyl acetate. The organic phase was separated, washed with water and saturated saline successively, dried over anhydrous sodium sulfate, and concentrated to obtain the crude intermediate 72-1 as an oil, which was used directly in the next step without purification. Intermediate 72-1 was dissolved in acetonitrile (10 ml), followed by the addition of 85% hydrazine hydrate (283 mg, 4.8 mmol). After reacting at room temperature for 3 hours, the reaction solution was added to water and extracted with ethyl acetate. The organic phase was separated, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and separated by silica gel column chromatography to give Compound 72-2 as a white solid (195 mg, 33 % efficiency in three stages).1H NMR (600 MHz, DMSO-cfe) δ 8.01 - 7.80 (m, 3H), 7.14 (d, J = 8.2 Hz, 1H), 6, 82 (s, 1H), 6.33 (d, J = 6.0 Hz, 1H), 5.38 (d, J = 5.9 Hz, 1H), 4.69 (t, J = 5.4 Hz, 1H), 4.34 - 4.28 (m, 1H), 4.26 - 4.21 (m, 2H), 3.95 - 3.90 (m, 1Η), 3.89 - 3.85 (m, 1H), 1.99 -1.92 (m, 1H), 1.40 -1.28 (m, 9H), 0.81 (t, J= 7.1 Hz, 6H) . Compound 72-2 (100 mg, 0.2 mmol) was added to a saturated solution of hydrogen chloride and methanol (5 ml). The mixture was stirred at 36 °C for 1 hour and the reaction was completed. The reaction solution was concentrated and isopropyl ether was added. The solid was precipitated and filtered to give Compound A72 as the hydrochloride, white solid (74 mg, 80% yield). 1H NMR (600 MHz, Methanol-Λ) δ 8.15 (s, 1H), 7, 12 (s, 1H), 4.75 (d, J = 5.2 Hz, 1H), 4.62 (dd, J= 12.1,7.4 Hz, 1H), 4.54 (dd, J = 12,1,2.8 Hz, 1H), 4.45 (td, J = 7.5, 2.8 Hz, 1H), 4.05 - 4.01 (m, 2H), 2.34 - 2.28 (m, 1H), 1.08 (d, J = 2.4 Hz, 3H), 1.07 (d, J= 2.3 Hz, 3H),13C NMR (151 MHz, Methanol-oL ) δ 168.15, 148.61, 135.04, 129.77, 114.70, 113.28, 112.57, 80.77, 79.53, 74.42, 70.17, 64.81, 57.56, 29.19, 16.48, 16.32. MS m / z = 392.0 [M + 1]+. Preparation Example 20: Synthesis of Compound A74 and A164 iv ze Ln / zznz / E / YiAi According to the synthesis method of Compound A144, with A10 (176 mg, 0.6 mmol, with a deuteration rate of 99%) as starting material, Compounds A74 and A164 were synthesized in five steps, and recrystallization Additional gave pure A164 as a white, solid compound (139 mg, 64% total yield). For compound A164:1H NMR (600 MHz, DMSO-cfc) δ 8.07 - 7.83 (m, 3H), 6.92 (d, J = 4.6 Hz, 1H), 6.88 (d , J = 4.6 Hz, 1H), 6.41 (d, J = 6.6 Hz, 1H), 5.21 (dd, J = 5.7, 3.3 Hz, 1H), 5.02 (s, 1H), 5.01 -4.97 (m, 1H), 4.25 (d, 4=3.2 Hz, 1H), 2.66-2.58 (m, 1H), 1, 17 (d, J = 7.0 Hz, 3H), 1.15 (d, J = 6.9 Hz, 3H). MS m / z = 364.0 [M + 1 ]+. Preparation Example 21: Synthesis of Compound A75 η / ζΓίη / ζζηζ / Ε / γίΛΐ According to the synthesis method of Compound A70, with A10 (176 mg, 0.6 mmol) as starting material, Compound A75 was obtained in three steps, as a white solid (109 mg, total yield of 50%). .1H NMR (500 MHz, DMSO-ofe) δ 8.03-7.82 (m, 3H), 6.92 (d, J= 4.5 Hz, 1H), 6.82 (d, J = 4 .5 Hz, 1H), 6.33 (d, J = 6.0 Hz, 1 H), 5.39 (d, J = 5.8 Hz, 1 H), 4.71 (t, J = 5 .5 Hz, 1 H), 4.24 (d, J = 6.6 Hz, 1H), 3.97 (q, J = 5.8 Hz, 1H), 2.57 - 2.53 (m, 1H), 1.07 (d, J = 2.5 Hz, 3H), 1.06 (d, J = 2.5 Hz, 3H). MS m / z = 364.0 [M + 1]+. Preparation Example 22: Synthesis of Compound A76 and A214 According to the synthesis method of Compound A213, with 74-2 (295 mg, 0.5 mmol) as starting material, Compound A214 was obtained in three steps, as the dihydrochloride salt, white solid (97 mg, total efficiency of 42 %).1H NMR (500 MHz, Methanol-cL) δ 8.17 (s, 1H), 7.49 (d, J= 4.8 Hz, 1H), 7.21 (d, J = 4.9 Hz, 1H), 5.53 (dd, J= 5.8, 3.1 Hz, 1H), 5.19 (d, J= 5.8 Hz, 1H), 4.50 (d , J = 3.1 Hz, 1H), 4.13 (d, J = 4.5 Hz, 1H), 2.58 - 2.50 (m, 1 H), 1.18 (d, J = 4 .6 Hz, 3H), 1.17 (d, J = 4.6 Hz, 3H). MS m / z = 393.0 [M + 1]+. If the mixture of 76-2a and 76-2b obtained from the second stage was directly deprotected, the mixture of A76 and A214 could be obtained, and the content of A76 was about 10%. Preparation Example 23: Synthesis of Compound A77 Α77 IV 7Γ ίη / ΖΖΩΖ / Ε / ΥΙΛΙ According to the synthesis method of Compound A72, with A10 (1.0 mmol, 293 mg) as starting material, Compound A77 was obtained in four steps, as the dihydrochloride salt, white solid (107 mg, total yield 23 %).MS m / z = 393.0 [M + 1]+. Preparation Example 24: Synthesis of Compound A84 Compound A1 (49 mg, 0.16 mmol) was added to acetone (3 ml), followed by the successive addition of 2,2-dimethoxypropane (83 mg, 0.8 mmol, 5 eq) and p-acid monohydrate. toluenesulfonic acid (30 mg, 0.16 mmol, 1 equivalent). After addition, the mixture was heated to 40 °C, stirred for 2 hours, and TLC showed that the reaction was complete. The reaction solution was added to a saturated aqueous sodium bicarbonate solution (20 ml) and extracted with ethyl acetate. The organic phase was separated, dried, concentrated and separated by preparative TLC chromatography to give Compound 84-1 as a white solid (27 mg, 48% yield). Compound 84-1 (27 mg, 0.077 mmol) was added to anhydrous tetrahydrofuran (3 mL), followed by dropwise addition of 3 M methylmagnesium bromide in 2-methyltetrahydrofuran (0.05 mL, 0.15 mmol, 2 eq) in an ice bath. After addition, the mixture was stirred for 5 minutes; Compound B (57 mg, 0.12 mmol, 1.5 equiv.) in anhydrous tetrahydrofuran (1 ml) was added dropwise. After addition, the reaction was carried out at room temperature for 2 hours and TLC showed that the reaction was complete. The reaction solution was added to a saturated ammonium chloride solution (20 ml) and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give Compound 842 as an oil which was used directly in the next step. The product obtained from the previous step was added to tetrahydrofuran (2 ml), followed by the dropwise addition of concentrated hydrochloric acid (0.4 ml) in an ice bath. Once the addition was complete, the mixture was stirred at room temperature until the reaction was complete. The reaction solution was added to a saturated aqueous sodium bicarbonate solution (20 ml) and extracted with ethyl acetate. The organic phase was separated, dried, concentrated and separated on preparative TLC plates to give Compound A84 as a white solid (10 mg, 21% yield).1H NMR (500 MHz, DMSO-dg) δ 8.12 ( brs, 1H), 7.88 (s, 1H), 7.42 (brs, 1 H), 7.36 (t, J = 7.7 Hz, 2H), 7.24 - 7.14 (m, 3H), 6.73 (s, 1H), 6.45 (d, J = 6.0 Hz, 1H), 6.12-6.02 (m, 1H), 5.39 (d, J= 6 .0 Hz, 1H), 4.56 (t, J= 5.2 Hz, 1H), 4.31 -4.19 (m, 2H), 4.16-4.06 (m, 1H), 4 .01 - 3.77 (m, 4H), 1.45 - 1.38 (m, 1H), 1.28 - 1.20 (m, 7H), 0.80 (t, J = 7.4 Hz , 6H),1H NMR (500 MHz, Methanol-di) δ 7.82 (s, 1H), 7.34 (t, J = 7.9 Hz, 2H), 7.27 - 7.16 (m, 3H), 6.72 (s, 1H), 4.73 (d, J = 5.2 Hz, 1H), 4.46-4.35 (m, 2H), 4.33-4.27 (m , 1H), 4.15 (t, J= 5.7 Hz, 1H), 4.06 (dd, J= 11.0, 5.8 Hz, 1H), 4.01 -3.90 (m, 2H), 1.53- 1.45 (m, 1H), 1.38- 1.30 (m, 7H), 0.89 (t, J= 7.5 Hz, 6H). Preparation Example 25: Synthesis of Compound A102 > your N C N N C -j C* N > C A102 Compound A1 (62 mg, 0.2 mmol) and 1,8-bis(dimethylamino)naphthalene (56 mg, 0.26 mmol, 1.3 eq) were added to trimethyl phosphate (3 ml) and shaken in an ice bath. Phosphorus oxychloride (153 mg, 1.0 mmol, 5 eq) was added slowly. Approximately 3 hours, the TLC showed that the raw material had been almost completely consumed. A solution of tributylammonium pyrophosphate (549 mg, 1.0 mmol, 5 eq) in DMF (3 ml) was added to the above-mentioned solution, followed by the addition of tri-n-butylamine (222 mg, 1.2 mmol , 6 eq). After stirring in an ice bath for 10 minutes, the reaction solution was heated naturally. The reaction was monitored by TLC until the amount of product stopped increasing. A 0.5 M aqueous solution of triethylammonium bicarbonate was added to the reaction solution to adjust the pH to 7.5, then deionized water (5 ml) was added and extracted with dichloromethane and ethyl acetate, respectively. The organic phase was discarded. The aqueous phase was separated on a gel column to obtain crude A102, which was further purified by reverse phase column chromatography to obtain A102 as the ditriethylamine salt, foamy solid (44 mg, 29% yield).1H NMR ( 500 MHz, D2O) δ 7.88 (s, 1H), 6.87 (s, 1H), 4.76 (d, J=5.2 Hz, 1H), 4.45 - 4.41 (m, 1H), 4.38 (t, J= 4.8 Hz, 1H), 4.17-4.10 (m, 2H), 3.12 (q, J= 7.3 Hz, 12H), 1, 19 (t, J= 7.3 Hz, 18H),31P NMR (202 MHz, D2O) δ -10.89 (d), -11.46 (d), -23.19 (t). MS m / z = 548.0 [M - 1]-. Preparation Example 26: Synthesis of Compound A106 Α9 η / ζΓίη / ζζηζ / Ε / γίΛΐ According to the synthesis method of Compound A102, with A9 (58 mg, 0.2 mmol, with a deuteration rate of not less than 97%) as starting material, A106 was obtained in the form of tritriethylamine salt, solid foam (55 mg, 33% yield).1H NMR (500 MHz, D2O) δ 7.92 (s, 1H), 7.02 (s, 1H), 4.92 (d, J= 4.4 Hz, 1H), 4.50 - 4.42 (m, 2H), 4.16 - 4.10 (m, 1H), 4.09 - 4.01 (m, 1H), 3.11 (q, J =7.3 Hz, 18H), 1.19 (t, J= 7.2 Hz, 27H),31P NMR (202 MHz, D2O) δ -10.90 (d), -11.52 (d), -23.29 (t). MS m / z = 531.0 [M - 1]-. Preparation Example 27: Synthesis of Compound A107 According to the synthesis method for Compound A102, with A10 (59 mg, 0.2 mmol, with a deuteration rate of 99%) as starting material, product A107 was obtained in the form of tetratriethylamine salt, foam solid (54 mg, 29% yield).1H NMR (500 MHz, D2O) δ 7.97 (s, 1H), 7.17 (d, J= 4.9 Hz, 1H), 7.07 (d , J= 4.8 Hz, 1H), 4.87 (d, J= 5.0 Hz, 1H), 4.48-4.40 (m, 2H), 3.12 (q, J = 7, 3 Hz, 24H), 1.20 (t, J= 7.3 Hz, 36H),31P NMR (202 MHz, D2O)or-10.92 (d), -11.45 (d), -23, 29 (t). MS m / z = 532.0 [M - 1] , Preparation Example 28: Synthesis of Compound A109 2-1 A109 Compound 2-1 (145 mg, 0.5 mmol) was added to trimethyl phosphate (2 ml), followed by the addition of phosphorus oxychloride (153 mg, 1 mmol, 2 eq) in an ice bath. After stirring for 3-4 hours, TLC showed that a large amount of raw material still remained. Additional phosphorus oxychloride (80 mg) was added and the mixture was stirred for an additional 2 hours in the ice bath. A suspension of tributylammonium pyrophosphate (1.1 g, 2 mmol, 4 eq) in acetonitrile (2 ml) and tri-n-butylamine (741 mg, 4 mmol, 8 eq) was added to the reaction solution, and The mixing continued, to be stirred for 2 hours. A 1 M aqueous solution of triethylammonium bicarbonate (8 ml) was added to the reaction solution, followed by the addition of distilled water (8 ml) and then stirred. The mixture was extracted with ethyl acetate and the organic phase was discarded. The aqueous phase was lyophilized and separated by preparative liquid chromatography to give Compound A109 as the tri-tri-n-butylamine salt, white solid (55 mg, 10% yield).1H NMR (400 MHz, D2O) δ 7.85 (s, 1H), 7.00 - 6.91 (m, 2H), 4.89 - 4.83 (m, 1H), 4.43 - 4.36 (m, 2H), 4 .13 - 4.04 (m, 1H), 4.03-3.94 (m, 1H), 3.04-2.93 (m, 18H), 1.60- 1.47 (m, 18H ), 1.29- 1.17 (m, 18H), 0.79 (t, J = 7.4 Hz, 27H). MS m / z = 530.0 [M -1]-. Preparation Example 29: Synthesis of Compound A112 nh2nh2hoVA™ ” ΎΠ HO OHHO 0H 2-1 A112 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 2-1 (291 mg, 1.0 mmol) was added to tetrahydrofuran (6 mL), followed by the addition of concentrated hydrochloric acid (3 mL) and the mixture was stirred at 45 °C. The reaction was monitored by TLC until completion. The solvent was evaporated and separated by silica gel column chromatography to obtain Compound A112 as a white solid (168 mg, 54% yield). 1H NMR (500 MHz, DMSO-ob) δ 7.77 (s , 1H), 7.72 (brs, 2H), 7.49 (s, 1H), 7.44 (s, 1H), 6.83 (d, J= 4.5 Hz, 1H), 6, 62 (d, J= 4.5 Hz, 1 H), 5.58 (s, 1H), 4.93 (s, 1H), 4.85 (d, J = 4.4 Hz, 1H), 4 .68 (s, 1H), 4.08 - 3.98 (m, 2H), 3.52 (d, J = 12.0 Hz, 1H), 3.34-3.29 (m, 1H) . MS m / z = 310.1 [M + 1]+. Preparation Example 30: Synthesis of Compound A173 and A188 According to the synthesis method for Compound A144, with A11 (294 mg, 1.0 mmol) as starting material, compounds A173 and A188 were obtained in five steps, and further recrystallization provided pure A188 as a white solid (91 mg, 25% total yield). For compound A188:1H NMR (600 MHz, DMSO-cfe) δ 8.07 - 7.83 (m, 3H), 6.88 (s, 1H), 6.41 (d, J= 6.6 Hz , 1H), 5.21 (dd, J = 5.7, 3.3 Hz, 1H), 5.02 (s, 1H), 5.01 - 4.97 (m, 1H), 4.25 (d, J = 3.2 Hz, 1H), 2.66 - 2.58 (m, 1H), 1.17 (d, J= 7.0 Hz, 3H), 1.15 (d, J= 6.9Hz, 3H). MS m / z = 365.0 [M + 1]+. Preparation Example 31: Synthesis of Compound A180 η / ζΓίη / ζζηζ / Ε / γίΛΐ According to the synthesis method for Compound A70, with A11 (147 mg, 0.5 mmol) as starting material, Compound A180 was obtained in three steps as a white solid (80 mg, total yield of 44%). ,1H NMR (500 MHz, DMSO-cfe) δ 8.03 - 7.83 (m, 3H), 6.82 (s, 1H), 6.32 (d, J= 6.1 Hz, 1H), 5.39 (d, J = 5.8 Hz, 1H), 4.71 (t, J = 5.5 Hz, 1H), 4.23 (d, J = 6.6 Hz, 1 H), 3 .97 (q, J = 5.8 Hz, 1 H), 2.57 2.53 (m, 1H), 1.10-1.01 (m, 6H). MS m / z = 365.0 [M + 1]+. Preparation Example 32: Synthesis of Compound A174 and A215 According to the synthesis method for Compound A213, with 173-2 (296 mg, 0.5 mmol) as starting material, Compound A215 was obtained in three steps as the hydrochloride salt, white solid (93 mg, 40 % efficiency).1H NMR (500 MHz, Methanol-cfe) δ 8.17 (s, 1H), 7.21 (s, 1H), 5.53 (dd, J = 5.8, 3.1 Hz , 1H), 5.19 (d, J = 5.8 Hz, 1 H), 4.50 (d, J = 3.1 Hz, 1H), 4.13 (d, J = 4.5 Hz, 1H), 2.58 - 2.50 (m, 1H), 1.18 (d, J= 4.6 Hz, 3H), 1.17 (d, J = 4.6 Hz, 3H). MS m / z = 394.0 [M + 1]+. If the mixture 174-2a and 174-2b obtained from the second step were directly deprotected, the mixture of A174 and A215 could be obtained, and the content of A174 was about 10%. Preparation Example 33: Synthesis of Compound A181 η / ζΓίη / ζζηζ / Ε / γίΛΐ According to the synthesis method for Compound A72, with A11 (147 mg, 0.5 mmol) as starting material, Compound A181 was obtained in four steps as the hydrochloride salt, white solid (75 mg, 32% performance).1H NMR (600 MHz, Methanol-cfc) δ 8.15 (s, 1H), 7.12 (s, 1H), 4.75 (d, J= 5.2 Hz, 1H), 4, 62 (dd, J= 12.1,7.4 Hz, 1H), 4.54 (dd, J= 12.1,2.8 Hz, 1H), 4.45 (td, J= 7.5, 2.8 Hz, 1H), 2.35 -2.28 (m, 1H), 1.08 (d, J= 2.4 Hz, 3H), 1.07 (d, J=2.3 Hz, 3H). MS m / z = 394.0 [M + 1]+. Preparation Example 34: Synthesis of Compound A198 A11 A198 According to the synthesis method for Compound A102, with A11 (59 mg, 0.2 mmol) as starting material, A198 was obtained in the form of tritriethylamine salt, solid foam (59 mg, 35% yield). 1H NMR (500 MHz, D2O) δ 7.90 (s, 1H), 7.00 (s, 1H), 4.84 (d, J= 4.6 Hz, 1H), 4.42 - 4.38 (m, 2H), 3.07 (q, J= 7.3 Hz, 18H), 1.15 (t, J= 7.3 Hz, 27H),31P NMR (202 MHz, D2O) δ -10, 93 (d), -11.46 (d), -23.31 (t). MS m / z = 533.0 [M - 1]'. Preparation Example 35: Synthesis of Compound A131 Compound 2-1 (58 mg, 0.2 mmol) was added to N,N-dimethylformamide (3 ml), followed by the addition of Ν,Ν-dimethylformamide dimethyl acetal (160 mg, 1.34 mmol, 6.7 eq). After addition, the reaction was carried out at room temperature and 1 hour later, the reaction was complete. Methanol was added and the reaction solution was concentrated. The residue was suspended in isopropanol and toluene to give Compound 131-1 as a white solid (59 mg, 85% yield). Compound 131-1 (59 mg, 0.17 mmol) was added to dichloromethane (5 ml), followed by the successive addition of triethylamine (138 mg, 1.36 mmol, 8 eq), DMAP (62 mg, 0. 51 mmol, 3 eq) and isobutyryl chloride (72 mg, 0.68 mmol, 4 eq) at room temperature and reacted overnight. The reaction solution was concentrated, followed by the addition of ethyl acetate (30 ml) and water (10 ml). The organic phase was separated, washed with dilute hydrochloric acid, saturated sodium bicarbonate and saturated sodium chloride respectively, dried and evaporated to give Compound 131-2 as a white solid (85 mg, 90% yield). Compound 131-2 (85 mg, 0.15 mmol) was added to acetonitrile (10 ml), followed by the addition of hydrazine hydrate (30 mg, 0.60 mmol, 4 eq), and after the addition, the reaction was complete in approximately 30 minutes. The reaction solution was added to water and extracted with ethyl acetate. The organic layer was separated, washed with dilute hydrochloric acid, saturated sodium bicarbonate and saturated sodium chloride, respectively, dried and evaporated to dryness. The residue was separated by silica gel column chromatography to give Compound A131 as a white solid (70 mg, 93% yield). 1H NMR (600 MHz, DMSO-ds) δ 8.04 (br, 1H) , 7.96 (br, 1H), 7.93 (s, 1H), 6.93 (d, J = 4.6 Hz, 1H), 6.75 (d, J = 4.6 Hz, 1H) , 6.08 (d, J = 5.7 Hz, 1H), 5.44 (dd, J = 5.7, 3.7 Hz, 1 H), 4.63 (q, J = 3.7 Hz , 1H), 4.33 (dd, J = 12.4, 3.3 Hz, 1H), 4.28 (dd, J = 12.4, 4.1 Hz, 1 H), 2.66 - 2 .57 (m, 2H), 2.50 - 2.46 (m, 1H), 1.17 (d, J= 7.0 Hz, 3H), 1.15 (d, J= 6.9 Hz, 3H), 1.12-1.09 (m, 6H), 1.05 (d, J=7.0 Hz, 3H), 1.02 (d, J= 7.0 Hz, 3H). MS m / z = 502.0 [M + 1]+. Preparation Example 36: Synthesis of Compound A151 rv ze Ln / zznz / E / YiAi According to the synthesis method for Compound A131, with A9 (58 mg, 0.2 mmol) as starting material, Compound A151 was obtained in three steps as a white solid (69 mg, total yield of 68%). .1H NMR (600 MHz, DMSO-ofe) δ 8.04 (br, 1H), 7.96 (br, 1H), 7.93 (s, 1H), 6.75 (s, 1H), 6, 08 (d, J = 5.7 Hz, 1H), 5.44 (dd, J = 5.7, 3.7 Hz, 1H), 4.63 (q, J = 3.7 Hz, 1H), 4.33 (dd, J = 12.4, 3.3 Hz, 1H), 4.28 (dd, J= 12.4, 4.1 Hz, 1H), 2.66-2.57 (m, 2H), 2.49-2.46 (m, 1H), 1.17 (d, J = 7.0 Hz, 3H), 1.15 (d, 6.9 Hz, 3H), 1.12 - 1.09 (m, 6H), 1.05 (d, J =7.0 Hz, 3H), 1.02 (d, J= 7.0 Hz, 3H),13C NMR (126 MHz, DMSO-cfe) δ 175.53, 174.90, 174.13, 155.58, 148.12, 120.98, 117.17, 115.44, 110.30, 81.25, 75.81,72.05, 70.30, 62.46, 33.20, 33.16, 33.09, 18.55, 18.46, 18.40, 18.35, 18.33, 18, 18. MS m / z = 503.0 [M + 1]+. Preparation Example 37: Synthesis of Compound A171 HO' 'OH 171-1 According to the synthesis method for Compound A131, with A10 (59 mg, 0.2 mmol) as starting material, Compound A171 was obtained in three steps as a white solid (70 mg, total yield of 69%). . MS m / z = 504.0 [M + 1]+. Preparation Example 38: Synthesis of Compound A196 IV 7Γ ίη / ΖΖΩΖ / Ε / ΥΙΛΙ According to the synthesis method for Compound A131, with A11 (59 mg, 0.2 mmol) as starting material, Compound A196 was obtained in three steps as a white solid (59 mg, total yield of 58%). . MS m / z = 505.0 [M + 1]+. Preparation Example 39: Synthesis of Compound A209 Compound 1-1 (0.5 g, 0.89 mmol) was added to DMF (9 mL), followed by the addition of NBS (0.16 g, 0.89 mmol, 1.0 eq) and stirred. at room temperature for 3-4 hours. TLC showed that the reaction was complete. A saturated solution of sodium thiosulfate (10 ml) was added to the reaction solution, then stirred and extracted with ethyl acetate. The aqueous layer was extracted with ethyl acetate (20 ml) again. The organic layers were combined, dried, concentrated, and separated by column chromatography to obtain Compound 209-1 as a white solid (0.5 g, 87% yield). Compound 209-1 (0.15 g, 0.23 mmol) was added to N,N-dimethylacetamide (5 ml), followed by the successive addition of Zn (2 mg, 0.031 mmol, 0.13 eq). , Zn(CN)a (0.06 g, 0.51 mmol, 2.2 eq), NICl2(dppf) (0.03 g, 0.043 mmol, 0.2 eq) and Pd2(dba)s (0, 02 g, 0.02 mmol, 0.1 eq). After addition, the reaction was carried out at 140 °C overnight. TLC showed that the reaction was complete. The reaction solution was poured into ethyl acetate / water (20 ml / 20 ml), the layers were separated and the aqueous layer was extracted with ethyl acetate (20 ml) again. The organic layers were combined, dried, concentrated, and separated on preparative TLC plates to obtain Compound 209-2 as a white solid (0.1 g, 74% yield). Compound 209-2 (0.1 g, 0.17 mmol) was added to dichloromethane (3 mL), and 1 M boron trichloride in dichloromethane (0.7 mL, 4.1 equiv.) was added dropwise. at -30°C. After addition, the mixture was stirred at the same temperature for 1-2 hours. TLC showed that the reaction was complete. Methanol (0.5 ml) and triethylamine (0.3 ml) were added successively to the reaction solution. The resulting solution was evaporated to dryness and separated on preparative TLC plates to obtain the Compound. Α209 as a white solid (15 mg, 28% yield).1H NMR (500 MHz, DMSO-cfe) δ 8.23 ​​(s, 1H), 7.50 (s, 1H), 6.30 (d, J= 6.1 Hz, 1H), 5.22 (d, J= 5.9 Hz, 1H), 4.93 (t, J= 5.7 Hz, 1H), 4.55 (t, J= 5.5 Hz, 1H), 4.11 - 4.03 (m, 1H), 3.94 (q, J= 5.8 Hz, 1H), 3.73 - 3.65 (m, 1H) ), 3.57 - 3.49 (m, 1H). MS m / z = 317.1 [M + 1]+. Preparation Example 40: Synthesis of Compound A87 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 11-1 (0.05 g, 0.15 mmol) was added to tetrahydrofuran (3 mL), followed by dropwise addition of 3 M methylmagnesium bromide in 2-methyltetrahydrofuran (0.1 mL, 0.1 mL). 3 mmol) in an ice bath. After addition, the mixture was stirred for 5 minutes and then the solution of compound B (0.1 g, 0.23 mmol) in tetrahydrofuran (1 ml) was added dropwise. After that, the mixture was stirred at room temperature for 2 hours. TLC showed that the reaction was complete. The reaction solution was added to a saturated ammonium chloride solution (10 ml) and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give crude Compound 87-1, which was used directly in the next step. The product obtained from the previous step was added to tetrahydrofuran (2 ml), followed by the addition of concentrated hydrochloric acid (0.4 ml) in an ice bath. After addition, the mixture was stirred at room temperature until the reaction was complete. The reaction solution was added to a saturated sodium bicarbonate solution (10 ml) and extracted with ethyl acetate. The organic phase was separated, dried, concentrated and separated by silica gel column chromatography to give Compound A87 as a white solid (0.03 g, 33% yield). 1H NMR (500 MHz, Methanol-cL) δ 7.89 (s, 1H), 7.367.30 (m, 2H), 7.24 - 7.15 (m, 3H), 6.94 (s, 1 H), 4.82 (d, J = 5.4 Hz, 1H), 4.46 - 4.37 (m, 2H), 4.35 - 4.28 (m, 1H), 4.20 (t, J = 5.6 Hz, 1H), 4.05 (dd, J = 10.9, 5.8 Hz, 1H), 3.98 - 3.88 (m, 2H), 1.51-1.44 (m, 1H), 1.37 - 1.30 (m, 7H), 0.88 (t, J = 7.5 Hz, 6H). MS m / z = 604.1 [M + 1 ]+. Preparation Example 41: Synthesis of Compound A138 η / ζΓίη / ζζηζ / Ε / γίΛΐ According to the synthesis method for Compound A70, with A9 (147 mg, 0.5 mmol) as starting material, Compound A138 was obtained in three steps as a white solid (65 mg, total yield of 37%). .1H NMR (400 MHz, DMSO-d6) δ 7.99-7.83 (m, 3H), 6.80 (s, 1H), 6.32 (d, J = 6.1 Hz, 1H), 5.38 (d, J= 5.8 Hz, 1H), 4.71 -4.65 (m, 1H), 4.33 (dd, J= 12.0, 2.8 Hz, 1H), 4 .25-4.19 (m, 1H), 4.15 (dd, J= 12.0, 5.5 Hz, 1H), 3.97-3.90 (m, 1H), 2.30 (q , J= 7.5 Hz, 2H), 1.00 (t, J= 7.5 Hz, 3H). MS m / z = 349.2 [M + 1]+. Preparation Example 42: Synthesis of Compound A140 According to the synthesis method for A70, with A9 (147 mg, 0.5 mmol) as starting material, Compound A140 was obtained in three steps as a white solid (77 mg, total yield of 41%).1H NMR (500 MHz, DMSO-d6) δ 8.03 - 7.80 (m, 3H), 6.80 (s, 1H), 6.32 (d, J=6.1 Hz, 1H), 5, 37 (d, J= 5.7 Hz, 1H), 4.70 (t, J= 5.3 Hz, 1H), 4.30-4.22 (m, 2H), 4.21 -4.14 (m, 1H), 4.01 -3.94(m, 1H), 1.09 (s, 9H). MS m / z = 377.2 [M + 1]+. Preparation of Example 43: Synthesis of Compound A146 Α70 Compound A70 (0.18 g, 0.5 mmol) was added to acetic acid (3 ml), then trimethyl orthoisobutyrate (0.37 g, 2.5 mmol) was added and the mixture was stirred at 50 °C until reaction was completed. The solvent was removed by evaporation to obtain an unstable intermediate 146-1. intermediate was dissolved in tetrahydrofuran (6 ml), followed by the addition of dilute hydrochloric acid 1 la (0.5 ml) and stirred at room temperature. The reaction was complete in approximately 1 hour. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution until the pH was neutral and extracted with ethyl acetate. The organic phase was dried and evaporated to dryness to obtain crude Compound A146. The crude product was recrystallized from isopropanol / water to obtain a white solid (0.18 g, 82% yield).1H NMR (600 MHz, DMSO-cfe) δ 8.05 - 7.83 (m, 3H), 6.85 (s, 1H), 6.56 (d, J= 6.5 Hz, 1H), 5.16 (dd, J= 5.6, 4.1 Hz, 1H), 5.09 (t , J= 6.1 Hz, 1 H), 4.46 (q, J= 4.3 Hz, 1H), 4.27 (dd, J= 12.2, 4.0 Hz, 1H), 4, 23 (dd, J= 12.2, 4.8 Hz, 1H), 2.67 - 2.58 (m, 1H), 2.55-2.49 (m, 1H), 1.16 (d, J= 7.0 Hz, 3H), 1.15 (d, J= 7.0 Hz, 3H), 1.05 (d, J= 7.0 Hz, 3H), 1.03 (d, J= 7.2Hz, 3H). MS m / z = 433.2 [M + 1]+. Preparation Example 44: Synthesis of Compound A147 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 151-1 (1.51 g, 4.34 mmol) was added to Ν,Ν-dimethylformamide (15 mL), followed by the addition of tert-butyldiphenylchlorosilane (2.39 g, 8.69 mmol) and imidazole. (1.18 g, 17.37 mmol) in an ice bath and stirred at room temperature for 5 hours. Water and ethyl acetate were added to the reaction solution. The organic phase was separated, washed with dilute hydrochloric acid, saturated aqueous sodium bicarbonate solution and saturated saline successively, dried over anhydrous sodium sulfate, concentrated and separated by silica gel column chromatography to give 2.05 g of Compound 147-1 as a solid foam. Compound 147-1 (2.05 g, 3.50 mmol) was added to dichloromethane (30 ml), followed by the addition of triethylamine (1.24 g, 12.26 mmol), DMAP (0.21 g, 1.75 mmol) and isobutyric anhydride (1.39g, 8.76 mmol). mmol) at room temperature and reacted for 1 hour under protection with nitrogen at room temperature. The reaction solution was concentrated and water and ethyl acetate were added. The organic phase was separated, washed with dilute hydrochloric acid, saturated aqueous sodium bicarbonate solution and saturated saline successively, dried over anhydrous sodium sulfate and concentrated to obtain crude Compound 147-2 as an oil, which was used directly in the following reaction without purification. The product obtained from the previous step was added to tetrahydrofuran (30 ml), followed by the addition of acetic acid (0.11 g, 1.75 mmol) and 1 M tetrabutylammonium fluoride (3.5 ml, 3.5 mmol ) in tetrahydrofuran, and stirred at room temperature for 2 hours. Water and ethyl acetate were added to the reaction solution. The organic phase was separated, washed with saturated aqueous sodium bicarbonate solution and saturated saline successively, dried over anhydrous sodium sulfate, and concentrated to obtain crude Compound 147-3 as an oil. The crude 147-3 obtained in the previous step was added to ethanol (20 ml), followed by the addition of acetic acid (4.2 g, 70 mmol) at room temperature and stirred overnight at 50 °C under protection. with nitrogen. The reaction solution was concentrated and then water and ethyl acetate were added. The organic phase was separated, washed with saturated sodium bicarbonate and saturated saline successively, dried over anhydrous sodium sulfate, concentrated and separated by silica gel column chromatography to give Compound A147 as a white solid ( 0.85 g, 56% efficiency in 3 steps).1H NMR (500 MHz, DMSO-ofe) δ 8.15 - 7.89 (m, 3H), 6.80 (s, 1H), 6.01 (d, J= 5.7 Hz, 1H), 5.44 (dd, J = 5.7, 3.1 Hz, 1H), 5.18 (dd, J= 6.1,5.2 Hz, 1H), 4.41 (q, J= 3.4 Hz, 1H), 3.71 -3.60 (m, 2H), 2.69-2.54 (m, 2H), 1.19 (d , J=7.0 Hz, 3H), 1.16 (d, J= 7.0 Hz, 3H), 1.11 (d, J= 2.4 Hz, 3H), 1.09 (d, J =2.4Hz, 3H). MS m / z = 433.2 [M + 1]+. Preparation Example 45: Synthesis of Compound A216 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 1-1 (0.2 g, 0.36 mmol) was added to dichloromethane (2 mL), followed by slow addition of 1.2 M diisobutylaluminum hydride in toluene (0.9 mL, 1.08 mmol ) at -78 °C. After addition, the reaction was stirred at the same temperature for 3-4 hours. TLC showed that the reaction was complete. Ethyl acetate (3 ml) was added dropwise to the reaction solution. After addition, the mixture was naturally warmed to room temperature, then a 20% aqueous sodium potassium tartrate solution (5 mL) was added and the mixture was stirred at room temperature overnight. The reaction solution was added to water (15 ml) and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to give Compound 216-1. Compound 216-1 (0.6 g, 1.06 mmol) was added to a mixture of ethanol (10 mL) and dichloromethane (10 mL), and NaBH4 (0.1 g, 2.6 mmol) was added portionwise. ) in an ice bath. After addition, the mixture was stirred at room temperature for 2-3 hours. TLC showed that the reaction was complete. Acetic acid was added to the reaction solution dropwise until no bubbles were generated. Water (30 ml) was added and the mixture was extracted with ethyl acetate. The organic layer was separated, washed with saturated sodium bicarbonate, dried, concentrated and separated by silica gel column chromatography to give Compound 216-2 as a white solid (0.48 g, 80% yield ). Compound 216-2 (0.48 g, 0.85 mmol), formic acid (2 mL), and 10% palladium on carbon (0.06 g) were successively added to methanol (6 mL), and the mixture was pumped with hydrogen at room temperature and stirred at normal pressure for 16 hours, the mixture was filtered, concentrated and separated by reverse phase column chromatography to obtain Compound A216 as a white solid (0.05 g, 20% performance).1H NMR (500 MHz, DMSO-ds) δ 7.80 (s, 1H), 7.61 (s, 2H), 6.81 (d, J= 4.4 Hz, 1H), 6 .73 (d, J = 4.4 Hz, 1H), 5.18 (d, J = 4.7 Hz, 1H), 4.89 (d, J = 6.9 Hz, 1 H), 4, 79 (t, J = 5.8 Hz, 1 H), 4.51 4.38 (m, 2H), 4.16 (dd, J = 11.6, 6.7 Hz, 1H), 3.99 (dd, J = 11.6, 4.7 Hz, 1H), 3.94 - 3.83 (m, 1H), 3.78 71 3.69 (m, 1 Η), 3.70 - 3.59 (m, 1 Η), 3.56 - 3.47 (m, 1H). MS m / z = 297.1 [M + 1 ]+. Preparation Example 46: Synthesis of Compound A28 η / ζΓίη / ζζηζ / Ε / γίΛΐ A solution of 0.5 M cyclopropyl magnesium bromide in tetrahydrofuran (18 ml, 9 mmol) was added dropwise to Compound 1-1 (0.5 g, 0.9 mmol) in an ice bath and stirred for overnight at room temperature after addition. Saturated ammonium chloride solution (10 ml) was added dropwise to the reaction solution in an ice bath. Then, water (50 ml) was added and the mixture was extracted with ethyl acetate. The organic layer was separated, dried, concentrated and separated by silica gel column chromatography to obtain Compound 28-1 as a white solid (0.2 g, 37% yield). Compound 28-1 (0.2 g, 0.34 mmol) was added to dichloromethane (4 mL) and methanesulfonic acid (0.1 g, 1.04 mmol) was added dropwise in an ice bath. Once the addition was complete, the mixture was stirred at room temperature for 10-12 hours. TLC showed that the reaction was complete. Saturated sodium bicarbonate solution (10 ml) was added to the reaction solution until the pH was neutral. Water (15 ml) was then added and the mixture was extracted with ethyl acetate. The organic phase was separated, dried, concentrated and separated by silica gel column chromatography to give Compound 28-2 as a white solid (0.1 g, 51% yield). Compound 28-2 (0.24 g, 0.42 mmol), formic acid (1 mL) and 10% palladium on carbon (0.03 g) were successively added to methanol (3 mL), pumped with hydrogen and stirred at atmospheric pressure for 16 hours, at room temperature. TLC showed that the reaction was complete. The mixture was filtered, concentrated and separated by silica gel column chromatography to obtain Compound A28 as a white solid (13 mg, 10% yield). 1H NMR (500 MHz, Methanol-d4) δ 7, 78 (s, 1H), 6.85 (d, J = 4.5 Hz, 1 H), 6.79 (d, J = 4.5 Hz, 1 H), 4.78 (d, J = 5 ,1 Hz, 1H), 4.01 - 3.95 (m, 1H), 3.95 - 3.89 (m, 1H), 3.81 (dd, J = 11.9, 2.8 Hz, 1H), 3.68 (dd, J = 11.8, 5.5 Hz, 1H), 2.02 1.92 (m, 1H), 0.68-0.52 (m, 2H), 0 .28-0.19 (m, 1H), 0.19-0.08 (m, 1H). MS m / z = 307.1 [M + 1]+. Preparation Example 47: Synthesis of Compound A218 A solution of 1.0 M isopropenyl magnesium bromide in tetrahydrofuran (40 ml, 40 mmol) was added dropwise to Compound 1-1 (2.2 g, 3.98 mmol) in an ice bath and stirred for overnight at room temperature after addition. Saturated ammonium chloride solution (10 ml) was slowly added to the reaction solution. After addition, water (40 ml) was added and the mixture was extracted with ethyl acetate. The organic layer was separated, dried, concentrated, and separated by silica gel column chromatography to obtain intermediate 218-1 as a white solid (1.6 g, 68% yield). Intermediate 218-1 (1.6 g, 2.69 mmol) was added to dichloromethane (30 mL) and methanesulfonic acid (0.77 g, 8.01 mmol) was added slowly. After addition, the mixture was stirred at room temperature overnight. TLC showed that the reaction was complete. Saturated sodium bicarbonate solution was added dropwise to the reaction solution in an ice bath until the pH was neutral. Water (40 ml) was added and the mixture was extracted with dichloromethane. The organic layer was separated, dried, concentrated, and separated by silica gel column chromatography to obtain intermediate 218-2 as a yellow oil (0.7 g, 45% yield). According to the method for the debenzylation step of Example 5, intermediate 218-2 (0.7 g, 1.21 mmol) was reacted with a solution of 1.0 M BCh in dichloromethane (6.0 ml, 6.0 mol) to give the product which was separated by column, chromatography to give 0.025 g of Compound A218 as a white solid.1H NMR (600 MHz, DMSO-cfe) δ 7.74 (s, 1H), 7.55 ( s, 2H), 6.82 (d, J= 4.5 Hz, 1H), 6.58 (d, J = 4.4 Hz, 1H), 5.03 (s, 1H), 4.83 - 4.73 (m, 3H), 4.72 - 4.64 (m, 2H), 4.05 - 3.94 (m, 1H), 3.84 - 3.76 (m, 1H), 3, 70 - 3.60 (m, 1 H), 3.51 - 3.42 (m, 1H), 1.59 (s, 3H), m / z = 307.2 [M+1 ]+. Preparation Example 48: Synthesis of Compound A219 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 1-1 (0.56 g, 1.0 mmol) was added to tetrahydrofuran (5 mL), followed by dropwise addition of 3 M methyl magnesium bromide in tetrahydrofuran (1.7 mL, 5.1 mmol) in an ice bath under nitrogen protection. After addition, the mixture was stirred at 60 °C for 2-3 hours. TLC showed that the reaction was complete. Saturated ammonium chloride solution (1.0 ml) was added dropwise into an ice bath. Water (10 ml) was added and the mixture was extracted with ethyl acetate. The organic layer was separated, dried, concentrated and separated by column chromatography to obtain Compound 219-1 as a white solid (0.38 g, 66% yield). According to the method for the debenzylation step of Example 5, intermediate 219-1 (0.2 g, 0.345 mmol) was reacted with a solution of 1.0 M BCh in dichloromethane (1.7 ml, 1. 7 mmol) to give the product which was separated with silica gel column chromatography to give Compound A219 as a white solid (0.05 g, 47% yield).1H NMR (600 MHz, DMSO-cfe) δ 7.99 - 7.43 (m, 3H), 6.79 (s, 1H), 6.62 (s, 1H), 5.49 (s, 1H), 5.10-4.93 (m, 1H), 4.83 -4.67 (m, 1H), 4.60-4.40 (m, 1H), 4.19-3.96 (m, 2H), 3.59-3.44 ( m, 1H), 3.27-3.16 (m, 1H), 2.30 (s, 3H). MS m / z = 309.2[M+1]+. Preparation Example 49: Synthesis of Compound A221 η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 49-2 (0.6 g, 1 mmol) was added to DMF (10 mL), followed by the successive addition of methyl iodide (0.28 g, 2.0 mmol) and 60% sodium hydride. (0.014 g, 2.0 mmol) in a container with ice, bathtub. After stirring for 15 minutes, TLC showed that the reaction was complete. The reaction solution was added to a saturated aqueous ammonium chloride solution (15 ml) and extracted with ethyl acetate. The organic layer was separated, dried, concentrated and evaporated to dryness to give Compound 221-1. This intermediate was used in the next step without purification. The intermediate 221-1 obtained from the previous step was added to acetonitrile (2 ml), followed by the addition of 85% hydrazine hydrate (0.24 g, 4.0 mmol) and stirred at room temperature for 1 hour. . TLC showed that the reaction was complete. The reaction solution was added to water (15 ml) and the mixture was extracted with ethyl acetate. The organic layer was separated, dried, concentrated and separated by column chromatography to give Compound 221-2 as a white solid (0.2 g, 37% yield in two steps). Compound 221-2 (0.2 g, 0.36 mmol) was added to tetrahydrofuran (2 mL), followed by the addition of 1 M tetrabutylammonium fluoride in tetrahydrofuran (0.4 mL, 0.4 mmol) and stirred at room temperature for 2 hours. TLC showed that the reaction was complete. The reaction solution was concentrated and separated on preparative TLC plates to give Compound A221 as a white solid (0.045 g, 41% yield). Ή NMR (500 MHz, DMSO-cfe) δ 8.07 - 7.78 (m, 3H), 6.87 (s, 1H), 5.30 (d, J= 5.4 Hz, 1H), 4 .94 (t, J= 5.8 Hz, 1H), 4.37 (d, J= 4.9 Hz, 1H), 4.11 (q, J=5.4 Hz, 1H), 4.08 - 4.02 (m, 1H), 3.71 - 3.62 (m, 1H), 3.55 (s, 3H), 3.54 - 3.48 (m, 1H). MS m / z = 306.0 [M+1 ]+. Preparation Example 50: Synthesis of Compound A36 Compound 35-1 (8.4 g, 31.5 mmol) was dissolved in pyridino (85 mL), followed by the addition of triphenylphosphine (33.1 g, 126.2 mmol), then heated to 30 °C under protection with nitrogen and iodine (32.0 g, 126.2 mmol) was added in portions at a temperature below 40 °C. The mixture was stirred for 1 hour and TLC showed that the reaction was complete. Saturated sodium thiosulfate solution was added and the mixture was separated by silica gel column chromatography (DCM: MeOH=100: 1-10: 1) to give Compound 36-1 (8.5 g, 72% performance). Compound 36-1 (3.0 g, 8.0 mmol) was dissolved in acetonitrile (60 mL), followed by the addition of DBU (2.4 g, 16.0 mmol) and stirred at 40 °C for 3 hrs. TLC showed that the reaction was complete. The mixture was separated by silica gel column chromatography (DCM:MeOH = 50:1-10:1) to give Compound 36-2 (600 mg, 30% yield). Compound 36-2 (200 mg, 0.8 mmol) was added to THE (5 ml), followed by the addition of DBU (731 mg, 4.8 mmol) and TBSCI (543 mg, 3.6 mmol) and It was stirred at room temperature for 2 hours. TLC showed that the reaction was complete. Methanol (1 ml) and saturated aqueous citric acid solution (4 ml) were added, stirred and extracted with ethyl acetate. The organic layer was washed with saturated saline solution and saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain crude Compound 36-3. Crude Compound 36-3 was added to dichloromethane (10 ml), followed by the addition of 2,4,6trimethylpyridine (194 mg, 1.6 mmol), silver nitrate (272 mg, 1.6 mmol) and triphenylchloromethane ( 374 mg, 1.2 mmol). After reacting at room temperature for 2 hours, methanol was added. The reaction solution was concentrated and ethyl acetate was added. The solution was washed with saturated copper sulfate and saturated sodium chloride, respectively, dried over anhydrous sodium sulfate, and concentrated to give crude Compound 36-4; Crude Compound 36-4 in THF (5 ml) was added, followed by the addition of tetrabutylammonium fluoride hydrate (508 mg, 1.6 mmol) in tetrahydrofuran. The mixture was stirred for 1 hour, then more tetrabutylammonium fluoride hydrate (508 mg, 1.6 mmol) in tetrahydrofuran was added and the mixture continued to stir for 1 hour. Water was then added and the mixture was extracted with ethyl acetate. The organic layer was concentrated and separated by silica gel column chromatography to obtain Compound 36-5 as a white solid (84 mg, 22% yield in three steps); Compound 36-5 (70 mg, 0.14 mmol) was added to acetonitrile (2 mL), cooled to -5 °C in an ice-salt bath, and triethylamine trihydrofluoride (35 mg, 0.21 mmol ) and iodosuccinimide (36 mg, 0.15 mmol) were added. The reaction was carried out at the same temperature for 2 hours, then the mixture was warmed to room temperature and reacted for 2 hours. A mixed solution of saturated sodium bicarbonate and saturated sodium thiosulfate was added. The mixture was extracted with ethyl acetate and the organic layer was washed with saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated to obtain crude Compound 36-6; Crude Compound 36-6 was added to dichloromethane (5 ml), followed by the successive addition of pyridino (114 mg, 1.4 mmol), isobutyric anhydride (162 mg, 1.0 mmol) and DMAP (5 mg). The reaction was carried out at room temperature for 2 hours. Methanol was added, then concentrated and ethyl acetate was added. The resulting solution was washed with saturated copper sulfate solution and saturated sodium chloride solution, respectively, then concentrated and separated by silica gel column chromatography (PE: EA=20:1-10:1 ) to give Compound 36-7 as a light solution, -yellow solid (28 mg, 20% yield). η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound 36-7 (28 mg, 0.036 mmol) was added to DMF (2 mL), followed by the addition of 18crown-6 (26 mg) and sodium isobutyrate (35 mg, 0.32 mmol). The reaction was carried out at 110 °C for 18 hours. Water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride and separated by silica gel column chromatography (PE:EA = 20:1-10:1) to obtain 20 mg of Compound 36-8 as a light yellow solid. Compound 36-8 (100 mg, 0.14 mmol) was added to acetic acid (3 mL) and water (1 mL). The mixture was heated to 85 °C, and after reacting for 10 minutes, the raw material disappeared. Saturated sodium bicarbonate solution was added to the reaction solution and extracted with ethyl acetate. The organic layer was concentrated and separated by silica gel column chromatography (DCM: MeOH = 100:1 -50:1) to obtain 50 mg of Compound A36 as a light yellow solid. MS m / z = 495.2[M+1 ]+. Preparation Example 51: Synthesis of nucleoside analogues Compounds A5, A6, A8, A13, A14, A28, A30, A37, A54, A55, A57, A58, A63, A73, A78, A79, A80, A81, A86, A88, A89, A91, A95, A97, A99 , A101, A105, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A125, A126, A127, A128, A129, A130, A132, A133, A134, A135, A136, 137 , A139, A141, A142, A143, A145, A148, A149, A150, A152, A153, A154, A155, A156, A157, A158, A159,A160, A161, A162, A163, A165, A166, A167, A168, A169, A170, A172, A175, A176, A177, A179, A182,A183, A184, A185, A186, A187, A189, A190, A191, A192, A193, A194, A195, A197, A199, A200, A201,A202, A203, A204, A205, A206, A207, A208, A210, A211 were obtained according to the method of Preparation Examples 1 -50, which differ in the use of different raw material compounds. Test example 1: study on the inhibitory effect of compounds on the replication of the new coronavirus Determination of the inhibitory activity of the compounds of the present invention on the replication of the 2019 novel coronavirus (SARS-CoV-2): Vero E6 cells were purchased from ATCC, and the SARS-CoV-2 virus was derived from the Microbiological Culture Collection Center of National Virus Resource Center. Vero E6 cells were cultured overnight at a density of 5 χ 104 cells / well in a 48-well cell culture plate. The cells were pretreated with different concentrations of the compound of the invention for 1 hour. Virus was then added at a multiplicity of infection (MOI) of 0.05. One hour later, the virus and compound mixture was removed, and the cells were treated with fresh medium containing the compound of the invention. At 24 h p.i., the cell supernatant was collected and lysed in lysis buffer. The number of virus copies in the cell supernatant was quantitatively determined by quantitative real-time RT-PCR (qRT-PCR). The results showed that at the concentration of 10 pm or 5 pm, many compounds significantly inhibited the replication of SARS-CoV-2 compared with the control group, with an inhibition rate > 99% against the novel coronavirus. The ECso values ​​of some compounds were at a low micromolar level and their antiviral activities were significantly better than those of the control compound, remdesivir. The ECso values ​​and inhibition rates of some preferred compounds are listed in Table 1. η / ζΓίη / ζζηζ / Ε / γίΛΐ Table 1. Inhibitory activities on the replication of the new coronavirus 2019 (SARS-CoV-2) Composite number Structure (free state) Inhibition rate (10 μΜ) Inhibition rate (5 μΜ) ECso (μΜ) A1 F nh2 o W ° UC» HO' 'OH 97% 80% / A2 Cl ^H2 VN'm^ 0 / N HO LJCN HO' OH < 50 % / / A3 । NH2 0 H0 VJ%N HO' 'OH < 50 % / / A4 0 / -γ'ΝΗ 0 ΛΝ'Ν^ H0 VT'CN HO' 'OH < 50 % / / A9 D NH2 n O f N HO ljcn HO ' 'OH / 99% 0.44 A10 nh2 / ^n V O Tn n'J H0^v__ / CN HO' 'OH / 99% 0.43 η / ζΓίη / ζζηζ / Ε / γίΛΐ Α11 d νη2 dx d v-n, χζ / ° \ / ν η ° \ _7 ον HOO OH / 99% / α12 F νη2 ν V ο xnn'J HO \ 2JCN ηο 'οη / 98% / α35 i ο ξε \ οζ 7 L ° νη ΣΕ / / / Α124 νη2 / =:=γ:'Ν 0 ΖΝ'Ν^ ΗΟοΎ?™ ^-~θ' OH 99% 99% 0.25 Α50 νη2 Ζ~<γ 'Ν θ W 1 0 \ / CN HÓ~ t>H 99 % 99% 0.23 Α212 νη2 0 / Ν ΗΟ V-T'CN °Y—Ó 't)H / νη2 99% 99% 0.11 Α52 νη2 V-v??-· 'νη2 .· ΗΟ' ΟΗ / 99% / η / ζΓίη / ζζηζ / Ε / γίΛΐ Α53 O HN'^O'^CHa VN^ J HO \^ pCN HÓ OH 65% / / Α144 D NH2 0 0H / 99% 0.24 Α70 D NH2 HÓ ÓH / 99% / Α213 D NH2 / ==γ: 'Ν o >N·^ “ t_rcN \ V o'' ÓH z nh2 / 99% 0.10 Α72 D NH2 NH2 )—ζ HÓ OH / 99% Α164 nh2 ''N D D V 0 f N Hg VTCN 0H / 99 %> 0.27 η / ζΓίη / ζζηζ / Ε / γίΛΐ Α75 νη2 0 D D V-N, 1 Χ / °χΖ Ν HÓ ΟΗ / 99% / Α214 νη2 D D %-Μ J V 0. )— <, HÓ 'ΟΗ / 99% / Α84 F νη2 hc / Lo ί'? .χαΗ '^Γη' ”vh ° 0 ¿ -ζ / = / HO ΟΗ W 82% / / Α109 νη20 0 0 η ΓΝ'Ν^ II II II .0^1 Ν HO-P-0-P-O-P-O^b and, CN OH OH OH .·—·. HO' OH 99 % 99% 0.58 Α112 nh2 / ===^ ''?N oN HO .· nh2 HO' OH < 50 % / / Α131 nh2 >°· γύ \ 0 / 99% / η / ζΓίη / ζζηζ / Ε / γίΛΐ Α151 D ΝΗ2 Λ==γ 'Ν ° Αν J vAVY Ν Τ 2 VJ-™ \ 0 / 99% 0.31 Α171 νη2 2 D D V-N J ν- \ ο / 99% / Α188 -^γοο οζ, ο L ° Ο'' 1 i \Χ <-Η '--Ζ ΙΌ / 99% / Α180 CXI Ζ---X τ / / As ζΑ ζ o J Q ' / 'Ό τ αΆ ο ο=^ / 99% / Α215 D ΝΗ2 V ο ί-Ά «ΑΑΑν \ A-θ' t>H 7 νη2 / 99% / Α181 D ΝΗ2 νη2 ?—·. ΗΟ' OH / 99% / Α196 D ° D D VN^A tWA >°· \ 0 / 99% / ÍV ίη / ΖΖΩΖ / Ε / ΥΙΛΙ A209 NC NH2 o HO \ ho' Oh / / / GS-441524 nh2 °\Z N'N^ H0 \_ / CN HÓ OH / 99% 0.48 Remdesivir nh2HaC7 PH3 0 pO s h ¿ MCN / = / HO' OH w 99% 65% 2.0 Favipiravir <N z z < 20% 0% / Note: 7” means indeterminate. η / ζΓίη / ζζηζ / Ε / γίΛΐ Test example 2: Determination of the average toxic concentration of compounds In this example, the mean toxic concentration (CCso) of the compounds of the present invention (each compound in Table 1) was determined and analyzed in Vero E6 cells using the CCK8 assay kit. The results showed that the test compounds had no cytotoxic effect on Vero E6 cells at the highest concentration (10 μΜ), which suggested that the CC50 of the compounds of the present invention is much higher than 10 μΜ. Test example 3: study of the inhibitory effect of the compounds on the RNA-dependent RNA polymerase (RdRp) of the new coronavirus According to the method reported in the literature (Virus Genes, 2015, 50: 498-504), the inhibitory activity of the compound of the invention on the RNA-dependent RNA polymerase (RdRp) of the new coronavirus of 2019 (SARS-CoV- 2) was determined using the fluorescence method: after the novel coronavirus RdRp solution, substrate, compound solution, buffer solution, etc. They were coincubated for 1 hour, the fluorescent DNA binding dye was added. 10 minutes later, data collection was carried out and the inhibitory activities of the compounds on RdRp were determined. The results showed that some compounds had significant inhibitory activities on RdRp, as shown in Table 2. Table 2. Inhibitory activity of compounds in RdRp of the new coronavirus 2019. Compound number Structure (free state) ICso(pM) A102 f NH2 ° 0 0 0 γν'ν^ 11 11 II Ό. f N HO-P-O-P-O-P-O'^f y,CN OH OH OH .·--ζ HO OH B A106 D NH2 N HO-P-O-R-O-P-CV y.,CN OH OH OH .·—. HO OH A A107 nh2 0 0 0 V Vn ¿ 11 II II .0. f N HO—P--O-P-O--P- O ( 7CN OH OH OH .·— HO' OH A A108 F nh2 N 0 0 V o Vn'n^ 11 II 11 X ,O. 1 n HO-P-O-P-O-P-O^ < y.,CN OH OH OH .·-- HÓ OH / A198 D NH2 O O 0 DxD VN'N^ II II II X / Ho-p-o-p-o-p-o^y y.,CN OH OH OH}— HO' OH A A: < 1 μΜ; B: 1 μΜ ~10 μΜ; C: > 1 μΜ; means indeterminate. η / ζΓίη / ζζηζ / Ε / γίΛΐ Test example 4. Study of the inhibitory effect of the compounds on the replication of other viruses The inhibitory effects of the compounds on the replication of respiratory syncytial virus (RSV), human coronavirus OC43, influenza A virus, Zika virus (Zika) were tested by cytopathic effect (CPE) assay. Cytopathic effect (CPE) assay The experimental cells were inoculated into a 96-well cell culture plate at a certain cell density and cultured in an incubator (5% CO2, 37 °C) overnight. Compounds and viruses were added on the second day. Cells were cultured in an incubator for 3 to 7 days under conditions of 5% CO2 and 33°C or 37°C, which varied depending on the virus tested, until a cytopathic effect of 80 to 95% was observed in the well. control of virus infection (without compound). Cell viability of each well was then detected using Cell Titer-Glo or CCK-8. If the cell viability of the well containing the compound was greater than that of the virus infection control well, that is, the ΟΡΕ was reduced, indicating that the compound had an inhibitory effect against the virus tested. The cytotoxicity test method was the same as the corresponding antiviral test method without virus infection. The antiviral activity and cytotoxicity of the compounds are respectively indicated by the inhibition rate (%) of the compounds on virus-induced cellular viral effects and cell viability (%). The calculation formulas are as follows: Inhibition rate (%) = (test well reading value - average value of virus control) / (average value of cell control - average value of virus control) χ 100; Cell viability (%) = (test well reading value - average value of medium control) / (average value of cell control - average value of medium control) χ 100; The EC50 and CC50 values ​​are calculated using Prism software, and the inhibition curve fitting method is “log (inhibitor) vs. response – Variable slope”. Dengue virus plaque reduction test Vero cells were inoculated into a 6-well cell culture plate at a density of 600,000 cells per well and cultured in an incubator (5% CO2, 37°C) overnight. Compounds and viruses (40-50 PFU / well) were added on the second day. The cells were incubated in an incubator under conditions of 5% CO2 and 37 °C for 2 h, then the supernatant was suctioned off and low-melting agarose medium containing the corresponding concentration of compounds was added. Cells were cultured in an incubator for 6-7 days under conditions of 5% CO2 and 33°C or 37°C until an obvious virus plaque could be observed microscopically in the virus infection control well (no compound). . Cells were fixed with 4% paraformaldehyde and stained with crystal violet. The number of plates in each well was calculated. The cytotoxicity experiment was carried out in parallel with the antiviral experiment. Vero cells were inoculated into a 96-well cell culture plate at a density of 20,000 cells per well and cultured in an incubator (5% CO2, 37°C) overnight. Compounds (1-5 concentration points, single point) were added the next day. Cells were cultured in an incubator for 6–7 days under conditions of 5% CO2 and 33°C or 37°C. Cell viability of each well was then detected using CCK-8. The antiviral activity (EC50 or inhibition rate) and cytotoxicity (CC50) of the compounds were calculated using the same method described above. Test for activity against porcine epidemic diarrhea virus (PEDV) Vero cells were digested and passaged. Cell density was adjusted to 1 χ 105 / ml using cell growth media. Cells were inoculated in a 96-well plate, 100 μΙ / well, and cultured in an incubator (37 °C, 5% CO2) for 24 hours. The 96-well plate was removed; The culture medium in the well was discarded and washed with 1 χ PBS three times. After centrifugation, the mixture of compound (10 point concentration) and virus (0.01 MOI per well) was added to each well with 8 replicates for each concentration and grown in an incubator at 37 °C and 5% CO2. . Virus control and cell control were established at the same time. After 36 h, η / ζΓίη / ζζηζ / Ε / γίΛΐ cell samples were collected and changes in virus content in different treatment groups were determined using fluorescence quantitative PCR. The ECso of the compound was calculated. The results showed that many compounds have significant antiviral activities against respiratory syncytial virus (RSV), human coronavirus OC43 (HCoV OC43), porcine epidemic diarrhea virus (PEDV), Zika virus (Zika), and dengue virus. (DENV). Compared with GS441524, deuterated derivatives have a stronger antiviral effect. The EC50 values ​​of some preferred compounds are listed in Table 3 and Table 4. Table 3. Inhibitory activity on the replication of respiratory syncytial virus (RSV), human coronavirus OC43 (HCoV OC43) IV 7Γ Ln / Zznz / E / YIAI Compound number Structure (free state) RSV (HEp-2) HCoV OC43 (Huh7) ECso (μΜ) CCso (μΜ) ECso (μΜ) CCso (μΜ) A1 F nh2 * 0. / N / 'CN HO' OH / / / / A9 D 7H2 ¿''CN HO' OH 0.56 > 10 1.77 > 10 A10 nh2 v o V-y HO \_ / CN HO' OH 0.63 > 10 1.98 > 10 A11 D NH2 D D y 'N H° vJ 'ON HÓ ÓH 0.66 > 10 1.99 > 10 A144 D NH2 N 0 / N 0H 0.47 > 10 1.88 > 10 Α70 D ΝΗ2 HÓ ÓH 0.58 > 10 1.90 > 10 Α213 D ΝΗ2 / ::=γϊ?Ν 0 ΛΝ hívtcn \ Vó OH 7 νη2 0.76 > 10 1.97 > 10 Α72 D ΝΗ2 HÓ 'ΟΗ 0.77 > 10 / / Α164 νη2 D D V 0 / Ν Hg CN °Η / / / / Α75 νη2 ν O D D II Χ / θχΖ Ν ^_pCN HÓ Ζ°Η 0.49 > 10 / / Α214 νη2 / ==<''''Ν D D V 0 / Ν HgX / cN \ ^-Ó ÓH 7 νη2 / / / / Α77 νη2 Λ'.'Μί·' ΝΗ2 HÓ ΟΗ / / / / η / ζΓίη / ζζηζ / Ε / γίΛΐ A84 F NH2 'θγύ \ o / / / / A151 D NH2 O V-N yW1 / “ T ? L / 'cn \ o 0.63 > 10 1.99 / A173 D NH2 v o r'M HOO U'CN ^-Q·' 'OH 0.46 > 10 / / A180 D 7H2 2 d D xA'V / Y ° \ 7cn HO OH / / / / GS-441524 NH2 0 / N'N^ / 'ΌΝ HÓ 'OH 0.73 > 10 1.88 > 10 Remdesivir nh2H3% CHs or CC / ü H3C / _,O^ !!_ 0 ^·°Ύ í Η * ΌΝ 0 ” / / 0.021 25.7 Note: 7” means indeterminate. η / ζΓίη / ζζηζ / Ε / γίΛΐ Table 4. Inhibitory activity on the replication of porcine epidemic diarrhea virus (PEDV), Zika virus (Zika), dengue fever virus (DENV) η / ζΓίη / ζζηζ / Ε / γίΛΐ Compound number Structure PEDV (Vero) Zika (Huh7) DENV (Vero) ECso (μΜ) EC50 (μΜ) 5 μΜ A9 D 7H2 N or ZN^ ΌΝ HÓ OH 0.016 12 100% A10 nh2 N D D \Z O / N H0 HO' OH 0.006 / / A11 D NH2 D D V-K HO \J' CN HÓ ÓH 0.005 / / A50 nh2 0 y. n \A0^<0y N Y ° Ύ 7cn HÓ OH 0.002 / / A144 D NH2 0>N·^ HfXYcN —^~0' 0H <0.1 / / A70 D NH2 1 o pO HÓ ÓH 0.002 ~27 %, 5 uM / Α164 νη2 V 0 >4 ΗομΓΌΝ ^~ΟΧ ΟΗ / / / Α75 νη2 Ν ° D D V-N. 1 Χ / °\Ζ Ν HÓ ''ΟΗ / / / Α131 νη2 _ / ;-γ :;'Ν 'Ά-νγ Τ ? VJ™ \ ο <0.1 / / Α151 ι ^=ο / γΟΟ Ο,, L ° ο=< § XX 7 ν / J <0.1 / / Α180 D ΝΗ2 9 D η VN'm^ HÓ ΟΗ / / / Α216 νη2 / ===7^ Ν V-N. ν ΗΟ Γ\ )---ζ ΟΗ ΗΟ ΟΗ 1.92 / 24% Α28 I Ο I / Ο / ' <α l χ° o'' blxíx 1 4 μ vzh 1,10 6 %η / ζΓίη / ζζηζ / Ε / γίΛΐ A221 nh2 . O / N HO^T / JCN HÓ OCH3 1.35 / 51 % GS-441524 nh2 V-N O / N H°X\Z ¿''CN HO' OH 0.026 15 / Remdesivir NI HsCl QH3 o o ρζ X Η 1 VJ CN0 O / O l2 N / / 100 % Ribavirin / / 17.4 Note: 7” means indeterminate. η / ζΓίη / ζζηζ / Ε / γίΛΐ Test Example 5: Pharmacokinetic Evaluation in Mice Experimental method: Male CD-1 mice were randomly divided into 5 groups, with 3 mice for each group. Before the experiment, they were fasted for 12 hours and allowed to drink water. 2 hours after dosing, the animals were fed. Among them, 4 groups were administered intragastrically with 50 mg / kg of GS-441524, A9, A10 and A11, respectively, and 30 μl of blood sample was collected from the femoral vein in an anticoagulant tube with heparin at 0 .25, 0.5,1.2, 4, 8 and 24 hours post administration. 20 μΙ of whole blood was immediately and accurately aspirated into a centrifuge tube containing 2 μΙ of PhosSTOP and 7 μΙ of DTNB (0.5 M), then mixed evenly and centrifuged at 4 °C. 10 μΙ of plasma was taken into a centrifuge tube containing 100 μΙ of precipitant (methanol:acetonitrile, 1:1, v / v), mixed evenly, centrifuged at 4 °C, then placed on dry ice for storage. and temporary transport and frozen at - 80 °C to measure. The remaining group was administered GS-441524 (25 mg / kg) intravenously and a blood sample was collected from the femoral vein at 5 min, 0.25, 0.5,1,2,4,8, 24 h after administration and heparin anticoagulant tube was placed. The processing method was the same as described above. The concentrations of GS-441524, A9, A10, and A11 in plasma were determined by the LC-MS-MS method. 20 μΙ of supernatant was mixed with 20 μΙ of deionized water and then the sample was injected for analysis. Samples were separated using a Waters HSS T3 chromatographic column (2.1*50 mm, 1.8 μιτι) and then detected by multiple reaction monitoring mode under positive ion conditions using an electrospray ionization source. The linear range of the samples was 10-30000 ng / ml. Table 5. Pharmacokinetic parameters of the compounds GS-441524, A9, A10 and A11 in mice. Compounds Parameters PK GS-441524 (p.o.) GS-441524 (v.) A9 (p.o.) A10 (p.o.) A11 (p.o.) Tmax (h) 0.8 - 1.2 0.8 0.7 Cmax (ng / mL) 1826 - 3227 1764 2117 T1 / 2 (h) 1.2 1.0 1.0 1.3 1.9 AUC(O-t) (ITng / mL) 4556 14513 5982 4551 5684 AUC(0-°°) ( h*ng / mL) 4616 14581 6013 4619 5754 F% 15.7% η / ζΓίη / ζζηζ / Ε / γίΛΐ Test example 6: pharmacokinetic evaluation in rats Experimental method: Male SD rats were randomly divided into 6 groups, with 3 rats for each group. Before the experiment, they were fasted for 12 hours (not for the intravenous experimental group) and allowed to drink water. 4 hours after dosing, the animals were fed. Among them, 3 groups were administered intragastrically with 10 mg / kg of A9, A146, and A151, respectively, and the remaining 3 groups were administered intravenously with 2 mg / kg of A9, A146, and A151, respectively. The vehicle for administration was DMSG / EtOH / PEG300 / 0.9% NaCl (5 / 5 / 40 / 50, v / v / v / v). min (intravenous only), 0.25, 0.5,1.0, 2.0, 4.0,6.0, 8.0 and 24 h after administration, 0.2 ml of blood sample from jugular vein into EDTA-K2 tubes and centrifuged at 11000 rpm for 5 min. Plasma was separated and frozen in a refrigerator at −70°C for analysis. The operation was carried out in an ice water bath. Plasma A9 concentration was determined by LC-MS-MS and pharmacokinetic parameters were calculated. Table 6. Pharmacokinetic parameters of compounds A9, A146 and A151 in rats. ^XComposite PK's Parameters. A9 (po-10mpk) A9 (iv2mpk) A146 (po-10mpk) A146 (iv-2mpk) A151 (po-10mpk) A151 (iv-2mpk) Tmax (h) 3.0 0.08 0.25 0.08 0.5 0.1 Cmax (ng / mL) 221 1260 576 770 498 513 Ti / 2 (h) 3.4 2.3 2.5 1.4 2.6 1.5 AUC(O-t) (h*ng / mL) 1336 1257 1888 779 1886 665 AUC(0-M) (h* ng / mL) 1726 1283 1998 821 1998 700 F% 21.3% 48.5% 56.7% η / ζΓίη / ζζηζ / Ε / γίΛΐ Test Example 7: Tissue Distribution Test Experimental method: Male CD-1 mice were randomly divided into 4 groups, with 4 mice for each group. Before the experiment, they were fasted for 12 hours and allowed to drink water. 2 hours after dosing, the animals were fed. The 4 groups received 200 mg / kg of A151 (dissolved in DMSOentanol-PEG300-saline, volume ratio: 5 / 5 / 40 / 50) by intragastric administration. At 1 h, 2 h, 4 h, and 8 h after administration, mice were anesthetized; Blood sample was collected by cardiac puncture and liver, kidney, heart and lung tissues were collected. The distribution profile of A9 in tissues was determined by HPLC-MS / MS. Table 7. Tissue distribution of metabolite A9 after oral administration of A151 (200 mg / kg) in mice. Organs Time'''-^ Pure blood nM Liver nMol / kg Kidney nMol / kg Lung nMol / kg Heart nMol / kg 1 h 30820 30853 47166 31441 25648 2h 18261 14281 26719 12830 12927 4h 4 6289 11059 5705 6256 8h 549 639 1220 1032 749 Test example 8: in vivo efficacy test against SARS-CoV-2 Experiment 8.1: 8-week-old Balb / c mice were divided into 5 groups: virus control group (vehicle: 40% PEG400 + 10% HS 15 + 50% ultrapure water), A151 hydrobromide salt (A151 -S) oral group (50 mg / kg, 100 mg / kg), Remdesivir oral group (50 mg / kg), Remdesivir intraperitoneal group (50 mg / kg). The animals in each group were transduced with adenovirus carrying the human ACE2 gene and infected with the new coronavirus 5 days after transduction. One hour after infection, vehicle, A151-S, and control drug Remdesivir were administered once daily by gavage or intraperitoneal injection, respectively. Mice were sacrificed on the second and fifth day after infection, and mouse lung tissues were taken to measure the copy number of viral RNA in mouse lung tissues. The viral RNA copies after administration for 2 days and 5 days are shown in Fig. 1 and Fig. 2, respectively. The results showed that oral administration of compound A151 -S at 50 mg / kg and 100 mg / kg could effectively reduce the amount of viral RNA in mouse lung tissue in a certain dose-dependent manner. After administration for 2 days at a dose of 50 mg / kg, the antiviral effect of oral administration of A151-S was better than that of the oral administration of Remdesivir group, and after administration for 5 days, the effect antiviral performance of oral administration of A151-S was better, better than that of the intraperitoneal injection group of Remdesivir. Experiment 8.2: The 8-week-old Balb / c mice were divided into two groups: virus control group (vehicle: 5% DMSO + 5% SolutolHS15 + 90% saline) and A151-S intraperitoneal injection group (100 mg / kg). The animals in both groups were transduced with adenovirus carrying the human ACE2 gene. A151-S was administered one day before infection with the novel coronavirus and was administered once daily by intraperitoneal injection from the day of infection to the fourth day after infection. The control group was treated in the same way. Mice were sacrificed on the fourth day after infection, and mouse lung tissues were extracted to detect the copy number of viral RNA in mouse lung tissues. The results are shown in figure 3. The results showed that Compound A151-S administered by intraperitoneal injection can significantly reduce the amount of viral RNA in mouse lung tissue, and the viral load decreased more than 30 times compared with the control group. Discussion The compound of formula (I) of the invention has notable anti-SARS-CoV-2 activity. In virus-infected Vero E6 cells, representative compounds A9 (Example 6), A10 (Example 7), A124 (Example 11), A50 (Example 12), A212 (Example 13), A144 (Example 16), A213 (Example 18), A164 (Example 20), A214 (Example 22), A151 (Example 36) can significantly inhibit virus replication. EC50 of them are 0.44 μΜ, 0.43 μΜ, 0.25 μΜ, 0.23 μΜ, 0.11 μΜ, 0.24 μΜ, 0.10 μΜ, 0.27 μΜ, 0.11 μΜ and 0.31 μΜ, respectively, which are significantly higher than the control compound Remdesivir (EC50 = 2.0 μΜ). In addition, A11, A12, A52, A70, A72, A75, A77, A131, A171, A180, A181, A188, A196, A215 and the like can significantly inhibit virus replication at the concentration of 5 μΜ, with an inhibition rate of more than 98%, which are significantly higher than (65%) of Remdesivir at the same concentration. A102, A106, A107, and A198 can significantly inhibit the RdRp activity of the novel coronavirus, indicating that these compounds exert their antiviral effect by targeting RdRp. The compounds of formula (I) of the present invention can also effectively inhibit the replication of other viruses, including respiratory syncytial virus (RSV), human coronavirus OC43 (HCoV OC43), porcine epidemic diarrhea virus (PEDV), Zika virus (Zika), dengue fever virus (DENV). It is worth noting that the antiviral effect of deuterated compounds is more obvious. PK test in mice showed that after oral administration of deuterated η / ζΓίη / ζζηζ / Ε / γίΛΐ compounds A9 and A11, their plasma exposure was higher than that of GS-441524, and was 1.3 times and 1. 2 times that of GS-441524, respectively; The oral bioavailability of A9 in rats was 21.3%, and the oral bioavailability of A146 and A151 were 48.5% and 56.7%, respectively, which were significantly higher than those of A9. Tissue distribution test in mice showed that after oral administration of A151 for 1 hour, the concentration of A9 metabolite in liver, kidney, lung and heart was the highest, and A9 was evenly distributed, without accumulation in liver or kidney. The hydrobromide salt of A151 (A151 -S) can reduce the viral load in the lungs of mice in a dose-dependent manner administered orally once a day in an adenovirus-transduced mouse model expressing the novel receptor of human coronavirus ACE2 and the anti-New Coronavirus effect of A151-S is better than Remdesivir at the same dose (50 mg / Kg). The above data show that A151-S has a significant anti-SARS-CoV-2 effect and has an advantage for oral use. Based on the above data, it can be suggested that the compounds of the present invention have a good application prospect as antiviral agents, especially as agents against the new coronavirus (SARS-CoV-2). All documents mentioned in the present invention are cited as references in this application, just as each document is individually cited by reference. Furthermore, it should be understood that, after reading the above teaching content of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent forms are also within the scope defined by the attached claims, of this application.

Claims

1. A compound of formula (I), or pharmaceutically acceptable salts thereof or crystalline hydrate thereof or solvate thereof or prodrug thereof: Re Y-N.. R5^Xv°7 N R7 ° R?W'R1R3° F?2 O) wherein, Ri is selected from hydrogen, deuterium, halogen, cyano, azide, amino, C1-e alkyl-substituted amino, C1-6 acyl, C1-6 alkyl, C1-6 alkoxy, C1-e alkanoyl-substituted amino, halogenated C1-6 alkyl, C2-6 alkenyl, C2-6 alkenoxy, C2-6 alkynyloxy, C2-6 alkynyl, C3-6 cycloalkyl, halogenated C3-6 cycloalkyl, carbamoyl, hydroxymethyl, cyanomethyl (-CH2CN), guanyl, guanidyl, carbamide, thiocyanate (-SCN), cyanate (-OCN); R2 is selected from hydrogen, halogen, OR3, cyano, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl;R3 is selected from hydrogen, C1-20 alkanoyl, C1-20 aminoalkanoyl, C1-6 amino alkyl, C1-6 alkoxy, C1-6 alkyl, amino acid a, and the carboxyl of amino acid a is linked to the hydroxyl on the furan ring through the ester bond; η / ζΓίη / ζζηζ / E / γίΛΐ R4 is selected from hydrogen, deuterium, halogen, azide, cyano, C1-6 alkyl, halogenated C1-6 alkyl azide, C1-6 alkyl cyano, C1-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C1-6 alkanoyl, C2-6 alkenoxy, C2-6 alkynyloxy, C1-6 alkoxy, C1-6 alkyl amino, C1-6 alkyl alkylamino, O e, guanyl, guanidyl, carbamido, thiocyanate, cyanate; Re is selected from amino, hydroxy, halogen, cyano, cyanate, thiocyanate, C1-6 alkoxy, C1-6 alkylamino, NHOH, NHCOR12, NHOCOR12, NHCOOR12; R7 is selected from hydrogen, deuterium, halogen, amino, methyl, NHCOR12, NHCOOR12;Rs is selected from hydrogen, deuterium, halogen, cyano, carbamoyl, C1e alkyl-substituted carbamoyl, C1 6 alkoxyamido, C1 6 alkoxycarbonyl, hydroxy, C1e hydroxyalkyl, amino, C1-6 alkanoyl-substituted amino, C1-6 alkyl-substituted amino, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl; X is selected from -CH2-, -CD2-, -CHD-; Rg is selected from C1-6 alkyl, C3-6 cycloalkyl, C6-20 aryl, 5-15 membered heteroaryl; R10 is selected from C1-18 alkyl, C6-20 aryl methylene; R11 is selected from C1-6 alkyl, C3-6 cycloalkyl, C6-20 aryl, 5-15 membered heteroaryl; R12 is selected from C1-20 alkyl;M is selected independently from hydrogen, metal, -NHU, or protonated organic amines.

2. A use of an active ingredient or a formulation containing such an active ingredient, wherein the active ingredient is a compound of formula (I) or pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof: R1 is selected from hydrogen, deuterium, halogen, cyano, azide, amino, C1e alkyl-substituted amino, C1b acyl, C1-6 alkyl, C1b alkoxy, C1e alkanoyl-substituted amino, halogenated C16 alkyl, C26 alkenyl, C26 alkenoxy, C2b alkynyloxy, C26 alkynyl, C3-6 cycloalkyl, halogenated C3-b cycloalkyl, carbamoyl, hydroxymethyl, cyanomethyl (-CH2CN), guanyl, guanidyl, carbamido, thiocyanate (-SCN), cyanate (-OCN); R2 is selected from hydrogen, halogen, OR3, cyano, alkyl C1 e, alkoxy G1 s, C2-6 alkenyl, C2-6 alkynyl;R3 is selected from hydrogen, C1-20 alkanoyl, C1-20 aminoalkanoyl, C1-6 alkylamino-C1-6 alkanoyl, C1-6 alkoxy C1b alkyl, amino acid a, and the carboxyl of amino acid a is linked to the hydroxyl on the furan ring through the ester bond; R4 is selected from hydrogen, deuterium, halogen, azide, cyano, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl azide, C1-6 alkyl cyano, C1-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C1-6 alkanoyl, C2-6 alkenoxy, C2-6 alkynyloxy, C1-6 alkoxy, C1-6 alkyl, C1-6 amino alkyl, C1-6 alkyl, C1-6 alkylamino, guanyl, guanidyl, carbamido, thiocyanate, cyanate; Re is selected from amino, hydroxy, halogen, cyano, cyanate, thiocyanate, C1-6 alkoxy, C1-e alkylamino, NHOH, NHCOR12, NHOCOR12, NHCOOR12; F¡7 is selected from hydrogen, deuterium, halogen, amino, methyl, NHCOR12, NHCOOR12;Rs is selected from hydrogen, deuterium, halogen, cyano, carbamoyl, C1-6 alkyl-substituted carbamoyl, C1-6 alkoxyamido, C1-6 alkoxycarbonyl, hydroxy, C1-6 hydroxyalkyl, amino, C1e alkanoyl-substituted amino, C1e alkyl-substituted amino, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2β alkynyl; X is selected from -CH2-, -CDz-, -CHD-; Rg is selected from C1-6 alkyl, C3-6 cycloalkyl, C6-20 aryl, 5-15 membered heteroaryl; R10 is selected from C1-18 alkyl, Ce20 methylene aryl; R11 is selected from Ci-e alkyl, C3-6 cycloalkyl, Ce-2o aryl, 5-15 membered heteroaryl; R12 is selected from C1-20 alkyl; M is each independently selected from hydrogen, metal, -NHL, or protonated organic amines; and the active ingredient or formulation containing said active ingredient is used to prepare (a) inhibitors to inhibit viral replication;and / or (b) medicaments for treating and / or preventing or alleviating diseases associated with viral infections.

3. The use of claim 2, wherein the virus is selected from: (1) coronaviruses that infect humans: severe acute respiratory syndrome coronavirus (SARSCoV), 2019 novel coronavirus (2019-nCoV or SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV); (2) coronavirus that causes the common cold: the coronavirus that causes the common cold is preferably selected from the group consisting of: human coronavirus 0043, human coronavirus 229E, human coronavirus NL63 and human coronavirus HKUL; (3) human respiratory syncytial virus (RSV); (4) human influenza viruses: influenza A virus, influenza B virus and influenza C virus; (5) flaviviridae viruses: hepatitis C virus (HCV), dengue virus (DENV), Zika virus (Zika); (6) filoviridae viruses: Marburg virus (MBV) and Ebola virus (EBV); (7) coronavirus that infects other mammals: porcine epidemic diarrhea virus (PEDV).

4. The use of claim 2, wherein the related diseases caused by the viruses are selected from the group consisting of (D1) common cold, high-risk symptom infection, respiratory tract infection, pneumonia and their complications caused by human coronavirus infection; (D2) common cold, high-risk symptom infection, respiratory tract infection, pneumonia and their complications caused by human respiratory syncytial virus (RSV) infection; (D3) common cold, high-risk symptom infection, respiratory tract infection,Pneumonia and its complications caused by human influenza virus infection; (D4) chronic hepatitis C and its complications caused by hepatitis C virus (HCV); (D5) dengue fever and its complications caused by dengue virus (DENV); (D6) Zika virus infection and its complications; (D7) hemorrhagic fever and its complications caused by Marburg virus (MBV) and Ebola virus (EBV); (D8) novel coronavirus pneumonia (coronavirus disease 2019, COVID-19) caused by SARS-CoV-2 (COVID-19); (D9) Porcine epidemic diarrhea caused by porcine epidemic diarrhea virus (PEDV); (D10) any combination of the foregoing diseases.

5. Use of Claim 2, wherein the compound of formula (I) is any of Compounds A1 to A221 having the following structure,o la combinación de los mismos: HO ÓH HÓ ÓH HÓ D ΗθΆ ÓH A3 HÓ ÓH HÓ ÓH HÓ ÓH ΗθΑ A1 A2 A4 A5 A6 nh2 nh2zc D NH2 / A^N Λ- A / CN nh2 D NH2 p NH2 / An / yA AA^n / y^N aí^n AA -°x / N AN F . 0 f NA VN~yn ? VN'n^ ,oy N υ^ / °\Γ N Ύ CN HO^^ ΥΟΝ pCN HO'^Y' / 'CN HO y' Ύ-'CN HÓ ÓH A7 D NH2 / AS Z°x / N HÓ ÓH A8 y TA . o / M HÓ •O. ÓH A9 NH2 / Ά^ν >A HÓ ÓH A10 zV / 0 / N HÓ ÓH HÓ ÓH A11 A12 nh2 f nh2 A / -°x / N -^* < / Ox / N ΗθΑ F' \ / ΌΝ / CN ho^^x n / \ 7cn H0OV / CN N3 \Z H3ó' \ / CN HO yf y-'CN A H3C ( HO' ÓH A13 F NH2 AN Á HÓ ÓH A14 nh2 V-N ύ O / N HÓ „0 ÓH A15 F ^2 / AfA / A HÓ ÓH A16 NH2 p J1 A / N HÓ ÓH hÓ ÓH A17 A18 F nh2 f nh2 AY <VN'rú vA 0 / n .

0. r n Ho^y YCN HCrfyf / CN ho^A< / CN H0 A / zon ηο^Α\ / CN Hcr\_ / Nj F—} 7 f7'' ΐ n3-' a. n3-' . HO' ÓH A19 NH2 An -°x / Nfhó 'oh A20 hn'oh / χΎν yj NFHÓ I ox ÓH A21 hn-oh 1 / Axn > A HÓ ÓH A22 NH2 aya Αν'ν^ Ό. / N HÓ OH HÓ 'OH A23 A24 hn'oh fp / An as oya ^0 ya ΗθΑ>< F \ A H0 ηοζ\ F \_ / N3HO H0A; A'^ H0 HÓ ÓH A25 F NH2 / A^n Ó / N HÓ 'OH A26 F NH2 XXN VAy ,0 / N HÓ J· ÓH A27 ,OH HN aAn yA HÓ ÓH A28 hn'0H АвА VNn^ zkA / N HÓ ÓH HÓ ÓH A29 A30 hn-oh / An<fA 0 y A -°x / N Ho^?y y Ηθ'Α HOq / .,^ HO^^Y 1 HO'x> y __ / f'~ \— / HÓ HO^A f' v ÓH A31 f nh2 / AA VN ,θΑ N HÓ 'OH A32 F NH2 y=yx Vn.J of N ho Af y N3·'' m H Ó n3 y 0., ÓH A33 D NH2 AgAN yA HÓ ÓH A34 D NH2 Λ=γΑ 0 z N hoa^ y NÓ' {HÓ ho'Aí' nA'} ÓH HO 0H A35 A36 nh2 nh2 / y^'N y=y^N 0 z N η / N ' y ho yy HÓ HoA F' / ÓH A37 F NH2 / AS Vn ,θA N HÓ ÓH A38 nh2 / A^N yy .a / J / n ho χ y f7'' A HÓ HO^A f7'' ; .0, ÓH A39 HÓ ÓH A40 V A' A H0 Al / cn HÓ HO'^ ÓH HÓ ÓH A41 A42 -•OH ..AH HN p HN / =A^n La^ν yA ,0. yn ..х,. / N / CN h0ACN HÓ ÓH A43 fó 'OH A44 fho' ÓH A45 HÓ F A46 HÓ F HÓ F A47 A48 A79 A80 A81 A82 A83 ÍV ín / ΖΖΩΖ / Ε / ΥΙΙΛΙ A111 A112 η / ζΓίη / ζηζ / Ε / γίΛΐ 100 η / ζΓίη / ζηζ / Ε / γίΛΐ 101 ÍV ín / ΖΖΠΖ / Ε / ΥΙΙΛΙ 102 preferably, the active ingredient is a nucleoside analogue selected from the following 103 group,o the sales farmacéuticamente acceptables of the mismos, the hydraulic crystalline of the mismo, the solution of the mismos, and the professors of the mismos: A1, A5, A6, A8, A9, A10, A11, A12, A13, A14, A28, A30, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A49, A50, A51, A52, A53, A54, A55, A57, A58, A63, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A84, A86, A87, A88, A89, A91, A95, A97, A99, A101, A102, A105, A106, A107, A108, A109, A110, A111, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156, A157, A158, A159, A160, A161, A162, A163, A164, A165, A166, A167, A168, A169, A170, A171, A172, A173, A174, A175, A176, A177, A178, A179, A180, A181, A182, A183, A184, A185, A186, A187, A188, A189, A190, A191, A192, A193, A194, A195, A196, A197, A198, A199, A200,A201, A202, A203, A204, A205, A206, A207, A208, A209, A210, A211, A212, A213, A214, A215, A216, A217, A218, A219, A220, A221, or a combination thereof.

6. A pharmaceutical composition comprising (a1) a first active ingredient, the first active ingredient being a compound of formula (I), and pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof: η / ζΓίη / ζζηζ / E / γίΛΐ wherein, Ri is selected from hydrogen, deuterium, halogen, cyano, azide, amino, C1-e alkyl-substituted amino, C1-6 acyl, C1-6 alkyl, C1-6 alkoxy, C1-e alkanoyl-substituted amino, halogenated C1-6 alkyl, C2-6 alkenyl, C2-6 alkenoxy, C2-6 alkynyloxy, C2-6 alkynyl, C3-6 cycloalkyl, halogenated C3-6 cycloalkyl, carbamoyl, hydroxymethyl, cyanomethyl (-CH2CN), guanyl, guanidyl, carbamido, thiocyanate (-SCN), cyanate (-OCN); R2 is selected from hydrogen, halogen, OR3, cyano, C16 alkyl, C1-6 alkoxy,C2-6 alkenyl, C2-6 alkynyl; R3 is selected from hydrogen, C1-20 alkanoyl, C1-20 aminoalkanoyl, (C1-6 alkyl, C1-6 amino alkanoyl, C1-6 alkoxy, C1-6 alkyl, amino acid a, and the carboxyl of amino acid a is linked to the hydroxyl on the furan ring via the ester bond; R4 is selected from hydrogen, deuterium, halogen, azide, cyano, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkyl azide, C1-6 alkyl cyano, C1-6 hydroxyalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C1-6 alkanoyl, C2-6 alkenoxy, C2-6 alkynyloxy, C1-6 alkoxy, C1-6 alkyl, C1-6 amino alkyl, C1-6 alkyl, C1-6 alkyl, e alkylamino, guanyl, guanidyl, carbamido, thiocyanate, cyanate; 104 η / ζΓίη / ζζηζ / Ε / γίΛΐ Re is selected from amino, hydroxy, halogen, cyano, cyanate, thiocyanate, alkoxy Ci e, Ci e alkylamino, NHOH, NHCOR12, NHOCOR12, NHCOOR12; R7 is selected from hydrogen, deuterium, halogen, amino, methyl, NHCOOR12, NHCOOR12; Rs is selected from hydrogen, deuterium, halogen, cyano, carbamol,carbamoyl substituted with C1-6 alkyl, C1-6 alkoxyamido, C1-6 alkoxycarbonyl, hydroxy, C1-6 hydroxyalkyl, amino, C1-6 alkanoyl substituted amino, C1-6 alkyl substituted amino, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl; X is selected from CH2, CD2, -CHD-; R10 is selected from C1-6 alkyl, C3-6 cycloalkyl, C6-20 aryl, 5-15 membered heteroaryl; R10 is selected from C1-18 alkyl, Ce20 methylene aryl; R11 is selected from C-ι-β alkyl, C3-6 cycloalkyl, Ce20 aryl, 5-15 membered heteroaryl; R12 is selected from C1-20 alkyl; M is each independently selected from hydrogen, metal, NH4, or protonated organic amines; and (b) pharmaceutically acceptable vehicles.

7. The pharmaceutical composition of Claim 6, wherein the compound of formula (I) is any one of Compounds A1 to A221,or a combination thereof.

8. A use of the pharmaceutical composition of claim 6 in the preparation of (a) inhibitors that inhibit the replication of coronavirus, influenza virus, respiratory syncytial virus, flaviviridae viruses, filoviridae viruses, and / or porcine epidemic diarrhea virus (PEDV); and / or (b) medicaments for treating and / or preventing or alleviating related diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae viruses, filoviridae viruses, and / or porcine epidemic diarrhea virus (PEDV) infection.

9. A method for inhibiting viral replication, comprising the step of contacting a first active ingredient or a formulation containing the first active ingredient with a virus,thus inhibiting viral replication; wherein the first active ingredient is a compound of formula (I) or pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof: 105 R8r® Αγ '~N Vn. aL R5wXv°V n R7 ° R^ ( RR3,